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Testicular tumours are rare and account for only 1% of cancers in men. These 
tumours constitute, however, the most common group of malignancies in young 
men. The vast majority of testicular tumours are germ cell tumours (GCTs). Malignant 
germ cell tumours originate most frequently in the testis (TGCT), and less commonly 
in extragonadal sites, in the retroperitoneum or mediastinum.
Two GCT categories are being recognized for treatment purposes: pure seminomas 
and a heterogeneous group with multivarious histological features, referred to 
as nonseminomas, which may consist of a combination of non-seminoma and 
seminoma.  Other tumours arising in the testis are the rare sex cord tumours, stromal 
cell tumours and other tumours such as malignant lymphomas. 95% of all germ cell 
tumours present between the age of 25 and 45 years, the highest incidence for non-
seminoma’s being in the second and third decade and for seminomas in the fourth 
decade.
Testicular cancer is most common in northern European populations with age 
standardized incidence rates between 4 and 10 per 100,000 males per year.1 Incidence 
rates are much lower in Asian, African and African American men, ranging between 
0.2 and 1 per 100,000. Worldwide, there is an observed increase in testicular germ 
cell tumour incidence with an annual increase of 1-6% in the global incidence rate 
over the last 40 years. This increase is intriguing and remains largely unexplained. 
A role for environmental factors has been suggested, which is supported by an 
increasing frequency of other testicular problems such as declining sperm counts 
and increasing incidence of testicular maldescent.
In The Netherlands, the incidence of malignant germ cell tumours has increased 
from 4.8 to 6.6 per 100,000 males per year between 1991 and 2002.2 Annually, more 
than 500 men are diagnosed with a germ cell tumour. Of all patients with testicular 
tumours, 47% had a seminoma (SGCT), 42% a non-seminoma (NSGCT), 6% a 
lymphoma, 4% a Sertoli-Leydig cell tumour and less than 1% had spermatocytic 
seminoma.  The annual mortality of testicular tumours is 0.3 per 100.000 males. 
About 25 men thus die of this disease each year in The Netherlands. Since the 
introduction of highly effective cisplatin-based chemotherapy the 10-year survival of 
men with seminoma has increased from 83% between the years 1970-1977 to 94% 
between the years 1988-1997. The 10-year survival for men with non-seminoma has 




Testicular GCTs often present as a painless, unilateral mass in the scrotum. Scrotal 
pain is the presenting symptom in approximately 20% of cases whereas in 10% of 
cases the symptoms are consistent with orchidoepididymitis. 
Testicular germ cell tumours are often rapidly growing tumours, which primarily 
metastasize to the ipsi-lateral para-aortal lymph nodes and via the bloodstream to 
the lungs and other organs. As prognosis improves with the smaller tumour volumes, 
awareness and self-examination are important to ensure early diagnosis. 
Risk factors 
There is a strong association between testicular cancer and an undescended testicle, 
poor testicular development and function, e.g. testicular atrophy, hypospadias, 
infertility and subfertility, a family history of testicular cancer among first-degree 
relatives (father and brother), the presence of a contralateral tumour or testicular 
intraepithelial tumour,  and HIV infection.3 Studies have led to the formulation of the 
hypothesis of the existence of a testicular dysgenesis syndrome in patients developing 
testicular tumours. Regular self-examination in these individuals at increased risk for 
developing GCT is of more importance. 
Approximately 10 % of testicular tumours occur in individuals with an undescended 
testicle and 25 % of cases occur in the contralateral, normally descended testicle. 
Orchiopexy decreases the risk for GCT only when performed in early childhood.4 
The intrascrotal position of the testis after orchiopexy facilitates self-examination and 
early diagnosis of testicular tumours.
About 1.5% of men with testicular cancer present with a synchronous bilateral tumour 
which are mainly pure seminomas.5 Up to 5% of GCT patients will have a contralateral 
(metachronous) testicular germ cell tumour (CTGCT).6 This incidence is similar to that 
of carcinoma in situ (CIS) observed in patients with unilateral testicular cancer who 
undergo biopsy of the contralateral testicle at the time of the orchidectomy.7 Other 
disorders such as Klinefelter syndrome, Down syndrome, Peutz-Jeghers syndrome, 
Carney’s complex, androgen insensitivity syndromes and mixed gonadal dysgenesis 




At the time of presentation with testicular germ cell cancers, the quality of sperm, 
both cell number and sperm motility, is very low. Almost two thirds of GCT patients 
present with Sertoli cell dysfunction and impaired spermatogenesis. Infertility is an 
important issue in most testicular GCT patients, as most of them are relatively young 
and will display a desire to father children in the years to come. Approximately half 
of patients with unilateral testicular cancer have oligozoospermia already before 
therapy because of suppressed spermatogenesis in the affected testis, possibly due 
to the presence of the malignant tumour and/or due to tumour products, although 
impaired spermatogenesis in the contralateral unaffected testis has been observed 
in a significant number of patients.8
Leydig cell function is impaired in patients with testicular carcinoma-in-situ. Post 
unilateral orchidectomy 20% of patients show low serum testosterone concentrations 
and this may decrease further due to impaired function of the contra-lateral unaffected 
testis. In long-term survivors partial hypogonadism may persist as evidenced by 
an increased serum luteinizing hormone (LH) concentrations  up to 10 years after 
orchidectomy.9
Diagnosis and treatment
Initial evaluation of men with a testicular mass suspected to be testis cancer 
consists of physical examination and ultrasound of the scrotum. After the diagnosis 
is established, the patient should undergo an inguinal orchidectomy with dissection 
of the spermatic cord at the internal inguinal ring. The tumour markers alpha-
fetoprotein (α-FP), the beta unit of human chorionic gonadotrophin (β-HCG) and 
lactate dehydrogenase (LDH) should be measured in men with suspected testis 
cancer before orchidectomy. In NSGCT the serum concentrations of α-FP and 
β-HCG are elevated in over 80% of men. In pure seminomas, α-FP is not elevated 
and fewer than 20% of men have elevated β-HCG levels. LDH is less specific but 
has independent prognostic value in patients with advanced GCTs. It is increased 
in 60% of NSGCTs and in 80% of seminomas. Serum tumour markers alone are not 
diagnostic of testicular cancer but very high values support a diagnosis of germ cell 
tumour. CT-scan of the thorax and abdomen is performed for staging purposes once 
the histopathological diagnosis of a malignant GCT is made.
Tumour markers are measured post orchidectomy to assess whether there is 
residual tumour. Persistence of elevated serum tumour markers or an increase 
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in serum tumour markers after initial normalization after unilateral orchidectomy 
indicates the presence of metastatic disease. Normalization of tumour marker levels 
after orchidectomy does not, however, rule out the presence of tumour metastases. 
In case of metastatic disease, the disease should be classified according to the 
International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification for 
metastatic GCT patients.
Adjuvant treatment
Non-metastatic Germ Cell Tumours
In case of stage 1 disease, non-seminoma germ cell tumours are often treated with 
unilateral orchidectomy followed by watchful waiting. Stage 1 seminoma can be 
treated with either a single intravenous administration of Carboplatin or with iliac 
and para-aortal lymph node radiation therapy at a dose of 20 Gray. Interestingly, the 
recurrence rates and survival rates of both treatments are similar.10 Watchful waiting 
is an option in stage 1 seminomas with tumours which are < 4 cm in size. Patients 
with stage 1 seminoma tumours with infiltrative growth into the tunica albuginea or 
funiculus and patients with perioperative tumour spill may be considered for radiation 
therapy of the ipsilateral groin region.
Metastatic Germ Cell Tumours
Patients with metastatic disease (stage II and higher) are usually treated with 
combination chemotherapy. Since the introduction of the cytotoxic agent cisplatin 
in 1974 as treatment for metastatic germ cell cancer, the survival of patients with 
carcinoma of the testis has been markedly improved, with cure potentially achieved 
in the majority of patients.11-13
Following the discovery of cisplatin, cisplatin-based chemotherapy consisting of a 
combination of cisplatin, vinblastin and bleomycin (PVB) has been introduced in the 
1970s. Because of the substantial neurotoxicity of PVB-chemotherapy, the efficacy 
and toxicity of the PVB regimen was later compared to that of the combination 
of bleomycin, etoposide and cisplatin (BEP). BEP-chemotherapy induced less 
neurotoxicity and resulted in similar or possibly higher remission rate in patients 
with advanced disease.14 Since then, the BEP regimen has been introduced as the 
standard worldwide chemotherapy regimen of choice for patients with metastatic 
testicular cancer. An additional advantage of cisplatin-based chemotherapy is the 
associated significantly 50% reduced risk of developing a CTGCT.15
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Mean 5 year overall survival for testicular cancer is currently 97.3% (95% CI 96.4-98.2) 16, 
with 5 year relative survival estimates of 97.6%, 93.3% and 93.6% in respectively 
classical seminomas, non-seminomas and mixed GCTs.17 Of the patients with GCT 
with haematogenous or lymphatic spread of the disease, a high percentage will 
achieve a complete remission.18 Eventually, 80% of all patients who present with 
testicular cancer can be cured and are expected to have a normal life expectancy. 
Chemotherapy-induced toxicity
Cytotoxic chemotherapy is associated with acute and long-term co-morbidity. As the 
prognosis of GCT patients has considerably improved over the last 5 decades, not 
only acute toxicity but also long-term morbidity related to chemotherapy are of clinical 
relevance in the management of these patients. The main acute effects of combination 
chemotherapy are gastro-intestinal disturbance, moderate myelosuppression 19, 
peripheral vasospastic disorder 20, thrombo-embolic events 21, pulmonary toxicity 
22;23, nephrotoxicity 24 and infertility 25, in view of which semen cryopreservation should 
be offered to all men diagnosed with testis cancer before starting chemotherapy if 
they so wish. Main long-term co-morbidities are polyneuropathy and ototoxicity 26, 
partial hypogonadism 9 and cardiovascular complications.27-29
Gonadal Function
More than 50% of testicular GCT patients experience significant gonadal dysfunction 
after curative treatment with cisplatin-based chemotherapy, with Sertoli cells 
being more sensitive to the deleterious effects of chemotherapy than Leydig cells. 
Spermatogenesis will recover to some extent within 12 to 36 months after completion 
of chemotherapy, but 25% of the patients will remain azoospermatic and nearly half 
of the patients will have persistent sperm abnormalities, such as decreased cell 
count and decreased mobility of the spermatozoa. After a median follow up of 12.6 
years, 68 % of GCT patients present with  a functional insufficiency of the Sertoli 
cells with impaired spermatogenesis and significantly elevated follicle-stimulating 
hormone (FSH) levels.30 Brenneman et al. found that in 60 % of the patients FSH 
levels remained elevated up to 8 years after chemotherapy, which reflects a functional 
insufficiency of the Sertoli cells.30
The sperm-producing germinal epithelium of the testes is more vulnerable to 
chemotherapy than the testosterone-producing Leydig cells, leaving many cancer 
survivors azoo- or oligozoospermic. The delayed recovery of sperm production is 
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also influenced by the relative hypo-androgenic intra-testicular milieu in these patients 
because of Leydig cell dysfunction. The impaired spermatogenesis also seems to be 
correlated with the patient’s pre-treatment gonadal function, with the patient’s age 
at the time of treatment, and with the dose and duration of the chemotherapy.31 
After chemotherapy, the concentration of spermatozoa and the volume of the 
remaining testis are significantly reduced in comparison to that in patients treated 
with orchidectomy who did not receive chemotherapy.32
Gonadal hormone function is also impaired in GCT patients and especially in 
patients treated with chemotherapy. Gerl et al. showed that high cumulative doses of 
chemotherapy cause a significant and persistent impairment of Leydig cell function 
up to 192 months after treatment, with increase of serum LH levels of 50% compared 
to GCT patients treated only with orchidectomy.33  Possible explanations for the 
mild Leydig cell hypofunction observed in patients with unilateral testicular cancer 
are that chemotherapy can lead to germinal epithelial damage, which results in a 
reduction in testicular volume and an associated decrease in Leydig cell function 
and azoospermia. Cisplatin-based chemotherapy may also induce a Raynaud’s 
phenomenon, which causes decreased vascular flow in the contra lateral testis and 
possible reduction in testosterone production.34;35 The fact that the mean testosterone 
level is inversely correlated with the cumulative cisplatin dose applied (> 400 mg/m2) 
36 support the latter hypothesis.
The risk of Metabolic Syndrome and Cardiovascular Disease 
The Metabolic Syndrome (MetS) is a cluster of metabolic and interrelated 
cardiovascular risk factors which has received considerable attention in recent 
years because of its association with, and predictive value for the development of 
type 2 diabetes mellitus 37 and cardiovascular disease (CVD).38 MetS risk factors are 
believed to directly promote atherosclerotic CVD. The common denominators of MetS 
are central (visceral) obesity and insulin resistance, which predispose individuals 
to metabolic risk factors such as elevated serum triglycerides, low high-density 
lipoprotein (HDL) levels, high fasting glucose levels, and high blood pressure.39
Various expert panels have developed classifications of MetS to facilitate screening 
for cardiovascular risk factors. The World Health Organization (WHO) Expert 
Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 
developed a working definition for MetS and the Adult Treatment Panel of the National 
Cholesterol Education Programme (NCEP-ATP III) modified the definition based on 
similar characteristics used by the WHO.40-42  Other classification systems include 
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the Metabolic Syndrome score developed by the International Diabetes Federation 
(IDF).43 A meta-analysis of 21 prospective American and European cohort studies 
using NCEP-ATPIII or WHO criteria indicated that patients with high MetS prevalence 
have an increased incidence for CVD and increased associated mortality.44 A further 
meta-analysis including 37 studies and 172.573 individuals 45 showed that MetS 
carried a nearly twofold increased relative risk (RR) of cardiovascular events and 
deaths of 1.78 (95% CI: 1.58-2.0).
Over the last decade, four cross-sectional studies evaluated MetS prevalence in 
GCT survivors. Nuver et al. observed a higher NCEP-ATPIII MetS prevalence and 
thereby an increased relative risk for MetS in a smaller cohort of 131 testicular cancer 
survivors.46 Interestingly, in this cohort the increased prevalence of MetS in patients 
treated with chemotherapy (26%) was lower compared to that observed in patients 
treated with orchidectomy alone (36%). Data from two cross-sectional studies from 
Norway were reported in 2007 (Table 5).47;48 One large multicenter study of five 
University Hospitals 48 reported an unusually high MetS prevalence of 52% in healthy 
subjects and respectively 45% and 33% in 1135 testicular cancer survivors treated 
with chemotherapy or orchidectomy alone. The other study 47 reports long term data 
in 589 testicular cancer survivors who underwent orchidectomy up to 15 years after 
treatment 47 with MetS incidences of 17.4%, 15.2% and 6.4% in patients respectively 
treated with combination chemotherapy, radiotherapy or only orchidectomy. Both 
Norwegian studies used modified NCEP-ATPIII criteria so that the absolute MetS 
incidence in GCT patients cannot be ascertained.
Haas et al. reported the prevalence of MetS and cardiovascular disease, vascular 
complications and the role of gonadal function in long-term survivors of disseminated 
non-seminomatous TC.49 They recorded a 25% MetS incidence in 173 GCT patients 
a median of 5 years (range 3-20 years) after chemotherapy and calculated a relative 
risk for MetS of 2.2 (CI 1.5-3.3) compared with the general population. They also 
found that a total testosterone of <15 nmol/l was associated with an age-adjusted 
OR of 4.1 (95%CI 1.8-9.3) for the MetS.
Loss of bone mass
Hypogonadism is associated with a decrease in bone mass. As the vast majority 
of GCT patients are hypogonadal at some stage before or after diagnosis and 
treatment of TC, they are at increased risk for bone loss. Four published papers 
have so far addressed this issue. Stutz et al. performed bone mineral density (BMD) 
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measurements using dual-energy X-ray absorptiometry (DXA) in 30 seminoma 
patients to compare BMD in irradiated and non-irradiated hips and lumbar spine.50 
A positive relationship was only found between lumbar BMD and log transformed 
time since orchidectomy. No significant relationship was observed between BMD 
and radiotherapy. Brown al compared BMD of men who had previously received 
curative treatment with BMD of a healthy age-matched population.51 They found no 
statistical difference in BMD between the GCT patients treated with chemotherapy 
and those treated without chemotherapy at either spine or hip BMD. The mean 
BMD values in both groups were not lower than the BMD of their control reference 
group. They also found no difference in gonadal hormone levels between treatment 
groups. Unfortunately, only half of their patients had GCT (N=64), the other half was 
treated for non-Hodgkin’s lymphoma or Hodgkin’s disease (N=61), and their control 
group consisted of GCT patients treated with orchidectomy only. Murugaesu et al. 
found no difference in BMD after orchidectomy with or without chemotherapy in 
a cross-sectional study of 39 GCT patients a mean 15.7 years after treatment.52 
Because the number of survivors studied by Murugaesu et al. is small and patients 
with metastasized disease had shorter follow-up (13.1 vs. 17.1 years) slowly evolving 
changes in BMD may have been missed. This may explain the discrepant findings 
from the recent study of Ondrusova et al. showing an unusual high incidence of 
osteopenia and osteoporosis of 49.1% in 823 patients with unilateral GCT a median 
89 months after primary orchidectomy.53
Mechanism of chemotherapy-induced toxicity
Cisplatin-based chemotherapy has been shown to increase the serum plasma 
concentrations of the highly toxic non-protein bound iron (NPBI), iron, and of ferritin 
concomitant with a decrease in plasma anti-oxidants as measured 4 days after 
start of treatment.54;55 This suggests that chemotherapy-induced oxidative stress 
may lead to lipid and protein peroxidation which is considered to be one of the 
most important underlying mechanisms of late cisplatin toxicity. There is substantial 
evidence from animal studies that experimental iron overload may result in oxidative 
damage to lipids, proteins, DNA, and cellular organelles including mitochondria 56;57, 
as manifested by vascular, renal and liver damage.58 When free iron is not bound 
to transferrin and enters the blood circulation, free radicals are formed due to the 
ability of free iron to donate and accept electrons. Secondly, free iron catalyzes the 
conversion of hydrogen peroxide which also results in toxicity. Under physiological 
conditions, iron is sequestered in transport proteins, e.g., transferrin and lactoferrin, 
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and in storage proteins, primarily ferritin in the liver, spleen, and bone marrow. The 
most important group of iron-binding proteins contains haem molecules to perform 
redox and electron transport reactions required for oxidative phosphorylation, the 
principal source of energy for human cells. Normally, only one third of transferrin is 
saturated with iron. However, when high amounts of the redox reactive non-protein 
bound iron (NPBI), often referred to as non-transferrin bound iron (NTBI), enter the 
circulation, transferrin and other iron transport proteins may become oversaturated, 
leading to a cascade of oxidative damage.59
The reported changes in serum lipids early after chemotherapy 60 in combination with 
the increased prevalence of the MetS documented in TC survivors 46;61 suggest a 
causal relationship between chemotherapy and the observed long term cardiovascular 
effects associated with disturbed glucose and lipid metabolism. These effects may 
be aggravated by direct vascular effects of the chemotherapy. It has indeed been 
shown in vitro that cisplatin inhibits vascular remodelling and regeneration 62 and that 
bleomycin and cisplatin induce endothelial damage.63 Electron microscopy studies 
have also demonstrated bleomycin-induced endothelial damage in capillaries and 
small arterioles.64 In the clinic, manifestations of arterial vascular abnormality are also 
observed, such as the frequently reported development of the Raynaud’s syndrome, 
as side effect of cisplatin and bleomycin-based chemotherapy in GCT patients.65 
Early detection and prevention of vascular events may substantially improve 
long-term prognosis in patients with GCT. Vascular stiffness has been related to 
cardiovascular morbidity and mortality 66;67 and changes in vascular stiffness can be 
reliably measured using magnetic resonance–based pulse wave velocity (MR-PWV) 
of the aorta.68
Various studies suggest that chemotherapy-induced oxidative stress may result in 
non-alcoholic fatty liver disease 69 and cisplatin-based chemotherapy has shown to 
be toxic to the liver.70 Chemotherapy toxicity may also be associated with short term 
disturbances in liver function which may present early signs of late development of the 
Metabolic Syndrome (MetS).61 Finally, visceral fat mass is known to be metabolically 
active and is identified as a major contributor to adverse effects on glucose and 
lipid metabolism, and possibly endothelial dysfunction. As such, increases in visceral 
fat are considered to be important for the development of MetS and for increased 
cardiovascular risk.71-73 Measurement of changes in visceral and subcutaneous 
abdominal fat mass after chemotherapy may be useful in predicting long term risk 





ouTline of The TheSiS
In this thesis several comorbidities are described in GCT patients. GCT patients are 
known to have an increased CVD risk and a number of authors have reported on the 
increased prevalence of the metabolic syndrome and of cardiovascular risk factors 
in GCT survivors. However, the reported MetS incidence differs widely between 
studies and does not correspond with the measured CVD risk in GCT survivors. An 
important cause for the discrepancy in findings is that the MetS incidence may vary 
considerably depending on the classification used. In Chapter 2 we report about 
the results of a study conducted to both assess MetS prevalence using two different 
classification systems and to assess the 10-year cardiovascular risk in the same 
cohort of GCT survivors.
The reported increased CVD prevalence mainly concerns GCT survivors with 
disseminated disease who received cisplatin-based combination chemotherapy. The 
cause of the increased CVD prevalence in these survivors is not fully understood. One 
fifth of GCT patients and especially GCT survivors treated with unilateral orchidectomy 
and combination chemotherapy, become hypogonadal after anti-cancer treatment.30 
Hypogonadism may result in obesity and insulin resistance, which may in the long 
run result in increased CVD risk. In Chapter 3 results of (proton) MRI measurement 
of abdominal fat volume, hepatic fattening and aortic wall stiffness are reported 
before, directly after and 6 months after combination chemotherapy and relationship 
of these data with serum gonadal hormone values was documented.
Cisplatin-based chemotherapy can lead to subacute changes in cardiac function 
and it is known that bleomycin and cisplatin induce endothelial damage. The direct 
toxic effect of cisplatin-based chemotherapy on the cardiovascular system could at 
least partially explain the observed increased CVD risk in GCT survivors. In Chapter 
4 data are presented on cardiac function and myocardial triglycerides measured in 
fourteen GCT patients before and after cisplatin-based chemotherapy.
The reported vascular toxicity of cisplatin-based chemotherapy is largely due to 
oxidative stress induced damage to endothelial tissue. Chemotherapy induced 
iron release in GCT patients may potentially contribute to the oxidative stress. 
Parameters of iron metabolism may provide an indication for oxidative toxicity during 
chemotherapy treatments. To better understand the chemotherapy induced damage 
on various tissues in GCT patients, NPBI and the kinetics of the various related 
iron parameters were measured in a homogenous group of GCT patients receiving 
standard first-line chemotherapy for metastatic GCT (Chapter 5).
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In addition to its association with metabolic changes, hypogonadism may also be 
associated with bone loss and increased fracture risk in GCT patients. Four studies 
so far reported contradictory data on bone mineral density (BMD) in GCT patients 
and none of the studies reported a possible relationship between hypogonadism 
and BMD. We have observed an unusual high incidence of fractures in some long-
term GCT survivors. We therefore performed DXA-scans, vertebral X-rays and serum 
gonadal hormone analysis in the whole cohort of GCT patients followed up long term 
in our institution. Data on prevalence of vertebral fractures and of osteoporosis and 
osteopenia are reported in Chapter 6.
As previously mentioned, post-unilateral orchidectomy hypogonadism is more severe 
and persists longer in GCT patients treated with cisplatin-based chemotherapy. GCT 
patients treated with chemotherapy are therefore at increased risk for bone loss. In 
addition to treatment-induced hypogonadism, chemotherapy may also have direct 
adverse effects on bone cell function, further increasing the risk of bone loss and 
of poor bone quality. In Chapter 7 we present the results of a prospective study on 
natural changes in BMD in GCT patients up to five years after orchidectomy with and 
without additional cisplatin-based chemotherapy.

  Chapter 2 
Prevalence of the metabolic syndrome and 
cardiovascular disease risk in chemotherapy-treated 
testicular germ cell tumour survivors
Published in the British Journal of Cancer. 2013 Jul 9;109:60-7.
P M Willemse
J Burggraaf 










background: Testicular cancer patients have an increased risk for cardiovascular 
disease, which might be related to the increased prevalence of the metabolic 
syndrome in this group of patients. 
Methods: We assessed the prevalence of the metabolic syndrome and calculated 
the 10-year cardiovascular disease risk in a cohort of 255 testicular germ cell tumour 
survivors (median age 38.7 years, IQR 31-48) at a mean of 7.8 years after anticancer 
treatment and compared these to data obtained in 360 healthy men.
results: Survivors had an age adjusted increased risk for metabolic syndrome of 
1.9 compared to healthy controls. The risk for metabolic syndrome was highest in 
survivors treated with combination-chemotherapy: 2.3 (NCEP-ATPIII classification) 
and 2.2 (IDF classification) respectively. The risk of metabolic syndrome was 
especially increased in survivors with testosterone levels in the lowest quartile (OR 
2.5). Ten-year cardiovascular risk as assessed by the FRS (3.0%) and SCORE (1.7%) 
algorithms was low, independent of treatment, and comparable to controls.
Conclusion: Testicular germ cell tumour survivors have an increased prevalence 
of metabolic syndrome with hypogonadism and chemotherapy treatment being 
clear risk factors for the development of the syndrome. The increased prevalence of 
metabolic syndrome was not associated with an increased ten-year cardiovascular 
risk.
Prevalence of MetS and CVD risk in GCT patients
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inTroduCTion 
Testicular cancer, the most common cancer in male patients between 25 and 35 
years of age, holds an excellent prognosis since the introduction of cisplatin-based 
chemotherapy in the treatment regimen.74 However, testicular cancer patients 
treated with chemotherapy (CT) or radiotherapy (RT) are reported to have a 25-year 
risk of long-term cardiovascular complications of approximately 16%.28 An increased 
incidence of cardiovascular events was indeed recently reported in germ cell tumour 
(GCT) survivors 29. Patients who had received chemotherapy were found to be more 
at risk than those patients treated with orchidectomy only.27 Over the last two decades 
concerns have been raised about the increased risk of cardiovascular morbidity and 
the increased prevalence of the metabolic syndrome (MetS) with the use of certain 
treatment modalities in specific cancer types.75-77 Studies in GCT survivors report a 
wide variation in prevalence of MetS ranging from 13% to 39% 47;48;78, compared to a 
prevalence of 15% in nondiabetic adult Europeans.39
MetS is a cluster of metabolic and interrelated cardiovascular risk factors which directly 
promotes atherosclerotic cardiovascular disease (CVD).38 Various expert panels have 
developed classifications of MetS to facilitate screening for cardiovascular risk factors 
including the Adult Treatment Panel of the National Cholesterol Education Programme 
(NCEP-ATP III) which modified the definition based on similar characteristics used by 
the WHO (Table 1) 40;41 and the MetS score developed by the International Diabetes 
Federation (IDF).79 A meta-analysis of 21 prospective American and European cohort 
studies  using NCEP-ATPIII or WHO criteria indicated that patients with high MetS 
prevalence have an increased incidence and mortality for CVD.44 Another meta-
analysis including 37 studies and 172,573 individuals 45 showed that MetS carried a 
relative risk (RR) of cardiovascular events and deaths of 1.78 (95% CI, 1.58-2.0).
In all classifications used for the MetS main risk factors for CVD such as smoking, age, 
prothrombotic state and proinflammatory state are excluded to simplify out-patient 
screening. Of particular interest for GCT patients is that androgen deficiency has been 
found to be a risk factor for the development of the MetS and cured survivors are 
often found to have some degree of chemotherapy-induced hypogonadism, which 
may persist for up to 10 years after treatment.9 Hypogonadism can itself promote 
obesity and insulin resistance and in turn visceral obesity promotes hypogonadism. 
Another possible explanation for the observed increased CVD risk in GCT survivors 
is the fact that patients testicular germ cell cancer may be etiologically linked to other 
male reproductive abnormalities as a part of the so-called ‘testicular dysgenesis 
syndrome’ (TDS).80 This syndrome is present in a proportion of GCT patients before 
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the diagnosis of the malignancy and thus in the survivors, and it is biologically 
plausible that the syndrome may predispose to development of MetS in later years.81
Increasing numbers of patients in Europe and the United States have risk factors for 
cardiovascular disease. This has led physicians to stratify patients according to risk 
algorithms of which the Framingham Risk Score (FRS) 82 and the Systemic Coronary 
Risk Evaluation (SCORE) are most commonly used.83 In contrast to the fasting blood 
samples used in the assessment of the MetS, the Framingham Risk Score (FRS) can 
be calculated using non-fasting blood samples for cholesterol and HDL-cholesterol 
and major CVD risk factors such as smoking and age are also included in the FRS. 
The SCORE project, which collected and analysed data from 12 European cohort 
studies, was developed to estimate cardiovascular risk in European clinical practice. 
The large differences in MetS and CVD prevalence reported in the literature in GCT 
patients has prompted us to use both risk CVD prediction models to calculate 10-
year cardiovascular risk in our cohort of long-term GCT survivors compared to 
healthy male subjects. We assessed MetS prevalence using both NCEP-ATPIII and 
IDF classifications to compare differences in outcome and facilitate comparison with 
other studies. 
PaTienTS and MeThodS 
In a cross-sectional study design all patients with a primary GCT originating in the 
testis, who attended the outpatient clinic of the Clinical Oncology Department of the 
Leiden University Medical Center (LUMC) between 2008 and 2010 for routine follow 
up were invited to take part in the study and 255 eligible patients were included (Figure 
1). Seventy-nine patients had stage I disease; 58 were treated with orchidectomy 
alone (“surgery patients”) and 21 seminoma patients also received one adjuvant dose 
of carboplatin (AUC7) (“carboplatin patients”). Patients (n=176) with disseminated 
disease were treated with orchidectomy and combination-chemotherapy, primarily 
bleomycin, etoposide, and cisplatin (BEP) (“combination-chemotherapy patients”).
Data of 360 healthy men from the general population living in the same geographical 
area were obtained from general practitioners health screening records were used 
as control. These data were obtained in 2009 as part of a programme in which 
apparently healthy subjects were screened for cardiovascular risk factors. 
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figure 1. Flowchart inclusion of GCT patients
Major events (dates of diagnosis and mortality of CVD, defined as coronary heart disease but not stroke 
or peripheral artery disease, date of most recent medical information, vital status during follow up, and 
discharge), including annual verification of mortality and cause of death from hospital medical records, 
general practitioner, municipal and national cancer data records were retrieved from the cancer registry 
and medical.
data analysis in 776 patients
from the Cancer Registry at the 




3   Myocardial Infarction
4   CVA or pulmonary embolism
8   other death cause
17 unknown
 N=221 discharged from follow-up
N=126 patients were under follow-up 
at a different department after RTx for 
stage 1 seminoma
N=20 no fasting blood tests
N=24 were excluded for various 
reasons:
10 bilateral orchidectomy
9   adjuvant radiotherapy
1   HIV infected
1   ≥70 years of age
3   trisomy 21
299 patients attended out-patient 
department over a 2 year period 
255 patients
Assesment of MetS prevalence 




For all patients and controls, medical history (including smoking behaviour) was 
taken, body weight, height, body mass index (BMI, kg/m2), and waist circumference 
(WHO standards) were recorded and blood pressure was measured in duplicate with 
the participants in a semi-recumbent position after at least 5 minutes rest. Blood 
samples were obtained after an overnight fast and measured for cholesterol, HDL-
cholesterol, LDL-cholesterol, triglycerides using routine assays. For the patients blood 
was also analysed for C-reactive protein (CRP) concentrations (standard assay), 
HbA1c and insulin (LEIA) and gonadal status. The latter was evaluated by measuring 
serum concentrations of luteinizing hormone (LH), follicle-stimulating hormone 
(FSH) using electrochemoluminescene immunoassays, total testosterone (TT) and 
estradiol (E2) using standard radioimmunoassays and sex hormone binding globulin 
(SHBG) using a luminescence enzyme immunoassay. Hypogonadism was defined 
as a fasting morning serum total testosterone concentration of <10.4nmol/L.84 Four 
patients with disseminated disease received testosterone replacement therapy and 
were excluded for hormonal analysis. 
Metabolic syndrome and ten year cardiovascular risk evaluation
We used NCEP-ATPIII criteria 42 and IDF risk score charts 79 (Table 1) to establish 
the prevalence of MetS. The 10-year cardiovascular risk profile was calculated using 
FRS82 and SCORE.83
Table 1. Metabolic Syndrome Criteria according to two classification systems.
nCeP-aTPiii idf
Hypertension RRsystolic ≥ 135 mmHg and
RRdiastolic ≥ 85 mmHg
RRsystolic ≥ 135 mmHg or
RRdiastolic ≥ 85 mmHg
Obesity Waist circumference ≥ 102 cm Waist circumference ≥ 94 cm or
BMI > 30 kg/m2
Insulin resistance fasting glucose ≥ 6.1 mmol/l 
(110 mg/dl)
fasting glucose ≥ 5.6 mmol/l 
(100 mg/dl)
Dyslipidemia HDL-cholesterol < 1.03 mmol/l
(40 mg/dl) or statin usage
HDL-cholesterol < 1.03 mmol/l
(40 mg/dl) or statin usage
Hypertrigliceridemia triglyceride ≥ 1.7 mmol/l 
(150 mg/dl)
triglyceride ≥ 1.7 mmol/l 
(150 mg/dl)
Metabolic Syndrome ≥ 3 criteria Obesity & ≥ 2 other criteria
NCEP-ATPIII: National Cholesterol Education Program Adult Treatment Panel III 2001 
IDF: International Diabetes Federation
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Statistical Analysis 
SPSS 19 for Windows software package (Chicago, IL, USA) was used for statistical 
analysis. Chi-square test for categorical variables and Student’s t-test or Mann-
Whitney test (two-sided) for non-normally distributed variables were used as 
appropriate. Results are expressed as interquartile range (IQR), mean ± SD or as 
median (range). Odds ratios for MetS were calculated using logistic regression 
analysis and with adjustment for age and kidney function as continuous variables and 
smoking and hypogonadism as binary variables. MetS incidence was also analysed 
according to serum testosterone quartiles using Chi-square test for categorical 
variables. A p-value of <0.05 (two tailed) was considered statistically significant. We 
also investigated if there was an association between the time elapsed between 
treatment and the occurrence of MetS by linear regression. 
Finally, we used the raw data provided in three reports 46-48 in the literature on MetS 
in GCT patients to calculate the odds ratios. 
reSulTS 
Patient Characteristics
The median (range) cumulative carboplatin dose administered to survivors was 
1015 (730-1700) mg (Table 2). Seven survivors who were eventually treated with 
combination chemotherapy were first treated with single dose carboplatin for stage 
1 seminoma and one survivor was treated with 3 cycles of carboplatin before they 
developed distant metastasis. The median cumulative cisplatin dose administered to 
the survivors receiving combination chemotherapy was 604 (0-1750) mg; two patients 
received carboplatin instead of cisplatin as part of their combination chemotherapy.
The summary of the patient characteristics (Table 2) showed that at the time of the 
analysis there were no major differences in age between the different treatment 
groups of GCT survivors and the controls. Seminoma patients (42.4 years, IQR 35-
50) were older than non-seminoma patients (38.0 years, IQR 29-45; p =0.003). BMI 
and waist circumference were comparable between the groups. 
Smoking behavior was comparable in all groups of patients and the controls and 
amounted to approximately 40%. Also, there were no major differences in blood 
pressure and renal function, assessed as creatinine clearance using the Cockroft 
formula, between the groups.
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Combination-chemotherapy patients had significantly higher fasting serum 
concentrations of cholesterol, LDL-cholesterol and triglyceride than controls and 
higher serum cholesterol and triglyceride concentrations compared to surgery 
patients (Table 3). Carboplatin patients had higher fasting serum cholesterol (p=0.04) 
and LDL-cholesterol (p=0.004) concentrations than healthy subjects. Survivors 
treated with surgery only had higher LDL-cholesterol concentrations than healthy 
subjects (p=0.04). Fasting serum HDL-cholesterol did not differ significantly between 
treatment groups. Fasting serum glucose concentrations did not differ between 
treatment groups and healthy subjects (Table 3) and only 5 patients developed 
diabetes in the follow-up period. CRP concentrations were elevated in 10 survivors 
(3.9%), but did not differ between the groups. Patients with disseminated disease 
treated with combination-chemotherapy had significantly lower testosterone and 
higher FSH levels than stage I patients who only underwent orchidectomy (Table 
3). Thirty-four (13.3%) GCT survivors had hypogonadism; three of whom (5.2%) 
had orchidectomy alone and 31 (17.6%) had combination-chemotherapy in addition 
to orchidectomy (Table 3). There were no differences in gonadal hormone levels 
between patients treated with orchidectomy only or patients treated with adjuvant 
single-dose carboplatin. 
Prevalence of the Metabolic Syndrome
Using the NCEP-ATPIII criteria, GCT survivors had a significantly higher prevalence of 
obesity, dyslipidemia, and hypertriglyceridemia compared to age-matched healthy 
subjects (Table 4, upper part). Particularly, survivors treated with combination-
chemotherapy had the highest prevalence of all NCEP-ATPIII criteria compared to 
healthy subjects. MetS prevalence did not differ between survivors treated with 
orchidectomy only or survivors treated with an orchidectomy and carboplatin. 
The prevalence of MetS in all groups was almost two-fold higher when classified 
according to IDF criteria compared to the NCEP-ATPIII criteria. There was only a 
minimal influence (ß-coefficient=0.02 cases/year) of the time elapsed between 
curative treatment and the prevalence of MetS.
GCT survivors had an increased age-adjusted NCEP-ATPIII risk of 1.9 (95%CI: 1.1-
3.2) and an IDF risk of 1.8 (95%CI: 1.2-2.7) respectively (Table 4). Compared to healthy 
subjects, combination-chemotherapy survivors had the highest age-adjusted risk to 
develop MetS, i.e. 2.3 (95%CI: 1.3-4.0, NCEP-ATPIII classification) and 2.2 (95%CI: 
1.4-3.3, IDF classification) (Table 4).
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In surgery alone survivors, age-adjusted risk to develop MetS was respectively 1.5 
(95%CI: 0.6-3.9, NCEP-ATPIII) and 1.7 (95%CI: 0.8-3.6, IDF), compared to healthy 
subjects. Irrespective of the use of the IDF or NCEP-ATPIII criteria, survivors with 
the lowest quartile testosterone levels (<12.0 nmol/L) had a MetS prevalence higher 
than the other three quartiles, (OR=2.5, 95%CI; 1.3-4.7 and OR=1.7, 95%CI; 0.8-
3.6, respectively). MetS prevalence was not associated with other gonadal hormone 
concentrations or with alcohol use (data not shown).
According to NCEP-ATPIII criteria, GCT survivors who were smokers had a 2.0-
fold increased risk (95%CI: 1.0-4.0) for MetS compared to non-smokers. In healthy 
subjects, smokers had a 1.6-fold increased risk (95%CI: 0.7-3.4) for MetS compared 
to non-smokers. Smoking-adjusted risk of MetS for all survivors and for combination-
chemotherapy survivors alone, compared to healthy subjects was respectively 1.8 
(95%CI: 1.1-3.1) and 1.5 (95%CI: 1.1-2.0).
Ten-year cardiovascular risk profile
According to the FRS analysis, the calculated 10-year cardiovascular risk was 3.0% 
(IQR 0.0-5.0) in the survivors and 3.6% (IQR 0.0-6.0) in the controls. When using 
the SCORE algorithm, these values were 1.6% (IQR 0.1-1.7) and 2.0% (IQR: 0.1-
2.7) respectively. There was no treatment-related difference in age-adjusted 10-year 
cardiovascular risk in GTC survivors.
diSCuSSion 
We observed that the prevalence of the metabolic syndrome (MetS) is 2.2 to 2.3-
fold higher at a mean duration of 7.8 years after cure in testicular germ cell tumour 
(GCT) survivors treated with combination-chemotherapy compared to age-matched 
healthy subjects. In particular abdominal obesity, hypertension, hyper-triglyceridemia 
and other dyslipidemias were more frequently observed in chemotherapy-treated 
cancer survivors. Notably, also fasting LDL-cholesterol, which is not included in any 
MetS classification was consistently higher in all GCT survivors. It is remarkable 
that in our cohort all GCT survivors, but in particular combination-chemotherapy 
survivors, had higher BMI and were significantly more overweight than controls. In the 
survivor population, low testosterone concentrations correlated with MetS and the 
patients treated with combination-chemotherapy had an average 2.7 nmol/L lower 
testosterone than those treated with surgery alone. After adjusting for testosterone, 
there still was a significant difference in MetS prevalence between the two groups, 
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also after adjusting for age and smoking. In GCT survivors MetS may be related to 
a possible pre-existing underlying testicular dysgenesis syndrome 80 as well as to 
partial hypogonadism induced by chemotherapy or both. The 10-year cardiovascular 
risk estimated with either FRS or SCORE was low (3.0% and 1.6% respectively) and 
did not differ between treatment groups or between treatment groups and controls.
Table 4. Prevalence of the Metabolic Syndrome in GCT patients. 




















Hypertension 81 (22.5) 8 (14.0) 4 (20.0) 54 (31.0) 66 (26.3) 1.6 (1.0-2.3) 1.2 (0.8-1.8)
Obesity 70 (19.4) 10 (17.5) 6 (30.0) 51 (29.3) 67 (26.7) 1.7 (1.1-2.6) 1.5 (1.0-2.2)
Insulin resistance 16 (4.4) 2 (3.5) 1 (5.0) 11 (6.3) 14 (5.6) 1.5 (0.7-3.2) 1.3 (0.6-2.7)
Dyslipidemia 36 (10.0) 7 (12.3) 4 (20.0) 35 (20.1) 46 (18.3) 2.3 (1.4-3.8) 2.0 (1.3-3.2)
Hypertriglyceridemia 84 (23.3) 13 (22.8) 6 (30.0) 61 (35.1) 80 (31.9) 1.8 (1.2-2.6) 1.5 (1.1-2.2)
Metabolic Syndrome 29 (8.1) 5 (8.8) 2 (10.0) 29 (16.7) 36 (14.3) 2.3 (1.3-4.0) 1.9 (1.1-3.2)
according to idf
Hypertension 170 (47.2) 21 (36.8) 8 (40.0) 83 (47.7) 112 (44.6) 1.0 (0.7-1.5) 0.9 (0.7-1.2)
Obesity 165 (45.8) 24 (42.1) 13 (65.0) 107 (61.5) 144 (57.4) 1.9 (1.3-2.7) 1.6 (1.1-2.2)
Insulin resistance 57 (15.8) 6 (10.5) 3 (15.0) 34 (19.5) 43 (17.1) 1.3 (0.8-2.1) 1.1 (0.7-1.7)
Dyslipidemia 36 (10.0) 7 (12.3) 4 (20.0) 35 (20.1) 46 (18.3) 2.3 (1.4-3.8) 2.0 (1.3-3.2)
Hypertriglyceridemia 84 (23.3) 13 (22.8) 6 (30.0) 61 (35.1) 80 (31.9) 1.8 (1.2-2.6) 1.5 (1.1-2.2)
Metabolic Syndrome 59 (16.4) 9 (15.8) 5 (25.0) 52 (29.9) 66 (26.3) 2.2 (1.4-3.3) 1.8 (1.2-2.7)
a  Four survivors diagnosed with Diabetes Mellitus before orchidectomy (N=1), single dose carboplatin 
(N=1) or combination-chemotherapy (N=2) are excluded in this table.
b  Odds-ratio for risk stratification between healthy subjects and combination-chemotherapy survivors.
c  Odds-ratio for risk stratification between healthy subjects and all GCT survivors.
Worldwide, different definitions are used for MetS and we show here that dependent 
on the classification that is used, the prevalence of MetS may vary greatly. There 
was an almost 2-fold higher absolute MetS prevalence when using IDF (26.9%) 
compared to using NCEP-ATPIII (14.6%). However, the relative risk for MetS was 
shown to be independent of the scoring system and showed that GCT survivors 
had a 1.9- (NCEP-ATPIII) or 1.8-fold higher MetS prevalence compared to controls. 
The increased prevalence of MetS according to the IDF criteria compared to NCEP-
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ATPIII has been repeatedly demonstrated in worldwide cohorts.85 The use of different 
or adapted scoring systems may also explain why the prevalence of MetS in our 
cohort varied with those previously reported. Three other cross-sectional studies 
reported different MetS prevalences in GCT survivors possibly due to the different 
methodologies used in the evaluation of the MetS (Table 5). In keeping with our 
data, Nuver et al. observed a higher MetS prevalence and an increased relative 
risk for MetS in a smaller GCT survivor cohort 46 with a similar incidence of MetS 
in their controls (Table 5). A large multicenter cross-sectional study conducted in 
five university hospitals in Norway 48, reported an unusually high MetS prevalence 
of 52% in healthy subjects and respectively 45% and 33% in GCT survivors treated 
with chemotherapy or orchidectomy alone. Discrepancies may be explained by non-
adherence to 2002 NCEP-ATPIII classification, the use of non-fasting blood samples, 
using (at least two) modified criteria to assess the MetS and of only serum total 
cholesterol. In another report from a single-institution 47 which participated in the 
multicenter study 48, the authors also did not adhere to abovementioned classification 
methodology, which may have led to an overestimation of MetS.
As in other studies the high prevalence of MetS does not necessarily translate 
into increased cardiovascular risk. In keeping with the 2.2% cumulative incidence 
reported by Haughnes et al in their patients 86, our GCT survivors have a low 10-
year cardiovascular risk of 3.0% as estimated by FRS. This risk estimate is similar to 
that observed in the general population by van den Belt-Dusebout et al.28 and to the 
3.0% cardiovascular risk reported for another Dutch cohort of 408 healthy males of 
the same age.87 Although FRS calculations for individuals under the age of forty are 
less specific, a main shortcoming of MetS prediction for cardiovascular events is that 
it does not take into account major risk factors for CVD such as age, exercise and 
smoking status.  The association between the severity of risk factors and CVD risk is 
also not taken in consideration in the MetS criteria.
Our cross-sectional single centre study has some limitations including the relatively 
short follow-up time after cure, related to the past policy of discharging GCT patients 
five years after establishment of cure. Also, the subgroup of patients who received 
only one single administration of carboplatin is relatively small since single dose 
adjuvant carboplatin has only recently been introduced as an alternative treatment 
in patients with stage one seminoma.10;88 Although few patients received adjuvant 
carboplatin treatment the data suggest that the cumulative dose of cisplatin added 
to that of cytotoxic drugs of the standard combination drug regimens is a decisive 
determinant to develop MetS. Although more of our GCT patients were smokers than 
controls, adjustment for smoking differences did not alter the significantly increased 
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MetS prevalence in combination-chemotherapy patients. This was also the case 
when all survivors were compared to healthy subjects. Finally, it may be argued that 
there was a substantial variability in the time that had elapsed between the diagnosis 
and initial treatment and the time of assessment of the survivors. However, we 
investigated whether there was a time-dependency between the time of assessment 
and the prevalence of MetS and there was only a weak association between these 
variables. This suggests that the effects of combination chemotherapy are likely to 
be acute and maintained over time. Thirty to fifty percent of GCT patients treated 
with chemotherapy are infertile and most of the GCT survivors have long-term 
partial or complete hypogonadism.36 Because a proportion of GCT patients already 
have testicular dysgenesis syndrome, it is unknown if the infertility results from this 
condition, the chemotherapy or both.89 Whatever the explanation, low testosterone 
and sex hormone-binding globulin (SHBG) levels are considered risk factors for MetS 
in otherwise healthy men.90-92 We indeed found an association between low serum 
concentrations of testosterone and MetS in all patients and in particular CT patients, 
but there was no association between SHBG, LH or FSH levels and MetS. We argue 
that because hypogonadism is associated with increased cardiovascular risk, GCT 
survivors should be treated with testosterone suppletion. Although testosterone 
supplementation has not (yet) been shown to prevent cardiovascular disease, clinical 
trials with testosterone supplementation have resulted in a significant reduction 
of cholesterol levels.93;94 Apart from these favourable effects on lipid metabolism, 
testosterone supplementation also results in increased BMD, musle mass and fat-
free body mass.95;96 In particular use of daily transdermal testosterone gel may be 
attractive as this is reported to be without side effects. As the risk to develop prostate 
cancer after long-term use of transdermal androgens is currently unknown it may be 
prudent to consider monitoring of PSA when initiating treatment.97
Our data confirm that according to NCEP-ATPIII and IDF criteria, the subgroup 
of hypogonadal GCT survivors who received combination-chemotherapy is the 
main group at increased risk for developing a metabolic syndrome compared to 
the general population.  We observed no clear increase in the calculated 10-year 
CVD risk in long-term GCT survivors, although the follow-up period was perhaps 
too short. Long-term chemotherapy-related cardiovascular toxicity may result from 
acute direct endothelial damage or from indirect long-term chemotherapy-induced 
hormonal and metabolic changes including liver and gut damage thereby affecting 
lipid uptake, transport and metabolism over a period of many years.
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Table 5. MetS prevalence & odds ratio’s in 4 cross-sectional studies.
Parameters nuver et al. 
2005
haugnes et al. 
2007
Wethal et al. 
2007




130 1135 589 251
Mean age (years) 38.5 (20-65) 42.5 (23-60) 42 (23-60) 39.6 (18 -70)
Mean Follow-up 
time (years)
7.5    (3-13) 11.2 (5-22) 11 (7.7-14.5) 7.8   (0.1-30.0)
Healthy subjects (N) 47 1150 8835 360
MetS definition NCEP-ATP III Modified
NCEP-ATP III 
≥ 2 criteria a
Modified
NCEP-ATP III
≥ 3 criteria a
modified criteria





All GCT survivors 38    (29.2) 447  (39.4) 92  (8.1) 82 (13.9) 36 (14.3) 66 (26.3)
Combination-
chemotherapy
22    (25.6) 191  (41.2) 40  (8.6) 38 (17.4) 29 (16.7) 52 (29.9)
Single dose 
carboplatin
~ ~ ~ ~ 2   (10.0) 5   (25.0)
Radiotherapy ~ 184  (42.0) 37  (8.3) 35 (15.2) ~ ~
Surgery only 16     (34.0)  72   (33.0) 15  (6.7) 9   (6.4) 5   (8.8) 9   (15.8)
Healthy subjects 4      (8.5) 584  (51.5) 170 (14.8) Not mentioned 29 (8.1) 59 (16.4)
odds ratio (95% 
Ci) adjustments b
GCT survivors vs. 
healthy subjects
4.4   (1.5-13.2) 0.6   (0.5-0.7) 0.5 (0.4-0.7) ~ 1.9  (1.1-3.2) 1.8 (1.2-2.7)
Combi-chemo vs. 
healthy subjects
3.7   (1.2-11.5) 0.7   (0.5-0.8) 0.5 (0.4-0.8) 3.7 (1.5-9.1) 2.3  (1.3-4.0) 2.2 (1.4-3.3)
Combi-chemo vs. 
surgery only
0.6   (0.3-1.3) 1.5   (1.1-2.1) 1.3 (0.7-2.4) 3.1 (1.4-6.6) 2.1  (0.8-5.7) 2.3 (1.0-5.0)
a non fasting blood samples.
b  Calculated from the raw data presented in the individual reports.
In conclusion, our findings suggest an increased prevalence of MetS in GTC survivors 
who received chemotherapy. Of these chemotherapy patients, we further identify 
patients with low androgen levels as a subgroup that is particularly at risk of developing 
MetS. Based on this important clinical finding we advocate that guidelines to monitor 
blood pressure, lipid- and glucose-metabolism and assessment of gonadal hormone 
status should be introduced in international urology/oncology guidelines rather than 
monitoring potential complications of treatment. This is particularly important as the 
current standard of follow up is focused on the detection of tumour recurrence. In 
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our opinion this would allow for evidence-based counselling of GCT survivors to 
adhere to a lifestyle that favourably affects the modifiable risk factors for MetS and 
cardiovascular risk such as regular exercise, low carbohydrate diet and smoking 
cessation. We would be in favour of correcting androgen deficiency more liberally in 
this group of relatively young male cancer survivors. Obviously, the beneficial effect of 
this intervention on prevention or reversal of the MetS remains to be established, but 
longer lasting intervention studies should be able to establish whether this approach 
of lifetime monitoring, lifestyle intervention and correction of hypogonadism by wider 
use of testosterone supplementation at some stage during the natural course of GCT 
may prevent or revert the development of MetS and associated risk of CVD in long-
term survivors of GCT. 
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background: Testicular cancer survivors treated with chemotherapy are at 
increased risk for metabolic syndrome (MetS) and cardiovascular disease (CVD). We 
explored acute effects of chemotherapy by assessing metabolic factors, abdominal 
fat volume, hepatic triglyceride content and aortic wall stiffness.
Methods: We studied nineteen testicular cancer patients (age 20-54 years) before, at 
3 and 9 months after the start of chemotherapy. Blood serum was analysed for lipids, 
glucose and insulin. Abdominal visceral and subcutaneous fat volume and aortic pulse 
wave velocity were assessed by magnetic resonance imaging techniques; hepatic 
triglyceride content was measured by proton magnetic resonance spectroscopy. 
results: Three months after start of chemotherapy visceral abdominal fat volume 
had significantly increased from 202±141 to 237±153 ml (p=0.009) whereas BMI and 
subcutaneous fat volume significantly increased nine months after treatment from 
24.4±4.0 to 26.4±4.1 kg/m2 (p=0.01) and from 556±394 to 668±460 ml (p=0.002) 
respectively.  Serum total cholesterol, LDL-cholesterol and insulin also significantly 
increased three months after start of treatment from 4.88±1.1 to 5.61±1.50 mmol/L 
(p=0.002), 3.31±1.16 to 3.73±1.41 mmol/L (p=0.02) and 5.7±4.4 to 9.6±6.3 mU/ml 
(p=0.03) respectively. Nine months after start of chemotherapy serum lipid and insulin 
concentrations had returned to baseline. Hepatic triglyceride content increased 
in 7 of the 19 patients (36.8%) during follow-up. Aortic aortic pulse wave velocity 
remained unchanged at the three time points measured.
Conclusions: Cisplatin-based chemotherapy was associated with acute insulin 
resistance, dyslipidemia and an immediate increase in abdominal visceral adipose 
tissue and abdominal subcutaneous adipose tissue in testicular cancer patients. A 
large prospective cohort study with long follow up is warranted to characterize the time 
course and relationship between acutely induced obesity and hypercholesterolemia 
and the development of metabolic syndrome and cardiovascular disease years later 
in individual testicular cancer survivors.
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inTroduCTion
Testicular cancer (TC), the most common form of cancer in young male adults, holds 
an excellent prognosis with cure achieved in the vast majority of patients since the 
introduction of cisplatin-based chemotherapy.74 Long-term testicular cancer survivors 
treated with chemotherapy are at increased risk for the Metabolic Syndrome (MetS) 
a constellation consisting of abdominal obesity, hypertension, insulin resistance and 
dyslipidemia with reported prevalences ranging between17% and 41%.46;48 During 
cisplatin, bleomycin and etoposide (BEP) combination chemotherapy acute life-
threatening vascular events are known to occur, while cured long-term survivors are 
at increased risk to develop cardiovascular disease (CVD).21;27;98 These observations 
suggest a causal relationship between chemotherapy and the increased prevalence 
of MetS and CVD reported in long-term TC survivors. It seems likely that disturbances 
in glucose and lipid metabolism are induced early during chemotherapy, which may 
aggravate possible direct effects of chemotherapy on the vasculature, and translate 
in increased prevalence of MetS and CVD years later. Cisplatin has previously been 
reported to induce hepatic toxicity 70, whereas chemotherapy using a.o. oxaliplatin, a 
platinum analogue, has been shown to induce marked non-alcoholic steatohepatitis 
(NASH). Furthermore, visceral fat mass has been shown to be metabolic active and is 
identified as a major contributor to adverse effects on glucose and lipid metabolism, 
and endothelial dysfunction.99;100 Increase in visceral fat mass, insulin resistance and 
chronic inflammation, or a combination of these, may contribute to the development 
of MetS and the CVD risk.101;102
There is ample preclinical and clinical evidence for deleterious effects of cytotoxic 
agents on vascular cells. For instance, cisplatin has been shown to inhibit vascular 
remodelling and regeneration in vitro 62, whereas bleomycin and cisplatin both 
induced endothelial damage.63 In TC patients, arterial vascular events and Raynaud’s 
syndrome have been frequently reported as side effect of cisplatin and bleomycin-
based chemotherapy.65 These findings underscore the importance of early detection 
of chemotherapy-induced metabolic and vascular damage because development 
of specific preventive measures may contribute to improved health in long-term TC 
survivors. 
Validated magnetic resonance imaging (MRI) provides an accurate assessment of 
abdominal adipose tissue. Proton magnetic resonance spectroscopy (1H-MRS) allows 
assessment of changes in hepatic triglyceride content reflecting fattening of the liver 
which may occur as a non-specific response of the liver to toxic insults.103 1H-MRS 
has also been shown to offer a suitable technique to measure acute increases in liver 
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triglyceride for instance as a consequence of high calorie intake.104 Indeed, MetS has 
been suggested to be a predictor of NASH or vice versa 105, and acutely induced liver 
changes which can be captured by 1H-MRS could be an early sign of MetS which 
will become clinically manifest years thereafter.61 The use of magnetic resonance–
based assessment of pulse wave velocity (PWV) of the aorta also enables to assess 
vascular stiffness, which has been shown to be related to cardiovascular morbidity 
and mortality.66;67
With increasing numbers of cancer survivors and greater recognition of metabolic 
syndrome, cardiovascular disease and other late effects of chemotherapy, 
investigation of early determinants of sequelae of cancer treatment becomes 
increasingly important. We explored if changes in hepatic triglyceride content, aortic 
PWV, and abdominal visceral and subcutaneous fat volume could be measured 
in testicular cancer patients undergoing curative treatment by using validated 
proton magnetic resonance spectroscopy and magnetic resonance imaging (MRI) 
techniques.
MaTerial and MeThodS
Between 2007 and 2009 patients with metastatic TC scheduled for first-line curative 
cisplatin-based combination chemotherapy in the Department of Clinical Oncology 
were included. The study was approved by the Medical Ethical Committee and all 
patients gave written informed consent to participate in the trial.  Exclusion criteria 
were co-morbidities, including cardiovascular disease, diabetes mellitus and hepatic 
diseases. Of the forty patients asked to participate, twenty-one (52.5%) were not able 
to participate; five (12.5%) for logistic reasons and sixteen (40.0%) had unwillingness 
to undergo frequent blood drawings during chemotherapy (n=13) or MRIs (n=3). 
Nineteen (47.5%) consecutive patients with an otherwise unremarkable medical 
history were included.
Patients received three or four cycles of BEP-combination chemotherapy repeated 
every 3 weeks. Each cycle consisted of intravenously administered etoposide (100 
mg/m2 over 1 hr, days 1-5), cisplatin (20 mg/m2 over 4 hrs, days 1-5), and bleomycin 
(30 IUSP over 30 min) at days 2, 8, and 15. One patient received additional paclitaxel 
(175 mg/m2) on day 1 of each of his 4 chemotherapy cycles. Another patient received 
2 additional courses of vinblastine, ifosfamide and cisplatin (VIP) after his 4 courses of 
BEP. The anti-emetic regimen consisted of intravenously administered granisetron (1 
mg, days 1-5) and high-dose dexamethasone (10 mg, days 1-5), which was tapered 
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according to the schedule oral dexamethasone  2 times 3 mg (days 6-7) and 2 times 
1.5 mg (days 8-9) in most patients.
Patients underwent three measurements, i.e. before, and 3 and 9 months after the 
start of chemotherapy. All patients filled in a form concerning medical history, drug 
use, life style and intoxications. Blood pressure, heart rate, body weight and height 
were recorded and body mass index (BMI, kg/weight2) was calculated. Overweight 
was defined as a BMI>25 kg/m2 and obesity was defined as a BMI >30 kg/m2. 
After an overnight fast, MRI measurements were performed and blood samples 
collected for assessments of lipid profile (total cholesterol, high-density lipoprotein 
cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides), and 
glucose, insulin and glycosylated hemoglobin (HbA1c) using standard assays. 
In addition, serum levels of aspartate transaminase (ASAT), alanine transaminase 
(ALAT), gamma-glutamyl transferase (y-GT), alkaline phosphatase (AP), lactate 
dehydrogenase (LDH) and creatinine were measured. Hormone levels i.e. luteinizing 
hormone (LH), follicle stimulation hormone (FSH), testosterone, estradiol and sex 
hormone binding globulin (SHBG) were also measured. All analytes were measured 
using routine laboratory assays at the Central Laboratories for Clinical Chemistry. 
Insulin resistance was quantified using the homeostatic model assessment (HOMA) 
(insulin (mU/L) * glucose (mmol/L)) / 22.5 106, and insulin resistance was considered 
above the 75th percentile (>94.95 pmol/L).107 Renal function was calculated using the 
Cockcroft formula.
Magnetic resonance measurements
All MRI measurements were performed in the morning after an overnight fast using a 
1.5-T whole-body MRI scanner (Gyroscan ACS/NT15; Philips, Best, The Netherlands). 
Proton Magnetic Resonance Spectroscopy (1H-MRS) of the liver was performed 
with an 8-ml voxel positioned in the liver, avoiding gross vascular structures and 
adipose tissue depots. The 12th thoracic vertebra served as a landmark to ensure 
the same position of the voxel during all measurements. Spectra were obtained 
with an echo time of 26 msec and a repetition time of 3000 msec. A total of 64 
data points were collected using a 1000-Hz spectral width with and without water 
suppression. Spectroscopic data were fitted using validated software (jMRUI version 
2.2; developed by A. van den Boogaart, Katholieke Universiteit Leuven, Leuven, 
Belgium). Hepatic triglyceride content (HTC) was calculated as the ratio of the signal 
amplitude of TGC over the signal amplitude of water x 100%. HTC measurement with 
respiratory navigator has a coefficient of variation of 17.9%.108
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Based on other reported data, we defined a HTC below 6% as normal.109 Abdominal 
visceral and subcutaneous fat volumes were assessed by imaging three consecutive 
transverse slices during one breath hold, with the middle image at a level just above 
the fifth lumbar vertebra. The volumes of the visceral and subcutaneous fat depots 
of all slices were calculated by converting the number of pixels to square centimetres 
multiplied by the slice thickness. The total volume of the fat depots was calculated by 
summing fat volumes of all three slices. 
Aortic pulse wave velocity (PWV) was measured as followed. A retrospective 
ECG-gated gradient-echo pulse sequence with velocity encoding was applied to 
measure through-plane flow at 2 predefined positions in the mid-ascending aorta 
and abdominal aorta just above the bifurcation. Images were analysed with MASS/
FLOW and aortic PWV was calculated as Δx/Δt, where Δx is the path length between 
the two measurement sites and Δt is the time delay between the arrivals of the foot 
of the pulse wave at the respective measurement sites.
For various different logistic reasons including claustrophobia (n=1) and withdrawal 
of informed consent (n=2), chemotherapy-related death due to an acute cerebral 
vascular event, and 1H-MRS measurements hardware problems (n=4), hepatic TGC 
content could not be measured at the 2 time points after start of chemotherapy in 
3 patients, could not be performed at time points 3 months in 2 patients and not at 
time point 9 months in another 2 patients.
Aortic PWV data was available for 16, 14, and 13 patients at baseline, second and 
third measurement respectively. The reasons for missing measurements were largely 
similar as for the hepatic triglyceride measurements, but only three of the 46 aortic 
PWV measurements failed. 
Statistical Analysis
In the text of the result section, data are provided as mean and SD or as median and 
range. To allow the use of all available data, including incomplete profiles, repeatedly 
measured parameters were compared with a mixed model analysis of variance with 
fixed factors time and random factor subject. The analysis of (co)variance and Pearson 
correlations were performed on log transformed data, to correct for the log-normal 
distribution of the data. The variables that could not be analysed parametrically 
because of non-normal distribution were analysed with a non-parametric Friedman 
and Wilcoxon test. The following contrasts were calculated: before chemo vs. 3 
months measurements and vs. 9 months measurements and when applicable the 
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3 months measurement was compared with the 9 months measurement. Estimates 
of differences of the different contrasts and a back transformed estimate of the 
difference in percentage for log transformed parameters, 95% confidence intervals 
(in percentage for log-transformed parameters) and Least Square Means (geometric 
means for log transformed parameters), and the p-value of the contrasts are provided 
in the Tables. All calculations were performed using SAS for windows V9.1.3 (SAS 
Institute, Inc., Cary, NC, USA). A Bonferroni-Holm adjustment for multiple testing was 
made per set of variables for comparison of clinical characteristics and laboratory 
values reported in Tables 2, 3 and 4 and for the MRI results in Table 5.
A Pearson correlation analysis was performed to assess the correlation between 
serum blood concentrations and MRI measurements, and correlations were 
expressed as coefficient r. A p-value of < 0.05 was considered significant. Correlation 
calculations were performed using IBM SPSS statistics version 20 software package.
Table 1. Baseline characteristics of all patients.









demographics (median and 
range)
Age (years) 35 (20-55) 46    (38-55) 29  (20-48) 0.01
Time after orchidectomy (months) 3.1 (0.4-74.6) 26.8 (0.8-74.6) 2.4 (0.4-12.0) NS
Characteristics (mean ± Sd)
Weight (kg) 83.4 ± 14.7 88.7 ± 18.4 81.5 ± 13.4 NS
BMI (kg/m2)c 24.3 ± 3.7 26.1 ± 4.4 23.7 ± 3.3 NS
Renal function (ml/min) 136 ± 39 117 ± 26 143 ± 41 NS
Life style; n (%)
Smoking 3 (15.8) 1 (20.0) 2 (14.3) NS
Alcohol use 2 (10.5) 1 (20.0) 1 (7.1) NS
Tumor Staging; n (%)d NS b
Stage II (regional lymph nodes) 10 (52.6) 2 (40.0) 8 (57.1)
Stage III (distant metastasis) 9   (47.4) 3 (60.0) 6 (42.9)
a  P-value for comparison between values of patients with respectively seminoma and non-seminoma 
testicular cancer (independent-samples Student’s t-test or independent-samples Mann-Whitney 
where appropriate); NS = not significant.
b  P-value for trend for comparison between values of patients with respectively seminoma and non-
seminoma testicular cancer.
c Of the 19 patients, 7 patients (36.8%) were overweight and 1 (5.3%) had obesity.





Baseline characteristics of all 19 patients are shown in table 1. Median age of the 19 
patient was 35 years (range 20 – 55) and median time interval between the study 
and initial diagnosis and prior orchidectomy  was 3.1 months (0.4 – 74.6). Mean 
glomerular filtration rate was 136±39 ml/min. With regard to life style, 3 patients 
(15.8%) were smokers and 2 patients (10.5%) had an alcohol intake of > 20 units/
week. Ten patients were classified as having good-risk and nine as intermediate risk 
metastatic disease according to the International Germ Cell Cancer Collaborative 
Group (IGCCCG). Histopathology of the tumour showed seminoma (26.3%) in five 
patients and non-seminoma (73.7%) in 14 patients. Fourteen patients received 3 
and five patients received 4 courses of BEP chemotherapy. The median (range) 
cumulative dose administered were 270 (120-360) mg for bleomycin, 650 (515-
1000) mg for cisplatin, and 3300 (2550-4200) mg for etoposide. All patients had a 
favourable antitumour response to treatment; one patient developed pulmonary and 
arterial emboli to the cerebrum and spleen after his 2nd chemotherapy course and 
was diagnosed with a hitherto unknown patent foramen ovale and factor-V Leiden 
mutation. 
Anthropometrics
At baseline, 7 patients (36.8%) were overweight and 1 (5.3%) had obesity. Resting 
blood pressure and heart rate did not change during the follow-up period. However, 
on average the patients gained weight and BMI increased from 24.3±3.7 kg/m2 at 
baseline, to 24.7±4.6 kg/m2 (N.S.) and 26.4±4.1 kg/m2 (p<0.001) respectively at three 
and nine months.
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Table 2. Comparison of serum liver enzyme values and body measurements.













9 months vs. 
before 
chemo




24.1 24.4 25.6 <0.001 NS   6.3% 
(3%,  9%) 
  p<0.001





127.9 125.8 123.2 NS NS NS NS
Diastolic RR 
(mm Hg)
77.7 74.7 78.4 NS NS NS NS
Pulse rate (bpm) 65.5 68.9 62.8 NS NS NS NS
ASAT (U/L) 32 28 24 NS NS NS NS
ALAT (U/L) 34 30 27 NS NS NS NS
γ-GT  (U/L) 30 30 25 NS NS NS NS
















Least square mean values, point estimates and 95% confidence intervals for difference to baseline, and 
p-values for contrasts for blood pressure, heart rate, BMI and routine liver chemistry parameters and 
sex steroids in testicular cancer patients before and 3 and 9 months after the start of treatment, i.e. after 
completion of chemotherapy treatment. NS = non significant.
Laboratory investigations
The routine liver chemistry parameters including transaminase, gamma-glutamyl 
transferase remained unchanged at the follow-up moments. In contrast, alkaline 
phosphatase and LDH (also a marker for TC disease activity) were decreased at the 
follow-up measurements (Table 2).
Median serum concentrations of the gonadotrophins LH and FSH markedly 
increased after the start of chemotherapy with serum LH significantly rising from 4.9 
U/L (0.1-20.9) to 13.2 U/L (5.9-30.4; p=0.004) at three months after chemotherapy 
and this increase was sustained at 9 months after chemotherapy (12.5 (8.0-28.5) 
U/L; p=0.003). Similarly, median FSH serum concentrations rose from 7.5 U/L (0.1-




p=0.02 at 9 months. Median serum SHBG was increased at 3 months (31.0 (7.7-
71.4) vs. 58.1 nmol/L (28.5-149.0) p<0.001), but returned to baseline at nine months. 
Testosterone and estradiol, however, remained unchanged (Table 3).
Table 3. Comparison of the prospectively measured serum gonadal hormones.
Parameter Median (min – max) p-values
Before 
chemo





















































<0.001 <0.001 NS <0.001
Median values (minimum-maximum) at three time points with p-value for time profile and p-value for 
paired samples t-test for gonadal hormones in testicular cancer patients before and at 3 and 9 months 
completion of chemotherapy treatment. 
NS = non significant.
Immediately after chemotherapy mean serum total cholesterol (4.88±1.31 vs. 
5.61±1.50 mmol/L; p=0.002) and LDL-cholesterol (3.31±1.16 vs. 3.73±1.4 mmol/L 1; 
p=0.02) significantly increased compared to baseline (Figure 1, Table 4). No significant 
changes were observed in serum triglyceride and HDL-cholesterol concentrations 
(Figure 1, Table 4). LDL-cholesterol remained increased at 9 months (3.31±1.16 vs. 
3.82±1.60 mmol/L; p=0.02), whereas all other lipid parameters returned to baseline 
values at this late follow up time point (Figure 1).
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figure 1. Serum insulin (upper left panel), total cholesterol (upper right panel), LDL-cholesterol 
(lower left panel) and triglyceride (lower right panel) concentrations before, three months and 9 
months after start of chemotherapy. The graphs show a 25th to 75th percentile box, whiskers 
(5th to 95th percentile) with the median, and a mean with the standard error.
Fasting glucose did not significantly change at the time points measured but insulin 
significantly increased at 3 months (5.7±4.4 vs. 9.6±6.3 mU/ml; p=0.03) and thus 
HOMA increased (1.33±1.14 vs. 2.11± 1.77; p= 0.02). After 9 months, insulin and HOMA 
returned to baseline values (Figure 1). Least Square Means estimations showed that 
while serum glucose levels remained constant, insulin and HOMA increased over 
time following institution of chemotherapy (Table 4). These disturbances in glucose 
metabolism did not translate into changes in HbA1c, although C-peptide slightly 
decreased (p=0.04, Table 4). 
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Table 4. Comparison of the prospectively measured serum lipid values and glucose 
metabolism.









3 months vs. 
before chemo
9 months vs. 
before chemo


















1.20 1.30 1.21 NS NS NS NS
Triglyceride
(mmol/L)
1.13 1.29 1.24 NS NS NS NS
Glucose
(mmol/L)
5.0 5.0 5.0 NS NS NS NS
Insulin
(mU/ml)
4.5 6.6 5.2 NS NS NS NS
C-peptide
(mg/L)
0.58 0.71 0.55 NS NS NS -22.4% 
(-39%, -1%) 
 p=0.04




HbA1c (%) 5.1 5.3 5.2 NS NS NS NS
 
Least square mean values with p-value for time profile and point estimates with 95% confidence intervals 
and p-value for contrasts for lipid and glucose metabolism parameters in testicular cancer patients 
before and at 3 and 9 months completion of chemotherapy treatment. NS = non significant.
Magnetic resonance measurements
Before chemotherapy administration all aortic pulse wave velocities were in the 
normal range (4.6±0.7 m/s) and aortic pulse wave velocity did not change over time 
with a mean velocity of 5.0±0.8 m/s at 3 months and 4.7±0.7 m/s at 9 months (Figure 
2, Table 5).
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figure 2. Magnetic Resonance Measurements of subsequently hepatic triglyceride content 
(upper panel, semi-logarithmic), aortic PWV (middle panel) and Visceral Fat Volume (lower 
panel) before, three months and 9 months after start of chemotherapy. The graphs show a 
25th to 75th percentile box, whiskers (5th to 95th percentile) with the median, and a mean 
with the standard error. 
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4.59 4.79 4.62 NS NS NS NS
HTC
(%)
2.41 3.36 2.96 NS NS NS NS
Subcutaneous 
fat volume (ml)










Least square mean values with p-value for time profile and point estimates with 95% confidence intervals 
and p-value for contrasts for magnetic resonance parameters in testicular cancer patients before and at 
3 and 9 months completion of chemotherapy treatment. NS = non significant.
In seven of the 19 (36.8%) patients, three of whom were overweight and one obese, 
1H-MRS showed an increase in hepatic triglyceride content at either 3 or 9 months. 
The largest increase in HCT was observed in 2 of these patients at 9 months; HTC 
increased from 22.3% at 3 months after start of treatment to 43.8% and from 8.7% 
at baseline to 39.8%, respectively. Overall, patients with overweight or obesity had 
significantly higher hepatic triglyceride contents than patients with a normal or low 
BMI (p=0.002). 
Hepatic triglyceride content correlated with serum triglyceride concentration (r=0.43, 
p=0.004) and serum LDL-cholesterol concentration (r=0.30, p=0.05), but not 
with alcohol use. There was no correlation between HTC at 3 and 9 months and 
cumulative dose of chemotherapy drugs (data not shown). 
Mean abdominal subcutaneous fat volume was 556±394 ml at baseline and did 
not change after three months (594±390 ml) but eventually increased to 668±460 
ml (p=0.002) at 9 months. Similarly, abdominal visceral fat volume increased from 
202±141 to 237±153 ml (p=0.009) and 246±170 ml (p=0.05) at 3 and 9 months, 
respectively (Figure 2, Table 5). Increase in visceral abdominal fat volume was 
correlated to serum HDL cholesterol changes (r=-0.62, p=0.05) and increase in BMI 
(r=0.75, p=0.003).
least square means Contrasts
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diSCuSSion
In our cohort of metastatic but otherwise healthy testicular cancer patients, 
significant increases of plasma insulin, insulin resistance, total cholesterol and LDL-
cholesterol, BMI, and a concomitant increase in the volume of the abdominal visceral 
and subcutaneous fat mass were observed within months after chemotherapeutic 
treatment. These measured changes in serum lipid concentrations in combination 
with an increase of visceral fat volume seem to reflect a change in fat metabolism 
during or shortly after chemotherapy administration. Serum gonadotrophins 
increased significantly after chemotherapy while serum testosterone and SHBG 
remained unchanged. No statistically significant changes in HTC or aortic PWV were 
observed. 
To our knowledge, this is the first report on GCT patients undergoing chemotherapy in 
which hepatic triglyceride content was measured using proton magnetic resonance 
spectroscopy. We used a landmark to ensure the same position of the voxel during all 
measurements hepatic TGC content to chemotherapy. Theoretically, the measured 
increase in HTC could be due to focal as opposed to generalized liver fattening, but 
it seems more likely that intravenously administered chemotherapy indeed induces 
generalized steatosis of the liver in susceptible patients. The lack of change in serum 
liver enzymes and other laboratory values at follow-up time points do not suggest the 
presence of a systemic inflammatory state or drug-induced hepatitis.
Intra-individual variation in response of HTC to chemotherapy could result from 
differences between patients with respect to daily caloric intake, e.g. due to 
chemotherapy-associated anorexia and nausea. However, co-administration of 
effective anti-emetics ensured a constant daily caloric intake in all TC patients, thus 
excluding this as a possible explanation for observed intra-individual differences. 
In agreement with observations of Mahmood et al.110, an increase in HTC was 
particularly evident in obese patients, suggesting an inherent difference between 
individuals to respond to toxic agents including alcohol by induction of fattening of 
the liver.111 The small number of patients precludes a firm conclusion about whether 
this finding could result from an a priori increased sensitivity of obese patients to 
develop metabolic abnormalities after chemotherapy.
Interestingly, Qi et al. recently reported their results of serial 1H-MRS measurements 
of hepatic lipids in patients with colourectal cancer over the time course of a 24-week 
chemotherapeutic regimen to determine whether 1H-MRS could be used to monitor 
the progression of chemotherapy-induced steatosis.112 Different cytotoxic agents and 
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routes of administration were part of the chemotherapy regimen employed; some 
patients received intravenously administered agents whereas others underwent 
hepatic arterial infusion with chemotherapy. They observed an increase in the ratio 
of fat to fat+water (FFW) after completion of treatment in approximately half of their 
patients, with both increases and decreases in FFW observed in comparison to 
baseline. Interestingly, also in this study, patients whose 6-week hepatic lipid levels 
had increased significantly relative to baseline had a high probability of lipid elevation 
relative to baseline at the completion of treatment.
In contrast with earlier documentation, mean serum testosterone after 
chemotherapeutic treatment remained unchanged in our small population of GCT 
patient. However, serum estradiol and gonadotrophins increased significantly, 
reflecting at least partial hypogonadism.  The increase in serum estradiol could 
be the result of an increased tissue aromatization of testosterone in body fat. 
Chemotherapy-induced (partial) hypogonadism, which may persist for more than 
2 years in approximately two third of TC patients, has been supposed to contribute 
to unfavourable changes in fat and glucose metabolism, obesity and ultimately to 
the development of MetS. We assessed an acute chemotherapy-induced increase 
in visceral and subcutaneous fat volume, dyslipidemia evidenced by increases in 
serum total cholesterol and LDL-cholesterol, and insulin resistance. These early 
increases in body weight, visceral and subcutaneous fat volume, together with 
the dyslipidemia and insulin resistance observed shortly after chemotherapy may 
potentially also contribute to the reported increased prevalence of MetS and CVD in 
long-term TC survivors.  Increased abdominal visceral fat has indeed been repeatedly 
shown to correlate with a complex of pro-diabetic and pro-cardiovascular disease 
characteristics supporting this hypothesis 72. An additional factor that may affect 
the fat metabolism is the use of corticosteroids as part of the antiemetic regimen 
administered concomitantly with chemotherapy.  
We could not demonstrate any significant changes in vascular stiffness as measured 
by aortic PWV. This is surprising because chemotherapy like cisplatin, bleomycin 
and paclitaxel have all been reported to acutely cause endothelial damage in vitro, 
in animal models and in TC patients 63;113 suggesting that  chemotherapy-induced 
endothelial damage could potentially result in an immediate increase in vascular 
stiffness, aortic PWV blood pressure and heart rate. Also, high blood glucose levels 
and insulin resistance have been found to be associated with vascular stiffness 
suggesting that hyperglycemia plays an important role in the pathogenesis of 
atherosclerosis and cardiovascular complications.114 Short term changes in aortic 
PWV could also result from a disbalance between sympathetic and parasympathetic 
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nerve activity.115 The lack of significant change in aortic PWV suggests that either 
more time may be required to develop vascular stiffness or that long term vascular 
abnormalities reported in testicular cancer survivors 27;29 are not accompanied by 
aortic wall stiffness. We cannot exclude a vascular effect due to the relatively small 
number of patients or because we used the wrong test to measure vascular changes. 
Another possibility is that more endothelial damage was induced by administration 
of chemotherapy than could be measured as acute vascular resistance with aortic 
PWV measurements.
This prospective single centre study has strengths and weaknesses, one of the 
limitations being the number of patients in this exploratory study testing feasibility 
of 1H-MRS measurements in patients undergoing chemotherapy. We did not 
perform 1H-MRS at similar time points in healthy controls, who did not undergo 
chemotherapy, but instead used patients as their own controls. Randomization of 
patients between chemotherapy and placebo infusions would not be ethical. The 
design of the study thus precluded to differentiate between effects of treatment and 
time. Although chemotherapy is most likely the culprit of observed insulin resistance, 
dyslipidemia and immediate increase in abdominal visceral and subcutaneous 
adipose tissue in individual patients, we cannot differentiate between effects 
mediated by chemotherapy or changes in life style, food intake or corticosteroids (as 
part of the anti-emetic regimen).  
It is known that high dose steroids may cause acute, transient periods of 
hyperglycaemia.116 Consequently, we consider it likely that steroid-induced changes 
in glucose homeostasis were present during the first half of each chemotherapy 
course, but we have no evidence that these effects persisted far beyond this episode, 
when we performed our assessments. Thus, although we cannot fully exclude the 
influence of steroids on glucose homeostasis, the time interval between last steroid 
dose and time point of blood measurements suggests that chemotherapy with 
its more profound inflict on the body’s defence mechanisms to be the more likely 
culprit of the observed insulin resistance. The disadvantage of not being able to 
unequivocally exclude the contribution of corticosteroids, or changes in lifestyle and 
food intake is off-set by the benefits of performing our research in routine clinical 
practice. Furthermore, we used aortic PWV as a surrogate for vascular stiffness 
instead of measuring endothelial damage itself, this could possibly result in an 
underestimation of the toxic effect of chemotherapy on the endothelial wall.
The exploratory nature of the study and the complex -if not impossible- logistics of 
more frequent MRI measurements in patients who required fixed accepted standard 
schedules of chemotherapy during several subsequent days, precluded assessment 
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at more frequent time points. From an oncological point of view, deviation from 
accepted curative chemotherapy schedules precluded measurements during the 
daily long hours of fixed chemotherapy infusions.
In conclusion: Standard treatment of testicular cancer patients with BEP 
chemotherapy immediately results in insulin resistance and dyslipidemia and – most 
strikingly in obese patients – an increase in liver triglyceride content. The concomitant 
increase in abdominal subcutaneous and visceral fat volume suggests that indeed 
chemotherapy acutely affects insulin sensitivity and fat distribution. This implies that, 
already early after treatment, GCT patients should be screened and subsequently 
treated for cardiovascular risk factors. Although long term TC survivors are at risk 
for hypertension and increased cardiovascular disease, vascular changes cannot be 
captured by aortic pulse wave velocity measurements within one year after cisplatin-
based chemotherapy. Prospective studies in larger groups of testicular cancer 
patients will enable to demonstrate if early changes in serum profiles reflecting fat and 
glucose metabolism and abdominal and hepatic fat content occur more frequently 
in subsets of patients, relate to individual sensitivity to respond to insults inflicted by 
chemotherapy and whether they predict for metabolic abnormalities in long-term 
survivors of testicular cancer.
Metabolic changes in GTC patients treated with chemotherapy
57

  Chapter 4 
Chemotherapy for testicular cancer induces acute 
alterations in diastolic heart function
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Purpose: After treatment with cisplatin-based chemotherapy for testicular cancer 
(TC), patients have a higher prevalence of cardiovascular complications after long-
term follow up. Little is known about acute cardiovascular effects of chemotherapy. 
Therefore, the purpose of the present study was to explore short-term effects of 
chemotherapy on cardiac function, using magnetic resonance (MR) techniques in 
patients treated for TC.
Methods: Fourteen TC patients (age 34.6 ± 12.3 years) were studied before and 
early after treatment with cisplatin-based chemotherapy. Assessment of cardiac 
function was performed with MRI. Serum glucose and insulin were measured after 
an overnight fast and insulin sensitivity, reflected by the Quicki index, was calculated.
results: At baseline and 3 months after start of the chemotherapy patients 
underwent MRI examination. Left ventricular (LV) end diastolic volume and LV stroke 
volume significantly decreased from 192.3 ± 26.8 ml to 174.7 ± 25.7 ml (p<0.05) and 
108.8 ± 17.6 ml to 94.7 ± 16.3 ml (p<0.05) respectively. The ratio of early (E) and atrial 
(A) filling velocities across the mitral valve (E/A ratio), a parametre of diastolic heart 
function, was significantly decreased after chemotherapy from 1.87 ± 0.43 to 1.64 ± 
0.45, p<0.01. After chemotherapy metabolic parameters were unfavorably changed, 
reflected by a significantly decreased Quicki index, which reduced from 0.39 ± 0.05 
to 0.36 ± 0.05 (p<0.05).
Conclusions: Chemotherapy for testicular cancer induces acute alterations in 
diastolic heart function, paralleled by unfavorable metabolic changes. Therefore, 
early after chemotherapy, metabolic treatment may be indicated to possibly reduce 
long-term cardiovascular complications.
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inTroduCTion
Testicular cancer (TC) is the most frequent form of cancer in young men. The 
prognosis of TC is good, with high cure rates since the introduction of treatment with 
cisplatin-based chemotherapy.74 Because of the increasing number of survivors with 
a long life expectancy, understanding and prevention of short-term and long-term 
cardiovascular effects of chemotoxicity is very important.
Treatment of TC with cisplatin, bleomycin and etoposide (BEP) combination 
chemotherapy is associated with acute vascular toxicity and subacute changes in 
cardiac function 98;117, as well as with long-term cardiovascular disease.28;29;47 Previous 
studies showed that cisplatin and bleomycin induce alterations in endothelial 
function and endothelial damage in vitro.62;63 These findings suggest direct toxic 
effects of chemotherapy on the cardiovascular system. Little is known about acute 
effects of cisplatin-based chemotherapy on cardiac function. More insight in the 
pathophysiology of the direct toxic effect of cisplatin-based chemotherapy on cardiac 
function and vessel wall is relevant to possibly prevent long-term cardiovascular 
disease. One previous study reported sub-acute deterioration of diastolic function, 
assessed with echocardiography ten months after cisplatin-based chemotherapy.117
Indirect effects of chemotherapy also seem to play a role in the increased risk of 
cardiovascular complications. For example, early after treatment with cisplatin-
based chemotherapy changes in serum lipids have been described.117 Additionally, 
higher incidences of hypercholesterolemia, hypertension, microalbuminuria, obesity, 
elevated insulin-glucose ratio, and thereby metabolic syndrome have been reported 
at least three years after chemotherapy.118-120 The acute effects of chemotherapy, 
defined as effects occurring three months after start of chemotherapy, on these 
risk factors are largely unknown. The aforementioned indirect risk factors are all 
independently associated with a higher risk of cardiovascular disease and may 
contribute to the overall increased risk of cardiovascular complications after treatment 
with cisplatin-based chemotherapy. The increased risk of cardiovascular disease in 
cured TC patients after cisplatin-based chemotherapy is probably a combination of 
direct and indirect effects of chemotherapy.74;120 Early changes in cardiac function and 
risk factors may have prognostic value for long-term development of cardiovascular 
complications.121 Magnetic resonance (MR) imaging is a highly reproducible imaging 
modality to assess cardiac function. Furthermore, myocardial triglyceride (TGC) 
content can be measured with proton magnetic resonance spectroscopy (1H-MRS).122 
Additionally, abdominal visceral and subcutaneous fat volume can be accurately 
assessed with MRI.123 Therefore, the purpose of this study was to investigate acute 
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changes in cardiac function and myocardial TGC, in relation to body fat distribution 
and metabolic parameters three months after start with chemotherapy for TC, 
assessed with MR-techniques.
MaTerialS and MeThodS
This study was approved by the local medical ethics committee and all subjects gave 
written informed consent. Metastatic TC patients, scheduled for first-line curative 
cisplatin-based combination chemotherapy in the Leiden University Medical Center 
were included between 2007 and 2009. Exclusion criteria were co-morbidities, 
including cardiovascular disease and diabetes mellitus.
Patients received three or four cycles of standard BEP-chemotherapy repeated every 
3 weeks. Each cycle consisted of intravenously administered etoposide (100mg/m2 
over 1 hr, days 1-5), cisplatin (20mg/m2 over 4 hr, days 1-5), and bleomycin (30 IUSP 
over 30min) at days 2, 8, and 15. According to Dutch oncological guidelines, TC 
patients with good prognosis were treated with three cycles of BEP and patients with 
intermediate prognosis were treated with four cycles BEP. One patient, in addition 
received paclitaxel (175mg/m2) on day 1 of each of his 4 chemotherapy cycles as 
part of a randomized phase III study comparing paclitaxel-BEP and standard BEP 
in patients with intermediate prognosis TC. All patients were orchidectomized before 
adjuvant chemotherapeutic treatment.
BMI was determined at baseline and after chemotherapy. Fasting serum glucose, 
insulin, total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein 
(LDL) and triglycerides were determined. Insulin resistance was assessed with the 
quantitative insulin sensitivity index (Quicki index), which is calculated using the 
formula: 1 / (log(fasting insulin µU/mL) + log(fasting glucose mg/dL)).124 Renal function 
defined as estimated glomerular filtration rate was calculated with the Modification 
of Diet in Renal Disease (MDRD) equation: 186 * (serum creatinine µmol/L / 88,4)-1.154 
x (age)-0.203.
Patients underwent MRI before start and shortly after the last chemotherapy cycle, 
which was approximately three months after start of chemotherapy. Blood pressure 
and heart rate were measured during MRI using a semiautomated sphygmomanometre 
(Dinamap, Critikon, Tampa, Fla, USA). We have included part of a studygroup from 
a previous study, describing metabolic changes and MRI assessment of hepatic 
triglyceride content, aortic pulse wave velocity and abdominal fat mass in TC patients 
undergoing curative chemotherapy at 3 and 9 months after start of chemotherapy.125
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MRI protocol
Left and right ventricular function
Cardiac imaging was performed using a 1.5 Tesla whole-body MRI scanner (Gyroscan 
ACS-NT15; Philips Medical Systems, Best, The Netherlands) after a night fast. The 
heart was imaged in short-axis orientation, using electrocardiographically gated 
breath-hold cine steady-state free-precession sequences as previously described.126 
Imaging parameters were: repetition time (TR) 3.4ms, echo time (TE) 1.7ms, flip angle 
(FA) 35º, field of view (FOV) 400×320mm, slice thickness 10mm, no slice gap was 
used. To assess LV and RV systolic function, endocardial contours were manually 
drawn, using MASS® software (Medis, Leiden, The Netherlands). LV and RV ejection 
fraction (EF), stroke volume (SV), end-diastolic volume (EDV) and end-systolic volume 
(ESV) were assessed. Epicardial contours of the LV were drawn to calculate LV end-
diastolic mass (LVED mass).
To assess LV and RV diastolic function, flow across mitral and tricuspid valve 
was measured using an electrocardiographically gated gradient echo sequence 
with velocity-encoding. Scan parameters: TR=9.1ms, TE=1.0ms, FA=20º, slice 
thickness=8mm, FOV=350mm2 and matrix=256x256 pixels. Flow velocities in early 
diastole (E) and at atrial contraction (A) were measured and peak flow ratio was 
calculated (E/A ratio) using FLOW® software (Medis, Leiden, The Netherlands). The 
downslope of the early filling phase (E deceleration peak) and LV filling pressures (E/
Ea) were calculated.127;128
Myocardial triglyceride content
Myocardial 1H-MR spectra were obtained as described before.122 A voxel was 
positioned in the myocardial interventricular septum in end-systole. An ECG 
triggering and a respiratory pencil beam navigator were used during acquisition. 
Spectra with water suppression were acquired with TE=26ms and TR≥3,000ms. 
1,024 data points were collected using a 1,000-Hz spectral width and averaged over 
128 acquisitions. Spectra without water suppression with TR=10s and four averages 
were obtained without changing other parameters. Spectroscopic data were fitted 
using validated software (jMRUI version 2.2, Leuven, Belgium).129 Myocardial TGC 




Pericardial fat was quantified as described previously using electrocardiographically 
gated breath-holds with balanced turbo-field echo MR sequence.130 Imaging 
parameters: TR=3.2ms, TE=1.60ms, FA=50°, slice thickness=10mm, FOV=400mm2. 
The four-chamber view was analysed, with the plane of respiratory mitral and 
tricuspid valves as margins. To quantify periventricular fat volume, contours around 
pericardial fat were drawn manually at end-systole and multiplied by the thickness of 
the slice. We used MASS® for postprocessing. 
Visceral and subcutaneous fat
Visceral and subcutaneous fat volumes were imaged using a turbo spin echo 
imaging sequence.123 During one breath-hold, three consecutive transversal slices 
of 10mm thickness were scanned at the fifth lumbar vertebrae. Imaging parameters: 
TR=168ms, TE=11ms and FA=90º. Contours were drawn around visceral and 
subcutaneous abdominal fat depots using MASS®. Visceral and subcutaneous fat 
areas of each slice were multiplied by the slice thickness to acquire a volume and the 
volumes of all three slices were summed. 
Statistical Analysis
Statistical analyses were performed using SPSS 17.0 (SPSS Inc.Chicago, Illinois, 
USA). We used two-tailed paired t-tests to compare the two study timepoints, 
since all data were normally distributed. To determine which significantly changed 
parameters influenced the differences of the other cardiac parameters, univariate 
regression analyses were performed. In these regression analyses the delta of 
the significantly changed parametre (the difference of the parametre before and 
after chemotherapy) was the independent variable and the delta of the cardiac 
parametre of interest was the dependent variable. In case of a significant influence 
the corrected difference between baseline and follow-up was extracted from the 
regression analysis. A P-value of < 0.05 was considered statistically significant. Data 
are expressed as mean±standard deviation (SD).
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reSulTS
Forty consecutive patients were asked to participate. Twenty-one patients could not 
participate, based on logistic reasons (N=5), refusal or non-eligibility (N=16). These 
patients had unwillingness to undergo frequent blood drawings during chemotherapy 
or MRI. Nineteen patients underwent baseline MRI. Five patients missed the follow-up 
MRI due to treatment-related sickness (N=2), study withdrawal (N=2) and treatment-
related death (N=1). Accordingly, 14 patients were included in data analysis of the 
present study. Three HDL-concentrations and 1 insulin-concentration were missing. 
Four patients (28.6%) had a seminoma, two patients (14.3%) a non-seminoma and 
eight patients (57.1%) had a combined tumor. Seven patients (50%) had para-aortic 
lymph node metastasis (stage II) and the other half of the patients had distant 
metastasis (stage III). Table 1 shows the patient characteristics at baseline and after 
chemotherapy. Average age was 35±12 years. Average time between the two MRI 
scans was 2.6±0.5 months. Time between the last day of chemotherapy and the 
MRI after chemotherapy was 18±18 days. Weight, BMI and blood pressure did not 
change during follow-up. Heart rate increased significantly from 64±9 beats per 
minute to 76±15 beats per minute (p=0.007). Laboratory parameters at baseline and 
at follow-up are described in Table 2. The Quicki index decreased, from 0.39±0.05 
to 0.36±0.05 (p=0.02), reflecting greater insulin resistance. 
Table 1. Patient characteristics at baseline and after chemotherapy.
Parameters
mean±Sd
baseline after chemotherapy p-value
Systolic blood pressure (mmHg) 123 ± 17 118 ± 11 NS
Diastolic blood pressure (mmHg) 73 ± 11 70 ± 12 NS
Heart rate (bpm) 64 ± 9 76 ± 15 0.007
Weight (kg) 83.3 ± 15.5 84.5 ± 18.5 NS
Body Mass Index (kg/m²) 24.4 ± 4.0 24.7 ± 4.6 NS
Cholesterol (mmol/l) 4.7 ± 1.3 5.5 ± 1.5 < 0.01
Estimated GFR ( ml/min) 102 ± 16 113 ± 18† < 0.01
HDL (mmol/l) 1.30 ± 0.31 1.36 ± 0.25 NS
LDL (mmol/l) 3.12 ± 1.15 3.74 ± 1.41 < 0.05
Triglycerides (mmol/l) 1.16 ± 0.60 1.64 ± 1.11 NS
Fasting glucose (mmol/l) 5.1 ± 0.5 5.2 ± 0.6 NS
Insulin (mU/l) 6.2 ± 5.0 9.8 ± 6.8 NS
Quicki index 0.39 ± 0.05 0.36 ± 0.05 0.02
NS = not significant.
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Left and right ventricular function
Due to technical difficulties two diastolic LV and RV scans and one systolic RV were 
missing. LV EDV and SV significantly decreased, respectively from 192±27ml to 
175±26ml (p=0.01) and from 109±18ml to 95±16ml (p=0.03) (Table 3). Although LV 
EDV and SV were significantly influenced by the increased heart rate, the difference 
between baseline and follow-up remained significant after correction for heart rate. 
The other systolic LV parameters did not change after chemotherapy (Table 3). 
LV E/A ratio decreased significantly after chemotherapy from 1.87±0.43 to 1.64±0.45 
(p=0.009). In addition, the atrial peak filling rate increased significantly after 
chemotherapy. The LV E/A ratio and the atrial peak filling rate were not significantly 
influenced by the increased heart rate, thus correction for heart rate was not required. 
Other LV diastolic function parameters did not change after chemotherapy. 
Right ventricular EDV and SV decreased significantly, from 210±32 ml to 196±32 
ml and from 105±14 (p=0.01) to 93±16 (p=0.04) respectively. Both parameters were 
influenced by the increased heart rate. After correction for heart rate the difference 
between baseline and follow-up remained statistically significant. All other RV 
parameters, systolic or diastolic, remained unchanged after chemotherapy (Table 2). 
Table 2. Parameters of myocardial function, assessed with MRI at baseline and after cisplatin-
based chemotherapy in TC patients.
left Ventricle right Ventricle
Baseline After 
chemotherapy




EDV (ml) 192 ± 27 175 ± 26 0.01 210 ± 32 196 ± 38 0.01
ESV (ml) 84 ± 16 80 ± 14 NS 105 ± 29 103 ± 25 NS
SV (ml) 109 ± 18 95 ± 16 0.03 105 ± 14 93 ± 16 0.04
CO (ml/min) 6816 ± 1112 7050 ± 1160 NS 6595 ± 927 6976 ± 851 NS
EF (%) 56.6 ± 5.3 54.3 ± 5.1 NS 49.9 ± 6.7 47.9 ± 4.6 NS
diastolic function
E peak filling rate (ml/s) 657 ± 119 662 ± 122 NS 415 ± 55 406 ± 60 NS
E deceleration  
(ml/s²x10-³)
6.3 ± 2.2 6.0 ± 1.7 NS 3.7 ± 1.9 3.0 ± 1.2 NS
A peak filling rate (ml/s) 362 ± 78 425 ± 111 NS 311 ± 57 325 ± 100 NS
E/A-peak ratio 1.87 ± 0.43 1.64 ± 0.45 0.009 1.37 ± 0.25 1.32 ± 0.31 NS
E/Ea 6.8 ± 2.0 6.8 ± 2.0 NS ~ ~
NS = not significant.
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Fat distribution
Baseline and follow-up data from eight myocardial 1H-MR spectra were present. 
Myocardial triglyceride content did not significantly change after chemotherapy; at 
baseline TGC content was 0.69±0.41% and after chemotherapy TGC content was 
0.74±0.35%. Pericardial fat volume did not change significantly after chemotherapy; 
27.0±3.9ml at baseline and 28.1±5.5ml early after chemotherapy.
One waist fat MRI scan was missing. Visceral fat volume increased significantly 
from 186±125ml to 227±162ml (p=0.04), whereas subcutaneous fat volume did not 
change. The visceral/subcutaneous fat ratio did significantly increase from 0.38±0.11 
to 0.42±0.12 (p=0.03).
diSCuSSion
The main finding of this study is that LV diastolic function is decreased 3 months 
after start of cisplatin-based chemotherapy for TC. Decreased diastolic function was 
accompanied by an unfavorable change in metabolic profile as measured by increased 
serum LDL and total cholesterol and decreased insulin sensitivity. Additionally, 
visceral fat volume and visceral/subcutaneous fat ratio increased. Several studies 
reported increased cardiovascular risk factors, increased incidence of cardiovascular 
disease and diminished cardiac function as long-term complications in TC patients 
within years after treatment with cisplatin-based chemotherapy.27;29;121;131;132 Only 
few studies report on the (sub-)acute cardiovascular effects of cisplatin-based 
chemotherapy.63;117;133 To the best of our knowledge we are the first to investigate the 
acute effects of chemotherapy on cardiac function. Altena et al. showed deterioration 
of diastolic heart function assessed with echocardiography approximately 10 months 
after chemotherapy.117 In contrast, we assessed cardiac function immediately after 
completion of chemotherapy. 
In the present study the LV E/A ratio decreased, reflecting deterioration in diastolic 
LV function. Since the E/A ratio is load dependent and thus influenced by the filling 
status of the patient, an estimation of LV filling pressure was determined (E/Ea) 128, 
which did not change after chemotherapy. Therefore, the decreased E/A ratio after 
chemotherapy presumably reflects disturbed intrinsic relaxation of the LV, rather than 
change in LV filling pressure. A previous study showed progressive deterioration of 
diastolic heart function, 10 months and 6.9 years after cisplatin-based chemotherapy 
49. Therefore, acute changes in diastolic function observed in the present study might 
be of prognostic clinical significance. Long-term follow-up data of our patient group 
would be interesting to have some information of the predictive value of these early 
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cardiac changes. LV ejection fraction (LVEF), an important parametre of systolic 
function, did not change. Change in LV diastolic function with preserved LVEF after 
treatment with cisplatin-based chemotherapy is in line with previous studies.117;121;132 
It is known that diastolic dysfunction precedes a decline in systolic function and 
can be regarded as an important prognostic marker of ongoing disease.63;129 For 
future studies it would be interesting to combine echocardiography with cardiac 
MRI, since previous studies suggest that early impairment of systolic function may 
also be detected using strain echocardiography and that it could be predictive of 
subsequent reduction in LVEF.134 Furthermore, in further studies biomarkers such as 
N-terminal pro-brain natriuretic peptide and troponin I could be determined, because 
determination of these biomarkers may be useful in evaluation of early cardiac 
toxicity.134
Cisplatin can directly injure cardiomyocytes through oxidative stress and 
mitochondrial damage.135 Additionally, cisplatin and bleomycin cause decreased 
endothelial cell survival and induce apoptosis of endothelial cells in vitro.63 These 
endothelial changes may promote inflammation and atherosclerosis, which can 
contribute to chemotherapy-induced vascular toxicity. In addition, endothelial cells at 
the endocardium play an obligatory role in maintaining cardiac function.136 Cisplatin-
based chemotherapy may also indirectly lead to cardiovascular disease, via increased 
prevalence of cardiovascular risk factors.29;61 Increased prevalence of cardiovascular 
risk factors, such as dyslipidemia, central obesity and insulin resistance, can lead 
to accelerated atherosclerosis.135 In this study the follow-up time is presumably too 
short for these indirect effects of chemotherapy to contribute to impaired cardiac 
function. We could not establish a direct relationship between cardiac function and 
metabolic profile. However, already 3 months after start of chemotherapy, we identify 
a shift to an unfavorable metabolic profile: visceral fat volume, visceral/subcutaneous 
fat ratio, LDL-cholesterol and total cholesterol were increased and insulin sensitivity 
decreased. Visceral fat is more deleterious than subcutaneous fat and is associated 
with the metabolic syndrome and cardiovascular disease.61;137;138 The metabolic 
syndrome consists of a cluster of risk factors: dyslipidemia, hypertension, central 
obesity and insulin resistance. This syndrome is associated with a long-term 
increased risk for atherosclerotic disease 61;79, with cardiovascular disease as one of 
the major complications. Via insulin resistance and the concomitant increased release 
of adipokines such as resistin, the metabolic syndrome is associated with endothelial 
dysfunction.139 High C-reactive protein (CRP) levels are associated with the metabolic 
syndrome and endothelial dysfunction.120 In this study we did not measure CRP levels 
unfortunately, but in subsequent studies these levels should be measured. A recent 
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study showed that the metabolic syndrome is more prevalent and develops at earlier 
age in TC survivors, treated with cisplatin-based chemotherapy 49. Visceral adipose 
tissue contributes to insulin resistance 138, which is associated with decreased 
cardiac function 118;140;141, even in absence of diabetes mellitus 119;142. In the metabolic 
syndrome, insulin resistance and (visceral) adiposity is correlated with myocardial 
TGC accumulation, which might negatively influence cardiac function.143;144 In this 
study we did not find a difference between myocardial TGC content before and after 
chemotherapy. The number of measurements of myocardial TGC (N=8) content is 
probably too small to draw firm conclusions regarding myocardial TGC changes 
early after chemotherapy. Another explanation could be that the follow-up period is 
too short, so the oxidative capacity of the myocardium is still sufficient, preventing 
storage of TGC in the myocardium.
Diastolic cardiac function progressively deteriorates in TC survivors treated with 
cisplatin-based chemotherapy.121 Subclinical changes in cardiac diastolic function 
may therefore precede late clinical dysfunction. If these early changes are predictive 
for later abnormalities in cardiac function, such changes may be used to monitor 
patients more specifically. Furthermore, patients treated with cisplatin-based 
chemotherapy are at increased risk of developing an unfavorable cardiovascular-risk 
profile, which can contribute to development of long-term cardiac failure. Accordingly, 
early detection of risk factors for cardiovascular disease is important, as treatment 
of the unfavorable metabolic changes with lifestyle intervention or medication can 
contribute to an improved long-term prognosis in patients treated with cisplatin-
based chemotherapy. 
In conclusion, treatment with cisplatin-based chemotherapy for TC induces acute 
alterations in diastolic cardiac function, paralleled by unfavorable metabolic changes. 
Although the predictive significance of the diastolic cardiac changes for long-term 
cardiovascular morbidity is not clear at present, it seems plausible that they may 
eventually lead to overt cardiovascular disease. As the detrimental metabolic 
changes can contribute to the development of cardiovascular disease, these risk 
factors should be monitored and treated if necessary.
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introduction: Iron overload can result in widespread organ dysfunction. 
Chemotherapy has been reported to induce a rise in serum iron. We aimed to assess 
the kinetics of serum iron and non-protein bound (“free”) iron (NBPI) in patients with 
germ-cell tumours (GCT) during curative chemotherapy. 
Methods: We studied 26 metastatic GCT patients (median age 39 years) undergoing 
cisplatin-based chemotherapy; 23 received  BEP (cisplatin 20 mg/m2 day 1-5, 
etoposide 100 mg/m2 day 1-5, bleomycin 30 mg/m2 day 2, 8 and 15; q 21d), 2 
also received Paclitaxel (175mg/m2 on day 3) and one patient received cisplatin 
and etoposide. Two baseline and 35 serial blood collections for iron parametre 
measurements were performed in 26 patients during the first and in 20 patients 
during the second chemotherapy cycle. 
results: Twenty-four hours after start of chemotherapy, serum iron (20±9 vs. 42±12; 
p<0.001) and NPBI (0.7±0.4 vs. 1.4±0.5; p<0.001) increased two-fold, whereas iron 
binding capacity (30±10 vs. 4±3; p<0.001) markedly decreased. Iron status remained 
unchanged between days 2-8. Ferritin increased two-fold after the first chemotherapy 
cycle, but serum transferrin remained unchanged.
Conclusions: These data indicate that chemotherapy treatment in metastatic 
GCT patients results in a steep rise in serum iron, full saturation of transferrin and 
appearance of highly toxic non-transferrin bound iron.  Further studies are warranted 
to establish the role of chemotherapy-associated iron overload and short- and long-
term chemotherapy-related toxicity in GCT patients.
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inTroduCTion
Iron is essential for many physiological processes and the amount in the human body 
is determined by the iron entering the circulation from the gut, whereas there is no 
physiological mechanism for excretion of excess iron. However, excess iron can lead 
to severe tissue damage by promoting the generation of reactive oxygen species 
by the Fenton reaction. The safe sequestration of such metals in non-redox-active 
forms, restricting the availability of catalytic iron ions in vivo, can be regarded as a 
component of the antioxidant defence network, this component being particularly 
important in the extracellular milieu. Iron homeostasis is tightly controlled and slight 
disturbances of iron metabolism will readily lead either to iron deficiency or to iron 
overload.
About two-thirds of body iron is found in hemoglobin, with smaller amounts in 
myoglobin, and various enzymes. Iron is also stored in ferritin, which can accommodate 
up to 4,500 atoms of iron.145  Normally, only one third of transferrin is saturated with 
iron and the amount of “free” iron available in the serum is expected to be zero.  Iron 
sequestration may be regarded as a contribution to antioxidant defences and by 
using transport proteins, e.g. transferring, and storage proteins, e.g.  ferritin, the size 
of the intracellular iron pool is minimized to prevent organ damage.
When the iron-binding capacity of transferrin and other iron transport proteins in the 
serum of iron-overloaded patients is exceeded, redox reactive non-protein bound 
iron (NPBI), often referred to as non-transferrin bound iron (NTBI), or ”free” iron, 
enters the circulation and becomes detectable 146-149 leading to a cascade of oxidative 
damage.59 The consequences of inability to dispose of excess iron are seen in iron 
overload following multiple blood transfusions and in idiopathic hemochromatosis. 
Clinical sequelae of transfusional iron overload has been shown to result in iron 
accumulation in the liver and other organs, leading to cardiac, pancreas, and pituitary 
dysfunction 150, a pattern of organ dysfunction similar to idiopathic hemochromatosis.
Also, experimental iron overload in animals was shown to result in oxidative cellular 
damage 56;57, manifested by vascular, renal and liver damage 58. Animal data support 
a link between iron and atherosclerosis151 whereas treatment of the animals with the 
iron chelator desferrioxamine has shown to delay the onset of both iron accumulation 
and atherosclerosis.152
Tissue injury also liberates catalytic metal ion and cells sense iron levels and 
subsequently respond by production of iron-sequestrating proteins, e.g. ferritin. Also 
during chemotherapy, release of iron as a result of cell injury has been observed 
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resulting in saturation of plasma transferrin and the appearance of non-protein bound 
iron in the circulation.55 Release of iron may not have been recognized up till now as 
a side effect of standard chemotherapy regimens in cancer patients.
The prognosis of patients with germ-cell tumours (GCT) has become excellent since 
the introduction of cisplatin-based chemotherapy, with cure achieved in the vast 
majority of patients with metastatic disease.21;153 Chemotherapy administered to 
these relatively young cancer patients is associated with acute as well as long-term 
toxicity, such as potentially life-threatening venous thrombo-embolic and arterial 
vascular complications during chemotherapy in about ten percent of patients, 
and an increased risk of cardiovascular disease and other late sequellae in long-
term GCT survivors.21;28;153;154 The aim of the current study was to investigate the 
kinetics of serum iron parameters in a homogenous group of male metastatic GCT 
patients receiving curative chemotherapy. These results may provide further insight 
in potential mechanism of treatment-related toxicity and tissue damage.  
MaTerial and MeThodS
Study Design
Between 2007 and 2009, we prospectively studied 26 metastatic GCT patients aged 
18 to 58 years (median age 38 years), referred to the Department of Clinical Oncology 
of the Leiden University Medical Center for first-line cisplatin-based combination 
chemotherapy (Table 1). During the same period 14 patients could not participate for 
logistic reasons or non-eligibility. Twenty-three patients had a favorable prognosis, 
and 3 patients had an intermediate risk using the IGCCCG Classification 155. Exclusion 
criteria were concomitant use of medication with known anti-oxidative activity, 
active cardiovascular diseases not related to the current malignancy, and elevated 
transaminases above three times the upper limit of normal. The majority of patients 
had an unremarkable medical history and no co-morbidity; one patient had a history 
of hypothyroidism and diabetes mellitus requiring oral medication and presented 
with venous thrombosis of pelvic veins as a result of local compression by lymph 
node metastases. Three patients used medication for mild hypertension. One patient 
received adjuvant single dose carboplatin (AUC7) for stage one seminoma 8 years 
before the start of BEP chemotherapy. Patients did not receive blood transfusions 
before chemotherapy or during chemotherapy.
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Table 1. Demographics and tumour characteristics.
demographics (median, min - max)
Age (years)  38.4 (18.4 -57.7)
Δ Time after orchidectomy (years)  0.1 (0.01-8.1)
Characteristics (mean ± Sd)
Height (m)  1.83 ± 0.08
Weight (kg)  85.7 ± 12.2
BMI (kg/m2)  25.4 ± 3.2
Systolic blood pressure (mmHg)  137  ± 20
Renal function (Cockroft clearance ml/min)  138  ± 34
life style; n (%)
Smoking (packyears)  9 (34.6)
Alcohol use (>20 U/week)  5 (19.2)
histology; n (%)
Seminoma 12 (46.1)
Non-seminoma  8 (30.8)
Combined tumour  6 (23.1)
TnM Tumour Staging; n (%)
Stage II (para-aortic lymph node metastasis) 16 (61.5)
Stage III (distant metastasis) 10 (38.5)
Dependent on the prognostic risk group, 23 patients were scheduled to receive 3 or 
4 courses of 3-weekly BEP chemotherapy consisting of intravenously administered 
etoposide (100 mg/m2 over 1 hr, days 1-5), cisplatin (20mg/m2 over 2 hr, days 1-5), 
and bleomycin (30 IUSP over 30 min), days 2, 8, and 15 (Figure 1). Two patients in 
addition received paclitaxel, 175 mg/m2 on day 1). One patient, a sport diver, did not 
receive bleomycin because of the potential pulmonary toxicity and was treated with 
etoposide and cisplatin (EP). The Medical Ethical Committee of Leiden University 
Medical Center (LUMC) approved the study protocol, and all subjects gave written 
informed consent before participation.
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figure 1. Time table of chemotherapy courses and blood sampling (triangles) on days 0, 
1, 2, 4, 8 and 15 of the 1st chemotherapy course (course I) and days 0, 1 and 2 of the 2nd 
chemotherapy course (course II) in 26 patients with a testicular germ-cell tumour (TGCT).
E: etoposide, CDDP: cisplatin and B: bleomycin. The dotted line is used to indicate the separation 
between the sampling days.
Blood Sampling
To investigate the kinetics of NPBI and related iron parameters blood was drawn 
at various time points during the first cycle (n=26) and the second cycle (n=20) of 
chemotherapy. Blood was put on ice and centrifuged immediately at 2000g at 4°C 
for 10 min. Samples were kept below -70°C until analysis. Samples obtained from 
individual patients were analysed in the same run to minimize assay variability. All 
assays were performed at the Central Laboratories of Leiden University Medical 
Center.
During the first course, blood was drawn at 25 different time points: before pre-
hydration (Day 0) and 24 blood samples drawn at fixed time points on days 1, 2 and 
4, prior to each individual infusion of etoposide, bleomycin and cisplatin (Figure 1); 
on days 1, 2 and 4 at 2, 4 and 6 hours after the start of the cisplatin infusion (Figure 
1) and on days 8 and 15; before and 30, 60 and 90 minutes after the start of the 
bleomycin infusion. During the second course blood was drawn on days 0, 1 and 2 
at similar time points as during course 1 (Figure 1).
Chemotherapy increases serum iron and NTBI in GTC patients
77
Analytical methods of iron status
All iron parameters were measured by routine procedures according to the 
manufacturer’s instructions. For total iron and latent iron-binding capacity (LIBC), 
measurements were made with a Cobas Integra 800 instrument (Roche Diagnostics, 
Basel, Switzerland) with lower limits of detection (total assay variability between 
brackets) were 0.24 µmol/L (<2.8%) for total iron and 4.2 µmol/L (<4.3%) for 
LIBC. Transferrin and ferritin were measured with a Elecsys E170 analyser (Roche 
Diagnostics, Basel, Switzerland) with lower limits of detection (total assay variability) 
for ferritin and transferrin of 13 mg/L (<1.2%) and 0.5 g/L (<5.4%) respectively. 
NPBI concentrations were measured using a colourimetric method as described 
previously by Kolb et al.156 Briefly, the serum samples were mixed 9:1 with a 40 mM 
NTA containing buffer of 5 mM Tris-HCl pH 6.5. After filtration and centrifugation 
thioglycolic acid sodium salt (3 mM) was added. Measurements were done using 
a Reader Spectra Max 250 plate reader at 537 nm. The (pooled) sera used for 
repeated experiments and patient sera were stored at -80 ºC until measurements. 
No influence of storage on the NPBI results was found. The lower limit of detection 
(total assay variability between brackets) was 0.01 µmol/L (<9.2%).
Routine hematology and chemistry 
Blood samples were collected between 8.00 and 10.00 a.m. after an overnight 
fast for routine hematology (hemoglobin and white blood cell count) and chemistry 
[LDH, alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline 
phosphate (AP) and gamma glutamyl transferase (y-GT), creatinine, and albumin] 
assays before each course and when clinically indicated. Normal laboratory reference 
ranges are shown in Table 2.
Statistical analysis 
To assess the changes within the first course (course 1) measurements of total iron, 
LIBC, NPBI at baseline, after pre-hydration, at the end of the first day, before and 
after the fourth day, before the fifteenth day, and before the second course were 
analysed using a mixed model analysis of variance (SAS proc. mixed) with visit as 
repeated factor within subject and time as fixed effects, and subject as random 
effect. To assess long-term treatment effects the course baseline and follow up 
measurements of all variables were analysed the same way. The time course of 
ferritin (after log-transformation because of non-normal distribution of the data) 
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and transferrin concentrations were analysed with repeated measures analysis of 
variance and after overall statistical significance was found, individual time points 
were compared within the model. The routine laboratory parameters obtained before 
the first and second course were compared using paired t-tests with Bonferroni-
Holm adjustment for multiple testing. All statistical analyses were performed using 
SAS for windows V9.1.2 (SAS Institute, Inc., Cary, NC, USA). All p-values are adjusted 
for multiple comparison.
Table 2. Serum concentrations of routine laboratory parameters.






Hemoglobin (mmol/l) 9.1 ± 0.8 8.1 ± 1.0 <0.001 8.5 – 11.0
Hematocrit (l/l) 0.432 ± 0.037 0.381 ± 0.043 <0.001 0.400 – 0.540
WBC (x109/l) 6.4 ± 1.9 3.3 ± 1.6 <0.001 4.5 – 10.0
iron parameters
Iron (μmol/l) 18 ± 8 17 ± 5 NS 11 – 28
LIBC (μmol/l) 35 ± 11 35  ±12 NS 27 – 54
NPBI (μmol/l) 0.63 ± 0.33 0.66 ± 0.34 NS < 2.0
Transferrin (g/l) 2.44 ± 0.47 2.28 ± 0.39 NS 2.04 – 3.60
Ferritin (μg/l) 224.2 ± 170.6 460.3 ± 261.2 <0.001 35 – 260
biochemical parameters
Creatinine (μmol/l) 79.7 ± 12.3 72.9 ± 10.3 0.03 62 – 106
Albumin (g/l) 45.8 ± 3.6 43.5 ± 3.9 NS 34 – 48
AP (U/l) 87 ± 25 79 ± 20 NS 40 – 120
γ-GT (U/l) 36 ± 32 41 ± 28 NS 5 – 55
ASAT (U/l) 33 ± 10 29 ± 8 NS 5 – 35
ALAT (U/l) 33 ± 19 37 ± 18 NS 5 – 45
WBC: White blood cell count, NPBI: Non-protein bound iron, LIBC: Latent iron binding capacity, AP: 
Alkaline phosphatase, y-GT: gamma glutamyl transferase, ASAT: Aspartate aminotransferase. ALAT: 
Alanine aminotransferase.
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figure 2. Time course of total serum iron (upper panel), latent iron-binding capacity (LIBC; 
middle panel) and non-protein bound iron (NPBI; lower panel) before the start of treatment 
(“pre-chemotherapy”), during the 1st BEP chemotherapy course, before the start of the 2nd 
chemotherapy course and during the first two days of the 2nd BEP chemotherapy course.
The data on the X-axis indicate the time (in hrs) at each observation day and the ‘X’ is used to indicate the 
separation between the sampling days. Sample times are noted according to the number of hours after 
start of daily chemotherapy infusion e.g. day one pre-infusion sample is noted as “Day 1, 0 hr sample” 





The demographics of the 26 patients and their tumour characteristics are shown 
in Table 1. Twenty-four patients obtained a complete remission after planned first-
line chemotherapy, whereas one patient required additional surgical resection 
ofresidual masses confirming a complete remission. Two patients developed major 
vascular complication during the 3rd chemotherapy cycle; one patient, aged 41 
years, developed hemiplegia in the 2nd week of his 3rd BEP cycle as a result of a 
thrombotic mass in the artery cerebri media leading to a large area of infarction (CT-
scan confirmed), and died of massive brain edema. Another patient, aged 34 years, 
was diagnosed with acute deep venous thrombosis of the popliteal vein and multiple 
pulmonary emboli four weeks after the start of his third and last BEP chemotherapy 
cycle. These events occurred in the absence of any known risk factor for vascular 
complications, hypomagnesia, and without any warning signs during the previous 
two chemotherapy courses. 
figure 3. Time course of serum transferrin (left axis) and serum ferritin (right axis) concentrations 
during the 1st chemotherapy course. 

















































































































































































































































































































































































































































































































































































































































































































































































































































































The first course of chemotherapy led to a significant decrease in serum hemoglobin, 
hematocrit, white blood cell count and creatinine and a significant increase in serum 
ferritin (Table 2).
Baseline variables and serial iron measurements 
At baseline, all iron parameters, including total serum iron, latent iron binding capacity, 
transferrin and ferritin were within the normal range of the laboratory measurements 
(Table 2, Figure 2 and 3). In all patients detectable serum concentrations of NPBI 
were present before dosing ranging from 0.10 to 1.58 µmol/l with a mean value of 
0.63 µmol/l (Table 2, Figure 2).
The pre-hydration preceding the administration of the cytostatics did not significantly 
alter total serum iron (p=0.34) and NPBI concentrations (p=0.59) (Table 3), but a 6.94 
μmol/l decrease (19%) in iron binding capacity was noted (Table 3, p=0.001) which 
was restored to baseline levels after the completion of the first day of chemotherapy. 
Transferrin (2.44±0.47 vs. 2.83±1.24; p=0.16) and ferritin (224±171 vs. 259±216; 
p=0.55) concentrations did not change significantly after pre-hydration (Figure 3).
Serum iron concentrations increased within 24 hr following the start of the first 
infusions of etoposide and cisplatin and remained elevated during days 2-8 (Figure 
2, Table 3). The distinct rise in total iron was accompanied by saturation of the 
iron-binding proteins, as evidenced by a decrease in LIBC and rise of NPBI. NPBI 
remained elevated at days 2-4. Iron parameters returned to baseline levels on day 
15, and remained unchanged up till 1.5 hrs post outpatient bleomycin infusion. 
Transferrin concentrations varied slightly with a mean of 2.44±0.47 g/l during the 
first course of chemotherapy and were slightly lower (2.28±0.39 g/l; p=0.22) at day 
21 at the beginning of second chemotherapy course (Table 2, Figure 3). Serum 
ferritin concentrations slightly increased from day 4 onwards and serum ferritin 
concentrations at the start of the 2nd chemotherapy course was significantly higher 
than at baseline (460±261 vs. 224±171 μg/l; p<0.001; Table 2, Figure 3).
Similar observations were made in the first days of the second course of chemotherapy, 
i.e. a rapid increase in total serum iron, depletion of the latent iron-binding capacity 
and increase in NPBI.
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diSCuSSion
We identify a striking increase in total serum iron, saturation of iron binding proteins 
and rise of NPBI within 24 hours after a single administration of etoposide and 
cisplatin in all GCT patients studied. These changes persisted during the following 
days of cytostatic infusions up till day 8 and iron parameters returned to baseline 
values on day 15 of the first cycle. Similar changes in iron parameters were observed 
during the second chemotherapy course at the time points measured. The changes 
in iron parameters were identical in the two patients who received paclitaxel on 
day 3, and in the patient who did not receive bleomycin. Two patients developed 
severe vascular toxicity during the 3rd respectively 4th cycle, with fatal outcome in one 
patient.
The observed rise in serum iron and NPBI at 24 hr post infusion can be attributed 
to the infusion of etoposide, cisplatin or both. We have not collected blood 
samples at 24 hr post bleomycin infusion on days 8 and 15, and are thus not able 
to assess whether a similar two-fold increase in serum iron occurred post single 
agent bleomycin administration. The observed closely linked changes in serum iron 
parameters indicate that   measurement of only serum iron and NPBI suffices to 
assess whether iron overload occurs.
Few reports exist concerning iron overload and release of catalytic non-protein-bound 
iron following chemotherapy.56;157-161 Most studies concern hematological malignancy 
patients who received multiple blood transfusions and underwent chemotherapy 
with a variety of cytostatic agents often followed by stem cell transplantation, and 
these studies have not measured NPBI at multiple time points after the start of 
chemotherapy. Gordon et al.162 also reported a rise in total serum iron in patients with 
hematological and solid tumours treated with chemotherapy or radiation, whereas 
Gordeuk et al.163 described a rise of bleomycin-reactive iron in six out of nine patients 
treated for acute non-lymphocytic leukemia. Although hematological malignancy 
patients may have abnormal serum iron parameters related to the inherent bone 
marrow abnormalities and frequent red blood cell transfusions, the variety of 
cytostatic agents used point to a common effect of different chemotherapeutic 
agents to induce release of highly toxic excess iron. 
 A previous study reported about vascular events during cisplatin-based chemotherapy 
21, we also encountered serious vascular toxicity during first-line chemotherapy in 
two of the current 26 patients studied. Acute and long-term vascular toxicity may 
be related to the chemotherapy-associated increase in iron; excess iron has been 
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associated with an increased risk of development of thrombo-embolic events 
and vascular dysfunction in animal experiments 160;164 and in humans. Excess iron 
increases the levels of adhesion molecules 161, and catalyses the oxidation of LDL-
cholesterol 159 thus providing a plausible explanation by which excess iron may be 
involved in the development and progression of atherosclerotic lesions. 
The marked changes in iron status during cisplatin-based chemotherapy could be 
caused by various mechanisms. Cytostatic drugs, in particular cisplatin, are known 
to inhibit erythropoiesis by blocking the biosynthesis of porphyrins and haem and 
iron incorporation into erythroid progenitor cells 157 resulting in subsequent release 
of free iron into the circulation.158;165 Binding of cisplatin to hemoglobin, leading to 
dissociation of haem from the hemoglobin molecule is another mechanism suggested 
by in vitro experiments.166 Preclinical studies and a few case reports suggest that 
lysis of iron-rich liver tissue or erythrocytes occurs during chemotherapy, but several 
studies have failed to detect significant liver damage or hemolysis 167;168, and this 
concurs with our own experience. However, chemotherapy-induced tumour lysis, 
specifically in chemosensitive tumours, and cellular damage of other tissues are a 
possible source of excess iron.
The current first-line cisplatin-based chemotherapy in patients with intermediate 
and good prognosis metastatic GCT leads to a cure rate exceeding respectively 80 
and 90%. Thus, chemotherapy-associated iron overload and release of potentially 
harmful catalytic non-protein bound iron in these healthy young men may hold 
significant clinical implications in view of the reported acute and long-term morbidity 
and mortality in cured long-term survivors. Moreover, particularly cisplatin-based 
chemotherapy is known to be accompanied by anemia requiring blood transfusion, 
supplementation with erythropoietin and even oral or intravenous iron, which may 
further aggravate the cyclical iron overload. Before our findings can be translated to 
other groups of cancer patients receiving chemotherapy, these disturbances of iron 
metabolism should be monitored in other centers. A prospective trial investigating 
the prophylactic use of iron chelating agents aiming at prevention of chemotherapy-
associated side effects is warranted. 
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  Chapter 6 
Prevalence of vertebral fractures independent of bMd 
and anticancer treatment in patients with testicular 
germ cell tumours
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Context: The prognosis of testicular germ cell tumours (GCT) is excellent and 
survival of GCT-patients has significantly increased. However, skeletal morbidity 
may potentially be increased in these patients due to chemotherapy-associated 
hypogonadism.
objective: A cross-sectional study of skeletal fragility in long-term survivors and 
newly diagnosed patients with GCT over a 2 year period.
Patients and Methods: We studied 199 cured long-term survivors of GCT, a mean 
of 7.4 years after unilateral orchidectomy, and 45 newly diagnosed patients within 
three months of unilateral orchidectomy but before anticancer treatment. Bone 
mineral density (BMD) measurements were performed and the presence of vertebral 
fractures (VF) was assessed in lateral thoracolumbar X-rays of the spine using the 
Genant’s semiquantitative method.
results: 63 patients (25.8%) had Z-scores between -1 and -2 SD and 12 patients 
(5.7%) had Z-scores below -2 SD. Moderate and severe VF (≥ grade 2) were observed 
in 13.6% of cured long-term survivors and in 15.6% of newly diagnosed patients. 
Including mild (grade 1) VF, the prevalence was 40.2% and 31.1%, respectively. 
There was no relationship between severity or number of VF and age, tumour type, 
stageing, prior chemotherapy, gonadal status, vitamin D levels or BMD values.
Conclusion: We identify a relatively high prevalence of mild to moderate VFs 
independently of BMD or prior chemotherapy, in long-term survivors and in newly 
diagnosed patients with GCT. Although the pathogenesis of these fractures remains 
unclear, their presence represents a potential cause of skeletal morbidity in otherwise 
healthy survivors of testicular GCT.
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inTroduCTion
Testicular germ cell tumours (GCT), the most common form of cancer in young men, 
hold an excellent prognosis, with cure potentially achieved in the majority of patients 
since the introduction of cisplatin-based chemotherapy.11-13 Unilateral orchidectomy 
with or without chemotherapy is associated with a potential increase in skeletal 
morbidity primarily due to the increased risk of hypogonadism. No deleterious effects 
of chemotherapy on bone mass have been reported in long-term GCT survivors, but 
fracture risk has not been addressed in these patients.51 The aim of our study was to 
assess skeletal fragility in a cohort of testicular GCT patients who have been followed 
up in our Unit for up to 28 years after initial diagnosis and treatment.
STudy deSiGn and MeThodS 
Patients
In a cross-sectional design, we studied 244 consecutive patients aged 18-66 years 
(median age 39.4 years), with a primary GCT originating in the testis, who were 
regularly followed up over a 2-year period at the Clinical Oncology Department of the 
Leiden University Medical Center. 
199 of the 245 long-term survivors, under control for 1-28 years after cure following 
orchidectomy and when required anticancer treatment, participated in the study; 15 
patients did not fulfil inclusion criteria, 40 could not participate for logistic reasons.
A second group consisting of 45 consecutive newly diagnosed GCT patients, 
referred within three months of unilateral orchidectomy but before the initiation 
of chemotherapy, was also studied. The primary tumour was staged by CT-scan 
and serum concentration of the tumour markers the beta unit of human chorionic 
gonadotrophin (β-HCG), alpha-fetoprotein (α-FP) and lactate dehydrogenase 
were documented as measured before and after orchidectomy. Demographic 
characteristics of the two patient groups are shown in Table 1. Informed consent 
was obtained from all patients before start of the study. 
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Table 1. Demographic characteristics of testicular germ cell tumor patients, grouped as 
cured long-term survivors and newly diagnosed patients, the latter assessed after orchidectomy 











demographics; median (min - max)
Age at orchidectomy (years) 30.3 (14.2 – 61.9) 29.6 (14.2 – 61.9) 31.9 (18.1 – 54.2) NS
Age at bone evaluation (years) 39.4 (18.2 – 66.9) 40.0 (18.2 – 66.9) 32.0 (18.3 – 54.3) P<0.001
Time interval between orchidectomy and 
study (years)
5.8 (0.01 – 27.9) 7.4 (1.0 – 27.9) 0.1 (0.01 – 0.2) P<0.001
evaluation; n (%)
Smoking 121 (49.6) 100 (50.3) 21 (46.7) NS
Alcohol use (> 20 units weekly) 33 (13.5) 30 (15.1) 3 (6.7) NS
evaluation; median (min – max)
Smoking (pack years) 0.00 (0.0 – 48.0) 0.30 (0.0 – 48.0) 0.00 (0.0 – 28.0) NS
Body weight (kg); (Mean ± SD) 83.5 (60 – 137.5) 84.0 (60 – 137.5) 81.0 (62 – 134.5) NS
Body mass index (body weight/body length2; 
kg/m2)
25.1 (16.8 – 38.5) 25.2 (16.8 – 38.5) 24.5 (18.9 – 37.7) NS
Creatinine clearance (Cockroft formula; ml/
min)
122 (23 – 208) 119 (56 – 208) 130 (23 – 208) NS
histology; n (%) 0.01
Seminoma 75 (30.7) 54 (27.1) 21 (46.7)
Non-seminoma 126 (51.7) 111 (55.8) 15 (33.3)
Combined tumor 43 (17.6) 34 (17.1) 9 (20.0)
TnM Tumor Staging (at time of diagnosis); 
n (%)
 NS b
Stage I (no metastasis) 94 (38.5) 74 (37.2) 20 (44.4)
Stage IS (stage I with elevated tumor 
markers)
9 (3.7) 9 (4.5) 0 (0.0)
Stage II (para-aortic lymph node metastasis) 102 (41.8) 85 (42.7) 17 (37.8)
Stage III (distant metastasis) 39 (16.0) 31 (15.6) 8 (17.8)
Treatment; n (%) p<0.001
No chemotherapy 92 (37.7) 47 (23.6) 45 (100.0)
Cisplatin or carboplatin combination 
chemotherapy
138 (56.6) 138 (69.4) 0 (0.0)
Single dose carboplatin, cisplatin or 
actinomycin-D
14 (5.7) 14 (7.0) 0 (0.0)
Dexamethasone 111 (45.3) 111 (55.8) 0 (0.0) ~
Dexamethasone dosage (mg; median, min 
– max)
204 (20 – 600) 204 (20 – 600) ~ ~
n sample size; NS: not significant.
a  p-value for comparison between values of patients with and without VF (independent-samples Student’s 
t-test, independent-samples Mann-Whitney or chi-square test where appropriate).
b chi-square test for trend used.
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Laboratory investigations
Blood samples were collected from all patients between 8.00 and 10.00 a.m after an 
overnight fast, and serum measured for creatinine, calcium (corrected for an albumin 
of 42 g/L), phosphate, alkaline phosphatase activity and for the  beta-carboxyl-
terminal cross-linking telopeptide of type I collagen (β-CTX) as bone resorption 
marker using semi-automated techniques. Serum concentrations of the bone 
formation marker osteocalcin, intact parathyroid hormone (PTH) and 25-hydroxy-
vitamin D (25(OH)D3) were measured using standard radio-immunoassays. Gonadal 
status was evaluated by measuring serum total testosterone (TT), estradiol (E2), sex 
hormone binding globulin (SHBG), luteinising hormone (LH) and follicle-stimulating 
hormone (FSH) using standard radio-immunoassays. Free testosterone (FT) was 
calculated using a standard formula.169;170 Normal laboratory reference ranges are 
shown in Table 2. Vitamin D deficiency was defined as a 25(OH)D3 concentrations 
of <50nmol/L.171;172 Hypogonadism was defined as a serum total testosterone 
concentration of <10.4nmol/l.84
Bone mineral density measurements
Bone mineral density (BMD) was measured at the time of the study at the lumbar 
spine (L1-L4) and femoral neck, using dual energy X-ray absorptiometry (DXA, 
Hologic QDR 4500; Waltham, MA, USA) equipped with reference values based on 
the National Health and Nutrition Examination Surveys (NHANES III) 173. World Health 
Organization (WHO) criteria were used to define osteopenia (T-score between -1 
and -2.5) and osteoporosis (T-score<-2.5) 174. Because of the wide age range (18-67 
years), results are also expressed as Z-scores (standard deviations above or below 
age- and sex-matched controls). Only femoral neck BMD data were used in patients 
who received radiotherapy to the para-aortic lymph nodes (n=21) because of the 
potential deleterious effect of radiotherapy on lumbar vertebral bone mass.50
Radiological investigations
Plain lateral radiographs of the thoracic and lumbar spine were obtained in all 
patients at the time of study using a standard protocol with a target to film distance 
of 115 cm, with the film respectively centered on T7 and L3. Radiographs were 
blindly and independently evaluated by three investigators, an investigator involved 
in the study, and two independent investigators one of whom with wide experience 
in skeletal radiology. All vertebrae from thoracic (T4) to lumbar 4 (L4) were evaluated 
for fractures using the validated Genant’s semiquantitative technique 175.  Vertebral 
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height reductions were graded as mild (grade 1, 20-25% reduction in anterior, middle 
and/or posterior height), moderate (grade 2, 25-40% reduction in anterior, middle 
and/or posterior height) or severe (grade 3, more than 40% reduction in anterior, 
middle and/or posterior height). Intra- and inter-observer concordance were both 
>95%.
Statistical analysis
The software package used for statistical analysis was SPSS 16.0 for Windows 
(Chicago, IL, USA). Binary logistic regression, Chi-square test and Student’s t-test 
or Mann-Whitney test (two-sided) were used as appropriate for categorical variables 
and for non-normally distributed variables. A p-value of less than 0.05 (two-tailed) 
was considered to be statistically significant. A Bonferroni-Holm adjustment for 
multiple testing was made for comparison of laboratory values reported in Table 2 
and for results in Table 3.
reSulTS
Cured long-term survivors of GCT
Patients were evaluated a mean of 7.4 years after cure (Table 1). Dexamethasone 
was administered intermittently as part of the anti-emetic regimen in 111 of the 138 
patients (72.9%) who received cyclical combination chemotherapy. Twenty-one 
patients needed additional radiotherapy to para-aortic lymph nodes (median dose 
30 Gy, range 26 – 70).
Prevalence of osteoporosis: Eighty-three of the 199 patients (41.7%) had osteopenia 
and 11 (5.5%) had osteoporosis. Fifty-two patients (26.1%) had Z-scores between 
-1.0 and -2.0 SD and 14 (7.0%) had Z-scores less than -2.0 SD at either femoral neck, 
lumbar spine or both sites. There was no significant difference in the prevalence of 
osteoporosis between patients who received standard combination chemotherapy 
(9/138 patients; 6.5%) and those who did not (2 /47 patients; 4.3%). 
Prevalence of vertebral fractures (VF): A total of 80 patients (40.2%) had one or more 
VF: 53 (26.6%) had mild grade 1, 25 (12.6%) had moderate grade 2, and two (1.0%) 
had severe grade 3 fractures. For further analysis, we focused on vertebral fractures 
grade 2 or more (reduction in height of 25% or more), since these have been shown 
to be predictive of future fracture risk and therefore to be of clinical relevance.176
Of the 199 patients studied, 27 (13.6%) had one or more moderate to severe VF. The 
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majority of patients had one VF, but six had two, and two patients had three deformed 
vertebrae. A total of 37 vertebral fractures were thus documented in 27 patients. 
Although the majority of these vertebral fractures were asymptomatic, four patients 
(15.4%) reported back pain of variable severity. Of the 27 patients with moderate to 
severe VF, 11 (40.7%) had osteopenia, one (3.7%) had osteoporosis, five (18.5%) had 
Z-scores between -1 and -2 SD and three (11.5%) had Z-scores below -2 SD.
Prevalence of non-vertebral fractures: Nine patients (3.7%) had sustained a non-
vertebral fracture following inadequate trauma at a median age of 42 years (range 
21-51 years), one 17 years after initial diagnosis and treatment of GCT. Only two of 
these patients had a Z-score below -1.0 SD. Vertebral fractures, one grade 2 and one 
grade 1, were documented in only one of these patients in the presence of a normal 
Z-score.
Laboratory investigations: 36 patients (18.1%) had a plasma testosterone 
concentration <10.4 nmol/L. Independently of testosterone levels or VF, high LH and 
FSH levels were respectively observed in 36 (18.1%) and 123 (61.8%) of patients. 
Serum estradiol was decreased in 91 patients (45.7%).
Compared to patients who did not receive anticancer treatment, patients who 
received prior chemotherapy had lower median testosterone (13.7;6.7-3.2 vs. 16.3;7.6-
28.8 nmol/L; p=0.04) and estradiol levels (68;28-151 vs. 76;10-187 pmol/L; p=0.03) 
and significantly higher LH (7.0;1.9-37.5 vs. 5.6;2.3-23.1 U/L; p=0.01) and FSH levels 
(14.9;2.4-80.0 vs. 9.7;3.6-34.7 U/L; p<0.001). Vitamin D deficiency as evidenced by 
a serum 25-hydroxyvitamin-D concentration of <50 nmol/L was documented in 66 
patients (33.2%). There was no significant difference in 25-hydroxyvitamin-D levels 
in patients with or without VF. Median serum concentrations of all other measured 
biochemical parameters including parameters of bone formation and resorption 
were within the normal laboratory reference range (Table 2).
Newly diagnosed patients
Demographic and tumour characteristics of newly diagnosed patients are shown in 
Table 1. 
Prevalence of osteoporosis: Thirteen of the 45 newly diagnosed patients (28.3%) had 
osteopenia and none had osteoporosis; 11 patients had Z-scores between -1 and -2 
and none below -2.0 at either femoral neck or lumbar spine.
Prevalence of VF: Fourteen patients (31.1%) had one or more VF: seven (15.6%) 
mild (grade 1), four (8.4%) moderate (grade 2), and three (6.7%) severe (grade 3) VF. 
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Focusing on the clinically relevant moderate or severe VF, four patients had one VF, 
one patient had two VF and two patients had three VF. A total of twelve VF were thus 
documented in seven newly diagnosed patients at a median age of 34.6 years (range 
18.3-54.2 years), within three months of unilateral orchidectomy but before institution 
of anticancer therapy. Of these 7 patients, 5 had a normal BMD, 2 had osteopenia 
(one with Z-score below -1 SD) and none had osteoporosis or Z-scores below -2 SD.
Presence of non-vertebral fractures: None of the newly diagnosed patients had 
sustained a non-vertebral fracture up to the time of the study.
Laboratory investigations: All patients had normal total testosterone levels at the 
time of assessment of skeletal status. Eight patients (17.8%) had elevated LH levels 
and fifteen (33.3%) had elevated FSH levels. Serum estradiol was decreased in 17 
patients (37.8%). Eleven patients (24.4%) had serum 25-hydroxyvitamin-D levels 
<50nmol/l.  Median serum concentrations of all other biochemical parameters were 
within the normal laboratory reference range (Table 2). Newly diagnosed patients had 
significantly higher median serum concentrations of testosterone (17.0; 10.5-33.9 
vs. 14.3; 6.7-32.1 nmol/L; p=0.008) and estradiol (84;4-373 vs. 74;10-187 pmol/L; 
p=0.03) and significantly lower median serum FSH concentrations (median 7.4;0.1-
46.7 vs. 13.3;2.4-80.0 U/L; p<0.001) than cured long-term survivors.
Analysis of potential risk factors for Vertebral Fractures
Because of the unproven clinical relevance of grade 1 mild VF 177, only moderate 
(grade 2) and severe (grade 3) VF were used in the data analysis of potential risk 
factors for their development. 
Life style factors: There was no relationship between number or severity of VF and 
BMI, smoking or alcohol use (Table 3). There was also no relationship between 
physical activity, also recreational, occupation, socio-economic status and the 
presence of vertebral fractures.
Prior chemotherapy: There was no relationship between severity or number of VF 
and prior chemotherapy or cumulative dose of cisplatin or dexamethasone used in 
the anticancer regimen (Table 3).
Gonadal status: Distribution of total testosterone, estradiol, LH and FSH in patients 
with or without VF is shown in Figure 1. Of the five cured long-term survivors with 
low total testosterone and high serum LH and FSH levels, one had one and one had 
three VF. Using univariate analysis, there was no significant relationship between 
number and severity of VF and total testosterone, estradiol, LH or FSH, in newly 
diagnosed or cured patients, also after log-transformation of the data.













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































figure 1. Gonadal status of long-term cured and newly diagnosed GCT patients. Data 
expressed as distribution of total testosterone (upper left panel), estradiol (upper right panel), 
LH (lower left panel) and FSH (lower right panel) measurements in the presence (●) or absence 
(○) of VF in 244 newly diagnosed and long-term survivors of GCT.
Vitamin D status: Vitamin D deficiency was more prevalent in cured long-term 
survivors with VF (40.7%) than in survivors without VF (32.0%). Four of the 66 patients 
with vitamin D deficiency had osteoporosis. In newly diagnosed patients only 1/7 
patients with VF (14.3%) and 10/38 without radiological changes (26.3%) had serum 
25-hydroxyvitamin-D levels <50nmol/L, all in the absence of increased PTH levels. 
There was no significant difference in median serum vitamin D levels between 
patients with or without VF.
Markers of bone turnover: There was no relationship between serum osteocalcin or 
β-CTX and number or severity of VF in either long-term survivors or newly diagnosed 
patients (Table 2).
Prevalence of vertebral fractures in GCT patients
97
Table 3. Demographic characteristics of testicular germ cell tumor patients, grouped 








demographics; median (min - max)
Age at orchidectomy (years) 30.3 (14.2-61.9) 30.1 (14.2-61.9) 30.2 (15.8-61.1) NS
Age at bone evaluation (years) 39.4 (18.2-66.9) 39.6 (18.3-66.9) 39.3 (18.2-65.8) NS 
Time interval between
orchidectomy and study (years)
5.8 (0.0-27.9) 5.6 (0.0-27.0) 5.9 (0.0-27.9) NS 
evaluation; n (%)
Smoking 121 (50.0) 21 (61.8) 100 (47.6) NS 
Alcohol use (> 20 units weekly) 33(13.5) 4 (11.8) 29 (13.8) NS 
evaluation; median (min - max)
Smoking (pack years) 0.00 (0.0-48.0) 0.00 (0.0-32.0) 0.0 (0.0-48.0) NS 
Body weight (kg) 83.5 (60.0-137.5) 86.0 (64.0-110.5) 82.0 (60.0-137.5) NS 
Body mass index
(body weight/body length2; kg/m2)
25.1 (16.8-38.5) 26.6 (21.5-32.3) 24.7 (16.8-38.5) NS 
Creatinine clearance
(Cockroft formula; ml/min)
122 (23-208) 131 (77-208) 120 (23-208) NS
histology; n (%) NS 
Seminoma 75 (31.0) 8 (10.7) 67 (89.3)
Non-seminoma 126 (51.4) 19 (15.1) 107 (84.9)
Combined tumor 43 (17.6) 7 (16.3) 36 (83.7)
TnM Tumor Staging; n (%) NS b 
Stage I (no metastasis) 94 (38.4) 12 (12.8) 82 (87.2)
Stage IS
(stage I with elevated tumor markers)
9 (3.7) 0 (0) 9 (100)
Stage II (para-aortic lymph node metastasis) 103 (42.0) 13 (12.7) 89 (87.3)
Stage III (distant metastasis) 39 (15.9) 9 (23.1) 30 (76.9)
Treatment; n (%) NS 
No chemotherapy 93 (38.0) 13 (14.1) 79 (85.9)
Cisplatin or carboplatin combination 
chemotherapy
138 (56.3) 18 (13.0) 120 (87.0)
Cisplatin combination
chemotherapy c
136 (55.5) 18 (13.2) 118 (86.8)
Carboplatin combination
chemotherapy c
6 (2.4) 2 (33.3) 4 (66.7)
Single dose
carboplatin, cisplatin or actinomycin-D
14 (5.7) 3 (21.4) 11 (78.6)
Dexamethasone; n (%) 111 (45.5) 116 (47.1) 59 (45.2) NS 
Dexamethasone dosage
(mg; median, min-max)
204 (20-600) 150 (40-600) 180 (20-600) NS 
n sample size; NS: not significant.
a p-value for comparison between values of patients with and without VF (independent-samples Student’s t-test, 
independent-samples Mann-Whitney or chi-square test used where appropriate and Bonferroni-Holm adjustment for 
multiple testing was made).
b  chi-square test for trend used.
c 4 of the 138 cured long-term survivors received cisplatin as well as carboplatin combination chemotherapy.
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Bone mineral density: Of the combined total of 34 long-term survivors and newly 
diagnosed patients who had moderate or severe VF, 25 (73.6%) had a normal BMD, 
six (17.6%) had Z-score between -1 and -2 SD, and only three patients (8.8%) had 
a Z-score below -2 SD at lumbar spine, femoral neck or both sites. There was no 
significant difference in Z-scores between patients with or without prevalent VF, 
either at the lumbar spine (-0.20±1.05 vs. -0.20±1.20; p=0.98) or at the femoral neck 
(-0.01±0.64 vs. 0.03±0.90; p=0.90).The distribution of T scores in patients with or 
without prevalent VF is shown for cured long-term survivors and newly diagnosed 
GCT patients (Figure 2).
figure 2. Distribution of Bone Mineral Density measurements at the lumbar spine (A) and 
femoral neck (B) expressed as T-scores in the presence (●) or absence (○) of VF in cured long-
term survivors of GCT (upper panel, n=199) and in newly diagnosed GCT patients (respectively 
C and D) within 3 months of removal of the tumor and before systemic anticancer treatment 
(lower panel, n=45).
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diSCuSSion
We identify a previously unreported prevalence of vertebral fractures in more 
than 30% of newly diagnosed patients with testicular GCT, within three months 
of unilateral orchidectomy but before initiation of chemotherapy and in more than 
40% of cured long-term survivors of these tumours. This prevalence remains high 
also taking in consideration only the more severe grade 2 and 3 VF, with 15.6 % 
of newly diagnosed patients and 13% of cured long-term survivors demonstrating 
these radiological changes. The vertebral fractures appear to have been sustained 
independently of age, tumour type or stage, prior chemotherapy, glucocorticoid use 
and presence of hypogonadism.
The potential to achieve cure in the vast majority of patients with GCT has translated 
in an excellent prognosis and long-term survival. Although the natural history 
of vertebral fractures is not known in patients with GCT, the prevalence of these 
fractures in a population of cured and otherwise healthy young men may represent 
a matter of concern in view of the widely reported morbidity and mortality attached 
to these radiological changes in patients with osteoporosis.178-180 GCT is commonly 
diagnosed between the second and fourth decade of life, and cured patients are 
still to bear the brunt of age-related bone loss, with its independently associated 
increased risk for fractures. The occurrence of vertebral fractures in the absence 
of significant changes in BMD is of importance in the clinical management of these 
patients as these fractures would go unsuspected and undetected if only BMD were 
to be measured. The independence of the documented VF from BMD measurement 
is not entirely surprising. Although BMD is a well established predictor of fracture risk, 
there has been growing awareness over the last decade, that bone mass represents 
only one of the components of bone quality and thus of bone strength. The Study 
of Osteoporotic Fractures (SOF) has thus shown that 54% of women aged 65 years 
or more with incident hip fractures were not osteoporotic at start of follow-up.181  In 
the MrOS study, the overall prevalence of vertebral fractures (grade 1-3) was 13% 
in a subset of 732 randomly selected men age 65 years or older, also using the 
Genant semiquantitative method of evaluating fractures. Interestingly, the majority 
of fractures were single, of grade 1 severity and most individuals had a normal BMD 
or osteopenia but no osteoporosis.182 It has also been demonstrated that the risk 
of fracture is increased in glucocorticoid users, regardless of whether osteoporosis 
was present or not.183 Finally it has also been observed that changes in BMD only 




The mechanism by which VF occur in GCT patients is intriguing. In germ cell 
tumours, the malignant process may potentially affect skeletal metabolism in a 
number of ways. Chemotherapy is a prime contender as it has been reported to 
have short-term as well as long-term effects on gonadal function.9;30;184 In keeping 
with recently published data in patients with GCT or lymphoma 51, we observed no 
significant difference in BMD and also no difference in the prevalence of VF between 
patients with or without prior chemotherapy. In support of the independence of the 
documented fractures from chemotherapy, we also observed a high prevalence of 
vertebral fractures in newly diagnosed patients even in those as young as eighteen 
years of age. We also found no relationship between gonadal status and either BMD 
or number and severity of vertebral fractures, also in newly diagnosed patients after 
unilateral orchidectomy but before initiation of chemotherapy. Notwithstanding, the 
consistently elevated FSH levels, an indirect biological indicator of Sertoli cell-function 
in patients with prior chemotherapy, supports the view that although chemotherapy 
may not affect testicular endocrine function, or may do so transiently, it may still have 
long-term effects on germinative cell-function, which is compensated by sustained 
increases in FSH levels. Our findings also confirm the previously reported finding of 
elevated FSH levels in newly diagnosed patients after unilateral orchidectomy but 
before start of anticancer treatment.25;185 In these patients, removal of one testis is 
unlikely to have led to endocrine deficiency and indeed none of these patients were 
hypogonadal at the time of evaluation. As previously reported in young patients with 
metastatic GCT, persistently high FSH levels in the presence of normal testosterone 
levels may also be due to persistently low serum inhibin concentrations.186 It has 
been recently proposed using data obtained from genetically manipulated mice 
and from in vitro studies, that FSH, previously thought to target only the gonads, 
may also directly act on osteoclasts, thus directly contributing to the maintenance 
of skeletal metabolism.187;188  Whether persistently increased FSH concentrations 
play a role in the increased skeletal fragility observed in patients with GCT remains, 
however, highly speculative.189;190 It has been also speculated that GCT may be part 
of a testicular dysgenesis syndrome, which comprises abnormal fertility, androgen 
insensitivity and/or cryptorchism.7;191 Brothers of GCT patients have also been 
shown to be at increased risk of infertility.192 Whether a dysgenesis syndrome may 
be responsible for altered bone quality leading to increased skeletal fragility remains 
however, questionable.
Nine patients had sustained a non-vertebral fracture following low-energy trauma 
since diagnosis and treatment, but there was no relationship between non-vertebral 
fractures and the presence or absence of VF. None of the patients had a history of 
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high energy trauma which may have caused the documented vertebral fractures. 
An additional factor that may affect skeletal metabolism is the use of high dose 
corticosteroids as part of the antiemetic regimen administered concomitantly with 
chemotherapy. However, these courses were short and no relationship was found 
between prevalent vertebral fractures and either prior corticosteroid use or its 
cumulative dose. Finally, although vitamin D deficiency was prevalent in about a 
third of GCT patients studied and may have contributed to decreased bone quality 
in patients with vertebral fractures, there was no significant difference in vitamin D 
levels between patients with or without VF.  
The relatively high prevalence of largely asymptomatic VF in long-term cured GCT 
survivors as well as in newly diagnosed patients with testicular germ cell tumours 
suggests that skeletal fragility is likely to have predated anticancer treatment, although 
the cross-sectional design of our study and the silent nature of the fractures preclude 
the determination of the time of occurrence of these fractures. It is conceivable that 
these fractures may have been sustained before surgical removal of the tumour, in 
which case, it cannot be excluded that a specific tumour product(s) may have been 
responsible for the increased fracture risk.
Our study has some strengths as well as limitations. Its main strength is the relatively 
large number of patients studied, the availability of lateral X-rays of the spine in all 
patients allowing the diagnosis of silent vertebral fractures, and the opportunity to 
study newly diagnosed patients before start of anticancer therapy, the presumed 
main culprit for skeletal morbidity. One of the study’s main limitations is its cross-
sectional design with the lack of sequential radiological data not allowing the 
dating of the VF. Although the homogeneity of the patients’ population as recruited 
from a single center may be perceived as a further limitation, our study included 
newly diagnosed patients as well as long-term survivors, treated with or without 
chemotherapy for various types and stages of GCT. Our Unit also closely follows 
International Guidelines for the management of GCT. A further limitation of our study 
is that we did not study the prevalence of VF in age-matched healthy controls. Data 
from the EVOS and EPOS studies, large population-based studies of 30 European 
cohorts, including the Dutch Rotterdam study cohort, documented a prevalence of 
vertebral fractures of about 12% in men older than 50 years.193-195
Although it may be argued that a different method was used to assess vertebral 
fractures in these population-based studies196, these figures are also in keeping 
with data from the Longitudinal Ageing Study Amsterdam197, which addressed the 
prevalence and severity of vertebral fractures in a population-based study of 260 
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Dutch men aged 65 years or older, and with data from the Framingham198 and the 
MINOS199 studies. The Framingham study addressed the prevalence of vertebral 
fractures in 252 men with a mean age of 53 years (range 37-72 years) and the MINOS 
study evaluated the prevalence of these fractures in 786 men, 51 years and older. 
The Framingham and MINOS studies document one or more prevalent vertebral 
fractures in 10-14% of the younger subsets of their cohorts. Of note is that the LASA, 
Framingham and MINOS studies evaluated the prevalence of vertebral fractures 
using the same Genant’s semiquantitative method we used in our study.175
Data from the LASA study show that in the youngest group of men studied aged 
65 to 69 years, 24.2% had any grade fracture (vs. 40.2% in our patients), 13.6% 
had a grade 1 fracture (vs. 26.6 % in our patients) and 4.5% had a grade 2 fracture 
(vs. 12.6% in our patients).197 Our data thus demonstrate an intriguing 2 to 3-fold 
increase in the prevalence of mild to moderate vertebral fractures in younger long-
term survivors or newly diagnosed patients with testicular germ cell tumours with a 
median age of 40 years.
In oncological terms, testicular GCT holds an excellent prognosis, with survival 
expected in over 90% of patients. The clinical significance of the unsuspected 
high prevalence of largely asymptomatic mild to moderate vertebral fractures 
observed in this relatively young and otherwise healthy population of men remains 
to be determined. Although we identified several factors potentially contributing to 
increased skeletal fragility, our data do not allow the drawing of conclusions regarding 
causality or temporal relationship of vertebral fractures to specific risk factors, largely 
because of the time frame since diagnosis and treatment, with potential reversal 
or disappearance of relevant risk factors with time. In view of the unpredictability 
of BMD measurements and in the absence of clear predictive factors for skeletal 
pathology, we propose that all patients with testicular GCT should be radiologically 
screened for the presence of vertebral fractures and that all efforts should be made 
to optimize bone quality by at least ensuring adequate vitamin D and gonadal status. 
Further studies are required to elucidate the mechanism underlying the intriguing 
increased skeletal fragility observed in patients with testicular GCT.
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  Chapter 7 
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introduction: Patients with germ cell tumours (GCT) have an excellent prognosis 
but have been shown to be at risk for silent fractures. Data on bone mineral density 
(BMD) following anti-cancer treatment are scarce. We therefore monitored BMD in 
newly diagnosed testicular GCT patients treated with or without chemotherapy at 
one, two and up to five years after anticancer treatment.
Method: We prospectively studied 63 newly diagnosed patients with GCT with a 
median age of 33 years (range 16-70) within 3 months of unilateral orchidectomy but 
before anticancer treatment. Twenty-seven patients (42.9%) did not have metastases 
(stage 1), fifteen of whom received a single dose of adjuvant carboplatin. Thirty-six 
patients (57.1%) with metastatic disease received combination-chemotherapy.
results: At baseline, total hip and lumbar BMD were not significantly different 
between patients with non-metastatic and metastatic tumours. There was no 
decrease in BMD observed in stage I patients during follow up.  A significant loss 
of  lumbar BMD (-0.016 g/cm2; p=0.004) and total hip BMD (-0.021g/cm2; p<0.0001) 
was observed at 1 year and remained stable thereafter up to 5 years of follow up 
in metastatic GCT patients receiving chemotherapy. BMD decline at 1 year did not 
relate to gonadal status, vitamin-D deficiency or markers of bone turnover, or to 
cumulative dose of cisplatin or (anti-emetic) corticosteroids. 
Conclusion: Metastatic GCT survivors suffer significant bone loss within the first 
year after curative combination-chemotherapy which persisted for up to 5 years after 
anticancer treatment. Based on these findings we recommend measurements of 
BMD in GCT patients receiving combination CT to allow timely treatment of bone 
loss and increased fracture risk. 
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inTroduCTion
Testicular germ cell tumours (GCT) are the most common form of cancer in young 
male adults. The introduction of cisplatin-based combination chemotherapy has 
led to significant improvement in prognosis, with cure achieved in the vast majority 
of patients.11 This translates in an increasing number of long-term survivors of this 
malignancy who would have undergone unilateral orchidectomy with or without 
chemotherapy at a relatively young age. Long-term detrimental effects of cancer 
treatments on the skeleton may be associated with increased morbidity and are 
potentially important to evaluate and treat as required.
GCT patients may potentially experience accelerated bone loss through the effects 
of chemotherapy.200 A high prevalence of osteopenia and osteoporosis has been 
reported in a large cohort of 823 GCT survivors with unilateral testicular cancer 
a median 89 months after orchidectomy and anticancer treatment.53 In contrast, 
another study reported no deleterious effects of chemotherapy on the skeletal 
health of long-term survivors of GCT or lymphoma.51 We have previously shown an 
increased prevalence of vertebral fragility fractures in cured long-term survivors of 
GCT. The high prevalence of largely asymptomatic vertebral fractures we observed 
in GCT patients was independent of tumour stage, chemotherapy or bone mineral 
density (BMD).201
Chemotherapy may be causally related to decreases in BMD because of potential 
negative effects of chemotherapy on bone remodelling. The widely used high doses 
of corticosteroid as part of the anti-emetic regimen concomitantly prescribed 
with chemotherapy may contribute to bone loss 202 as well as to femoral head 
osteonecrosis.203
Cytotoxic chemotherapy is associated with significant gonadal damage, with germ 
cells being more sensitive to treatment than Leydig cells, with infertility being a 
more commonly encountered adverse effect than hypogonadism. Whether bone 
quantity and/or quality are directly affected by chemotherapy or indirectly so by 
chemotherapy-mediated partial hypogonadism is not known. Various studies 
reported hypogonadism as evidenced by increased serum LH and low-normal 
testosterone  up to sixty months after chemotherapy in GCT survivors9;30;204 although 
the  diurnal pulsatile pattern of testosterone secretion and the different parameters 
used to define hypogonadism preclude comparison between the various studies. 
Interestingly, partial hypogonadism has shown to be already present before 
orchidectomy in up to one third of GCT patients.205
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Although the vast majority of patients remain or become eugonadal in time9 the 
sometimes severe bone loss associated with abrupt iatrogenic hypogonadism may 
not be fully reversible. The aim of our study was to establish whether bone mineral 
density is affected by chemotherapy in newly diagnosed GCT patients one, two and 
up to five years after anticancer treatment.
PaTienTS and MeThodS
Patients
We studied 63 newly diagnosed GCT patients aged 16 to 70 years (median 33 years), 
who were referred to the Department of Clinical Oncology of the Leiden University 
Medical Center (LUMC) between 2007 and 2009 after unilateral orchidectomy but 
before anticancer treatment as required. The primary tumour was staged on the basis 
of tumour histology, CT-scan and serum concentrations of tumour markers, beta unit 
of human chorionic gonadotrophin (β-HCG), alpha-fetoprotein (α-FP) and lactate 
dehydrogenase (LDH), measured at the time of diagnosis. Patients were divided into 
two groups based on diagnosis and anti-cancer treatment; a first group of patients 
with non-metastatic disease (stage 1) were treated with unilateral orchidectomy only 
(non-seminomas, n=12) or unilateral orchidectomy plus a single dose of adjuvant 
carboplatin (AUC7) (pure seminomas, n=15). In our experience carboplatin is not 
associated with chemotherapy-related complications 201 so that it was decided to 
include these patients in the non-metastatic group of patients.
A second group of patients had metastatic GCT and had received multiple courses of 
cisplatin-based combination-chemotherapy. Most GCT patients were asymptomatic, 
were leading an active life and were in good clinical condition. Only eight of the 
patients had co-morbidity in the form of diabetes mellitus (n=3), hypertension (n=2), 
COPD (n=1), ulcerative colitis (n=1) or epilepsy (n=1).
Baseline evaluation included medical history, prior and current medication, prior 
use of corticosteroids, smoking habits and alcohol use. All patients underwent a 
full clinical examination including body height, weight, waist and hip circumference, 
pulse rate and blood pressure. 
Laboratory measurements
Blood samples were collected at baseline after orchidectomy and one, two and up 
to five years thereafter. Serum was measured for creatinine, calcium (corrected for 
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albumin), phosphate and alkaline phosphatase concentrations using semi-automated 
techniques. Serum was also measured for the marker of bone resorption beta-
carboxyl-terminal cross-linking telopeptide of type I collagen (β-CTX). Serum intact 
parathyroid hormone (PTH), 25-hydroxy vitamin-D (25(OH)D3) and 1,25-dihydroxy 
vitamin-D (1,25(OH)2D3) were measured using standard radioimmunoassay’s. 
Gonadal status was evaluated by measuring luteinising hormone (LH), follicle-
stimulating hormone (FSH), total testosterone (TT), estradiol (E2) and sex hormone 
binding globulin (SHBG) using standard radioimmunoassay’s. Free testosterone (FT) 
was calculated using a standard formula.169;170 Hypogonadism was defined as a serum 
total testosterone concentration of <10.4nmol/l.84  Vitamin D deficiency was defined 
as a 25(OH)D3 concentrations of <50nmol/L.
171;172 Renal function was calculated using 
the Cockcroft formula. Serum concentrations of the beta unit of human chorionic 
gonadotrophin (β-HCG), alpha-fetoprotein (α-FP) and lactate dehydrogenate (LDH) 
were used for stageing of the disease at the time of diagnosis. 
Bone mineral density measurements
Bone mineral density (BMD) was measured at the lumbar spine (L1-L4) and total hip 
using dual energy X-ray absorptiometry (DXA, Hologic QDR 4500; Waltham, MA, 
USA). The coefficient of variation of BMD measurements was 1%, and the machine 
was calibrated at regular intervals. The DXA-scan used in this study was equipped 
with reference values based on the National Health and Nutrition Examination Surveys 
(NHANES III) 173, which are compatible with those of a Dutch control population. World 
Health organization (WHO) criteria were used to define osteopenia (T score between 
-1 and -2.5) and osteoporosis (T score < -2.5) 174. Lumbar BMD was assessed from 
L1 to L4 in posterio-anterior incidence. Total hip BMD was reported as the mean of 
left and right total hip BMD measurements. Results were also expressed as Z-score, 
indicating the number of standard deviations below the mean of age- and sex- 
matched controls. 
Statistical analysis
The SPSS for Windows software package (Chicago, IL, USA) and SAS for 
windows V9.1.3 (SAS Institute, Inc., Cary, NC, USA) were used for statistical 
analysis. Results are expressed as mean±SD or as median (minimum-maximum). 
Two-tailed paired sample Student’s t-test was used to compare single, normally 
distributed measurements between study groups. The Wilcoxon signed-rank test 
was used to compare unevenly distributed measurements between study groups. 
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The comparability of the study groups at baseline was assessed as appropriate by 
one-way ANOVA analysis of variance. The serial measurements of the biochemical 
markers and BMD are analysed with a repeated measures model analysis of variance, 
with an autoregressive first order covariance structure. The estimated least square 
means and their p-values for the difference from zero test are used to establish if the 
patients are deviant from their peers.








demographics (median, min - max)
Age (years) 33 (16 – 70) 35 (22 – 70) 34 (16 – 59) NS
Δ Time (years) 0.1 (0.0 – 6.2) 0.2 (0.0 – 0.8) 0.1 (0.0 – 6.2) NS
Characteristics (mean ± Sd)
Weight (kg) 83 ± 12 82 ± 12 83 ± 11 NS
BMI (kg/m2) 24.7 ± 3.3 24.3 ± 2.7 25.1 ±  3.7 NS
Waist circumference (cm) 92 ± 10 94 ± 12 90 ± 8 NS
Systolic blood pressure (mmHg) 128 ± 15 126 ± 16 130 ± 15 NS
Renal function 
(Cockroft clearance ml/min)
135 ± 30 126 ± 25 141 ± 32 NS
life style; n (%)
Smoking 24 (38.1) 7 (25.9) 17 (47.2) NS
Alcohol use (>20 U/week) 9   (14.3) 7 (25.9) 9   (25.0) NS
histology; n (%) NS
Seminoma 27 (42.9) 15 (55.6) 12 (33.3)
Non-seminoma 22 (34.9) 7   (25.9) 15 (41.7)
Combined tumor 14 (22.2) 5   (18.5) 9   (25.0)
TnM Tumor Staging; n (%) ~
Stage I    (no metastasis) 27 (42.9) 27 (100.0) 0   (0.0)
Stage I S 
(elevated serum tumor markers)
1     (1.6) 0   (0.0) 1   (2.8)
Stage II 
(para-aortic lymph node metastasis)
23 (36.5) 0   (0.0) 23 (63.9)
Stage III  (distant metastasis) 12 (19.0) 0   (0.0) 12 (33.3)
Treatment; n (%) ~
No adjuvant treatment 12 (19.1) 12 (44.4) 0   (0.0)
Single dose carboplatin 15 (23.8) 15 (55.6) 0   (0.0)
Combination chemotherapy 36 (57.1) 0   (0.0) 36 (100.0)
n sample size; NS: non-significant.
a p-value for comparison between values of patients treated with and without chemotherapy.
Δ Time: Time between orchidectomy and first measurement (years).
BMD changes in GCT patients after anti-cancer treatment
111
reSulTS
Patients and disease characteristics
Demographic and anthropometric characteristics of the sixty-three consecutive 
testicular GCT patients included in the study are summarized in Table 1. Twenty-
seven patients (42.9%) had stage I disease (no metastases) and thirty-six patients 
(57.1%) had metastatic disease (Table 1). Of the patients with metastatic disease, 
one (1.6%) had stage IS (elevated tumour markers but negative CT scan indicating 
micro metastases), 23 (36.5%) had stage II disease (metastases in one or more loco 
regional para-aortic lymph nodes) and 12 (19%) had distant metastases, mostly in 
the lungs (Table 1). Median age was similar in the two patient groups (Table 1).
Patients with metastatic disease received first-line cisplatin-based combination 
chemotherapy consisting of three (n=22) or four (n=14) cycles of BEP (bleomycin, 
etoposide and cisplatin) or 4 cycles of EP (etoposide and cisplatin). Each cycle 
consisted of intravenously administered etoposide (100 mg/m2 over 1 hr, days 1-5) 
and cisplatin (20 mg/m2 over 4 hours, days 1-5), with or without bleomycin (30 
IUSP over 30 min) at days 2, 8, and 15. As part of the anti-emetic regimen all 36 
patients received intravenously administered high doses of corticosteroids (10 mg 
dexamethasone intravenously daily during days 1-5 of their 3-weekly chemotherapy 
courses, with rapidly tapering of oral dexamethasone thereafter: twice daily 3 
mg (days 6-7) and twice daily 1.5 mg (days 8-9). Two patients received two extra 
cycles of VIP (vinblastine, ifosfamide and cisplatin) consolidation chemotherapy and 
consequently higher administrative doses of corticosteroids.
Two patients aged 53 and 35 years developed avascular necrosis of the hip, 
respectively one and four years after chemotherapy, started with bisphosphonates, 
and were excluded from further analysis thereafter. A third patient, aged 21 years, 
was diagnosed with osteoporosis after one year, started with calcium and vitamin D 
suppletion, and was also excluded from further analysis.
Laboratory measurements 
Laboratory measurements, before, after one and two years and up to five years 
after treatment, are shown in Table 2A, 2B and 3. Median serum concentrations of 
measured biochemical parameters were normal at baseline and thereafter and did 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Vitamin D deficiency was documented at baseline in 23 patients (36.5%), was 
equally distributed between the two patient groups and did not significantly change 
thereafter. At baseline, β-CTX concentration was increased above the normal 
laboratory reference range in 17 of the 63 patients (27.0%); in 10 (37.0%) of the stage 
one patients and in 7 (19.4%) of the patients with metastatic disease. There was no 
change in β-CTX concentration during follow up.
figure 1. Time profile graph of LH, FSH, testosterone and estradiol with SD as error bars for 
both measurement groups (patients with stage one and patients with disseminated disease) 
at baseline and after anti-cancer treatment.


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































BMD changes in GCT patients after anti-cancer treatment
117
At baseline, four of the 63 patients (6.3%) had plasma testosterone concentrations 
<10.4nmol/L. Independently of testosterone levels, elevated LH and FSH levels were 
observed in respectively 11 (17.5%) and 28 (44.4%) patients. Serum estradiol was 
decreased in 23 patients (36.5%). There was no significant difference in mean levels 
of serum testosterone, LH and FSH between the two treatment groups (Figure 1A 
and 1B). Before chemotherapy patients with metastatic disease had significantly 
higher serum estradiol concentrations compared to patients with stage one disease 
(91.0 pmol/L; 3.0-240.0 vs. 74.5 pmol/L; 28.0-98.0; p=0.007) (Figure 1D).
Patients with disseminated disease had significantly higher serum FSH (7.4 U/L; 0.1-
44.5 vs. 20.8 U/L; 5.5-46.0; p<0.001) and LH (4.8 U/L; 0.1-24.8 vs. 8.2 U/L; 3.4-
18.7; p=0.008) concentrations in the absence of a decrease of serum testosterone 
and estradiol concentrations one years after anti-cancer treatment (Table 3, Figure 
1). Gonadal hormone concentrations did not fluctuate significantly during follow-
up in stage one patients (Figure 1). No significant changes were observed in free 
testosterone over time.
BMD measurements
At baseline: Femoral and lumbar BMD did not significantly differ at baseline between 
patients with stage I non-seminoma, patients with stage I seminoma scheduled to 
undergo adjuvant single dose carboplatin, or patients with disseminated disease 
(Table 4).
One year after anti-cancer treatment: There was no significant change in BMD in 
stage I patients one year after orchidectomy or thereafter. There was no significant 
difference in BMD changes in patients who did or did not receive one additional 
dose of carboplatin. In patients with metastatic disease, who were treated with 
multiple chemotherapy courses, BMD decreased at the lumbar spine (1.05±0.12 
vs. 1.03±0.11g/cm2; p=0.03) and at the hip (1.04±0.12 vs. 1.01±0.12g/cm2; p<0.001) 
compared to the pre-treatment values (Figure 2). Two patients with metastatic disease 
aged 16 and 18 who may not have reached peak bone mass both received cisplatin-
based chemotherapy. The youngest patient had normal hip BMD but osteopenia at 
the lumbar spine which improved at 1 year after anti-cancer treatment and thereafter, 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Prevalence of low bone mass at baseline: Two of the 63 patients (3.2%) had 
osteoporosis of the lumbar spine, none at the hip. Eighteen patients (28.6%) had 
osteopenia; six patients (9.5%) at both the lumbar spine and hip, nine (14.3%) only 
at the lumbar spine and three (4.8%) only at the total hip. There was no significant 
difference in the prevalence of osteopenia and osteoporosis between patients with 
stage one GCT (29.6%) or those with disseminated disease (33.4%). Four of the 63 
patients (6.3%) had Z-scores less than -2SD. Twelve patients (19.0%) had Z-scores 
between -1 and -2 SD at either lumbar spine, total hip or at both sites.
Prevalence of low bone mass status one year after anti-cancer treatment: At one 
year after anti-cancer treatment osteoporosis persisted in the two patients in whom 
it was observed at baseline. After one year, we observed no osteoporosis at the hip. 
Twenty-two patients (34.9%) had osteopenia; eight patients (12.7%) at both lumbar 
spine and hip, thirteen (20.6%) only at the lumbar spine and one patients (1.6%) 
had osteopenia at the left hip. There was no significant difference in the prevalence 
of osteopenia and osteoporosis between patients with stage one GCT (33.3%) 
and those with disseminated disease (41.7%). Three of the 63 patients (4.8%) had 
Z-scores less than -2SD. Seventeen patients (27.0%) had Z-scores between -1 and 
-2 SD at either lumbar spine, hip or both.
Potential risk factors for bone loss in GCT
At baseline, hip BMD was only related to age (ß=-0.31, p=0.01) and weight (ß=0.43, 
p=0.001). One year after anti-cancer treatment, bone loss was not significantly related 
to the number of chemotherapy cycles, cumulative dose of individual chemotherapeutic 
agents or cumulative dose of corticosteroids administered as anti-emetic during 
chemotherapeutic treatment.  The difference in BMD before and after chemotherapy 
in patients with metastatic disease remained after correction for age and weight.
There was no relationship between BMD and smoking or alcohol use. BMD changes 
were also independent of gonadal status, vitamin-D deficiency or β-CTX. Decrease of 
lumbar spine and hip BMD a year after anti-cancer treatment was not related to the 
number of chemotherapy cycles or dosage of individual chemotherapeutic agents or to 
the total dose of corticosteroids given as part of the antiemetic regimen. In patients with 
vitamin D deficiency (34.9%), lumbar spine and hip BMD were not significantly lower 
compared to BMD in patient with normal serum vitamin D concentrations. There was 
no relationship between either bone markers and BMD or any biochemical parameters 
including gonadal hormones and BMD in patients receiving chemotherapy.
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figure 2. Time profile graph of lumbar BMD (g/cm2) and total hip BMD (g/cm2)  LSMs with 
95% CI as error bars for both measurement groups (patients with stage one and patients with 




This is to our knowledge the first study examining the natural course of changes in 
BMD in GCT patients from baseline and up to five years after anti-cancer treatment. 
We have previously established in a cross-sectional study that silent vertebral 
fractures are prevalent in long-term survivors of GCT.201 It was not clear at what stage 
of their follow up patients sustained these fractures. Our findings from this study 
suggest that patients with metastatic GCT experienced bone loss at the lumbar 
spine and total hip within the first year after chemotherapy and femoral bone loss 
did not recover up till 5 years after anti-cancer treatment.  Bone loss at one year 
was independent of gonadal status, 25-hydroxy vitamin-D concentrations, smoking 
habits or changes in bone turnover markers.
In patient with non-metastatic GCT who underwent unilateral orchidectomy, there 
was no observed bone loss at either lumbar spine or total hip. BMD also remained 
unchanged in those patients who received adjuvant carboplatin after orchidectomy. 
Vitamin D levels were low in 23 percent of patients, and despite remaining uncorrected, 
were not related to the loss in BMD.
We did not measure potential deleterious effects of a single dose of carboplatin on 
the skeleton, so that it seemed appropriate to include the fifteen patients concerned 
in the group of patient with non-metastatic GCT who do not require chemotherapy. 
In keeping with our previous findings from a cross-sectional study in long term 
survivors of GCT 201 we show that a relatively high percentage of newly diagnosed 
GCT patients already experience evidence of bone loss suggesting that skeletal 
fragility may predate anti-cancer treatment. The decrease of in BMD of both femoral 
and lumbar spine in patients with metastatic GCT treated with chemotherapy is 
most likely an early direct effect of chemotherapy and/or concomitant corticosteroid 
treatment on bone remodelling cells or indirectly by deleterious effects on gonadal 
function. The design of the study did not allow to assess the relative contribution of 
the transient hypogonadism induced immediately after chemotherapy 9;30;184, which 
may have -in part- recovered to baseline values at one year.
Consistent with the known detrimental effects of chemotherapy on the germinal 
epithelium which may be accompanied by an increase in FSH levels and/or 
reduced sperm counts 8;206 FSH and LH increased significantly in GCT patients with 
metastatic disease one year after anti-cancer treatment, while serum estradiol and 
testosterone concentrations decreased albeit not significantly at 1 year as compared 
to baseline. Little is known about the gonadal status in patients with GCT before 
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the tumour is diagnosed, although there is some evidence that patients with the 
testicular dysgenesis syndrome 191 developed partial hypogonadism long before the 
diagnosis of GCT is established. This could explain why a relatively large percentage 
of these patients have abnormal BMD already at time of diagnosis of their GCT. 
These hypotheses need to be confirmed by studies addressing potential correction 
of bone loss in the long term by adequate correction of gonadal and vitamin D status.
Corticosteroids have been shown to exert multiple effects on osteoblasts as well as 
osteoclasts 207;208 culminating in bone degradation and a state of low bone turnover 
as shown in animal models 209 and may have contributed to the observed decline 
in BMD in survivors who underwent curative combination chemotherapy. Although 
cumulative doses were not large, treatment was intermittent and only given for 9 to 
12 weeks to prevent emesis associated with chemotherapy.
Four other cross-sectional studies have reported BMD data in long-term survivors 
of GCT treated with and without chemotherapy. Brown et al.51 performed a cross-
sectional study in 165 testicular cancer survivors and 51 lymphoma patients and 
found no difference in BMD in GCT patient treated with or without chemotherapy. 
Consistent with these data 2 smaller studies in respectively 30 and 39 GCT survivors 
did not demonstrate deleterious effects of chemotherapy on bone mass of long-term 
GCT survivors.50;52 On the other hand, Ondrusova et al.53 reported a high prevalence 
of osteopenia and osteoporosis in a large cohort of 823 GCT survivors a median 89 
months after orchidectomy and anticancer treatment. These last data correspond 
with our previously published finding in 199 GCT survivors, in which we demonstrate 
a high prevalence of osteopenia and osteoporosis of 41.7% and 5.5% respectively.201
Our study has some strengths as well as limitations. To our knowledge this is the 
first study addressing long term effects of chemotherapy on skeletal health in GCT 
survivors. Secondly, we measured BMD in GCT patient with and without distant 
metastasis, allowing us to measure the possible deleterious effect of intense 9 to 
12 weeks of combination chemotherapy in these patients. We also measured the 
hormonal status and biochemical parameters of bone turnover and vitamin D status 
at one year allowing us to analyse for potential contributions of these risk factors 
in skeletal health in the long term, although we did not measure these parameters 
during the 12 months between baseline and one year.  The main limitation of our 
study is the relatively small size of the cohort studied.  
We have only included one bone resorption marker (β-CTX) in our serum analysis. 
Unfortunately, our laboratory was not able to determine procollagen type 1 N-terminal 
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propeptide (P1NP) at the start of this study. Serum P1NP values were therefore only 
available for the last two measurement moments. However, the available serum 
P1NP concentrations in the fifth year were positively correlated to serum β-CTX 
values (β=0.53; p=0.006). Thus at least during follow-up, bone resorption was 
accompanied by bone formation.  And this suggests that the loss of BMD after 
chemotherapy administration is not due to osteoblast inactivity.
ConCluSion
The prognosis of germ cell tumours is excellent largely due to the high rates of cure 
obtained with cisplatin-based combination chemotherapy in patients with metastatic 
disease. The hitherto unsuspected decline in BMD at one year post chemotherapy in 
metastatic GCT survivors which did not recover in the years thereafter may translate 
into increased morbidity in these patients, particularly considering their prolonged 
survival time. Combination-chemotherapy plus high doses of corticosteroids and 
transient partial hypogonadism may be the cause of the decline in BMD after 
curative chemotherapy. Pre-existing testicular dysgenesis syndrome might also be 
at the source of the disturbed bone quality observed in patients with GCT. Whether 
the observed changes in BMD are a predictor for risk of fractures remains to be 
established.
Based on our data we advise to screen GCT patients for skeletal abnormalities at 
diagnosis and to closely monitor their BMD after chemotherapeutic treatment to 
allow timely therapeutic intervention. Further studies are required to understand the 
relationship between GCT, intense curative chemotherapy and decline in BMD after 
chemotherapy.
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  Chapter 8 
Summary and General discussion
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The Main findinGS PreSenTed in ThiS TheSiS
The studies described in this thesis were performed to investigate the short and 
long-term effects of chemotherapy on bone metabolism, fat metabolism and 
cardiovascular risk in testicular germ cell tumour (GCT) patients. 
In Chapter 2 we report an increased prevalence of Metabolic Syndrome (MetS) 
in GCT patients who received chemotherapy. We demonstrate that the two used 
classification systems (IDF and NCEP-ATPIII) led to discrepancies in reported 
prevalence of MetS in GCT patients. We found, however, that independently of the 
classification system used to assess MetS, the relative risk of MetS in GCT patients 
treated with chemotherapy is twofold increased compared to that in patients with 
stage 1 disease who did not receive chemotherapy, or to that in healthy controls.
In Chapter 3 we report the results of magnetic resonance imaging (MRI) and proton 
magnetic resonance spectroscopy (1H-MRS) in a small cohort of GCT patients with 
metastatic disease before and after treatment with combination chemotherapy. 
Visceral and subcutaneous abdominal fat mass increased significantly concomitant 
with an increase in serum cholesterol, LDL-cholesterol and insulin concentrations. 
These early changes in fat metabolism may predict the development of MetS in 
GCT patients. However, we were unable to demonstrate changes in aortic pulse 
wave velocity. Hepatic triglyceride content only increased in less than 40% of the 
patients during follow-up so that we could not demonstrate a conclusive relationship 
between chemotherapy and changes in hepatic triglyceride concentrations. 
Chapter 4 summarizes our findings in the same group of patients regarding a 
number of aspects of cardiac function. It was observed that left ventricular volume, 
diastolic volume and left ventricular stroke volume significantly decreased following 
chemotherapy. Taken together these findings suggest that acute alterations in 
diastolic heart function in combination with the disadvantageous changes in fat 
metabolism measured several months after chemotherapy may, at least partially, 
be responsible for the increased long-term cardiovascular disease (CVD) risk and 
increased incidence in MetS in GCT patients.
In Chapter 5 we report on the changes in iron metabolism in GCT patients during 
standard BEP chemotherapy treatment. Non-protein bound iron (NBPI), latent iron 
binding capacity (LIBC) and serum iron measurements were measured serially in 26 
GCT patients. Within 24 hours of treatment, concentrations of the highly toxic NPBI 
had increased twofold during treatment and remained elevated up to one week after 
start of chemotherapy. Serum NPBI concentrations were inversely related to the 
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latent iron-binding capacity. Similar changes in serum NBPI, LIBC and serum iron 
were observed during a second chemotherapy cycle. Chemotherapy-associated 
iron overload may thus play a role in short and long-term chemotherapy induced 
toxicity in GCT patients.
In Chapter 6 data on bone mass density (BMD) and morphometric vertebral fractures 
(VF) from a cross-sectional study in 199 cured long-term survivors of GCT and 45 
newly diagnosed patients within 3 months of unilateral orchidectomy but before anti-
cancer treatment are reported. Vertebral fractures were observed in 13.6% of cured 
long-term survivors and in 15.6% of newly diagnosed patients independently of BMD 
or prior chemotherapy. These VF represent a potential cause of skeletal morbidity in 
survivors of testicular GCT.
The natural history of changes in BMD in 63 newly diagnosed GCT patients after 
anti-cancer treatment are reported in Chapter 7. Immediately after orchidectomy, 
hip and lumbar BMD are not significantly different in patients with metastatic GCT 
compared to patients without metastases. However, after chemotherapy a significant 
decline of 2% in (age-adjusted) femoral and lumbar BMD was observed in patients 
with metastatic GCT. This significant loss of lumbar and total hip BMD observed at 
1 year remained stable thereafter for up to 5 years of follow up in metastatic GCT 
patients receiving chemotherapy. BMD decline at 1 year did not relate to gonadal 
status, vitamin D deficiency or markers of bone turnover, or to cumulative dose of 
cisplatin or (anti-emetic) corticosteroids. Whether the decline in BMD after curative 
chemotherapy is directly caused by chemotherapy, or results from the induced 
transient partial hypogonadism, either alone or in combination with the hormonal 




Germ cell tumour patients treated with combination chemotherapy have a more 
than twofold increased prevalence of the metabolic syndrome compared to age-
matched healthy subjects.46-49;210 Especially abdominal obesity, hypertension and 
hypertriglyceridemia were more frequently observed in this group of patients. We 
also found an elevated serum fasting LDL-cholesterol in all GCT survivors, which is in 
agreement with several other published reports.46;131;210;211
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The exact cause of the increased risk for MetS in GCT survivors is not well established. 
Some groups report an association between testicular cancer and increased caloric 
intake in GCT patients 212;213, and increased insulin resistance during follow-up has 
also been implicated.46;49 Other reports suggest a causal relationship between 
the documented hypogonadism in GCT patients and increase in MetS incidence. 
Chemotherapy, which leads to long-term partial or complete hypogonadism in most 
GCT survivors 30;36, and low testosterone and sex hormone-binding globulin (SHBG) 
levels are considered to be risk factors for MetS in otherwise healthy men.90;91;214  Our 
data are in keeping with the latter finding, as we found an association between low 
serum concentrations of testosterone and MetS in all patients, in particular in those 
treated with chemotherapy.
In keeping with the results from worldwide cohort studies 85, the increase in the 
absolute prevalence of MetS was strongly dependent on the scoring system used. 
Indeed, we also found a different MetS prevalence in GCT patients when we used 
different scoring systems. The prevalence of MetS in GCT patients was almost two 
fold higher when classified according to the IDF criteria compared with the NCEP-ATP 
III criteria. However, the relative risk for MetS between the different patient groups 
or between all patients and healthy subjects remained the same, independent of the 
scoring system used.
Our data further suggest that the group of GCT survivors who received combination-
chemotherapy and who were hypogonadal, had an increased risk for developing 
MetS compared to the general population. We therefore advocate assessment of 
gonadal function and correction of androgen deficiency more liberally in this group 
of patients although the beneficial effect of this approach remains to be established. 
We also recommend that guidelines for lifestyle counselling and gonadal hormone 
substitution should be introduced in international urology/oncology guidelines rather 
than only monitoring the development of potential complications which is the current 
standard of follow up for the detection of co-morbidities.
GCT patients treated with chemotherapy (CT) or radiotherapy (RT) are reported 
to have a 25-year risk of long-term cardiovascular complications of approximately 
16%.28;29 Patients who had received chemotherapy were found to be more at risk 
than those treated with orchidectomy only; Huddart et al. reported an odds ratio 
(OR) for cardiovascular disease (CVD) of 2.6 (95%CI: 1.2-5.8) after a median follow-
up of 10.2 years for patients with disseminated disease, treated with combination 
chemotherapy compared to patients with stage I disease who only underwent an 
orchidectomy. 27 Van den Belt-Dusebout et al. calculated a moderately increased 
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standardized incidence ratio (SIR) for coronary heart disease of 1.17 (95% CI: 1.04-
1.31) at a much longer follow up in a Dutch GCT cohort treated in the period between 
1971 and 1985.28 The increase in cardiovascular events in GCT patients compared 
to the general population data (SIRs) was especially observed in patients who 
underwent combination CT more than 25 years previously. They also identified RT 
as one of the risk factors for CVD. However, high RT doses (40-50 Gy) administered 
in patients with non-seminoma GCT is no longer standard treatment. Hence, the risk 
assessment reported for patients with GCT by these authors cannot be generalised 
to that of currently treated patients. Haugnes et al. reported a 2.2% cumulative 
incidence in their patients 1-14 years after diagnosis 86, an incidence similar to that 
observed in the general population. They also reported an increased long-term CVD 
prevalence 13 - 28 years after treatment (OR 3.1; 95%CI: 1.2-7.7).
We analysed our cohort of GCT patients who were treated in the LUMC between 
1977 and 2008 for incidence of cardiovascular events.215 A complete set of data 
was available for 490 GCT patients. Three patients died of myocardial infarction and 
one of ischaemic CVA before the start of the study. Of the 425 patients currently 
alive and under regular follow-up, 5 had a myocardial infarction, 4 had an acute 
coronary syndrome, and 4 had an ischaemic CVA. Thus a total of 17 out of 490 
patients (3.5%) had a cardiovascular event at a median age of 54.4 years (23-76 
years), 0.1 to 29 years (median 12.5 years) after their anti-cancer treatment. Fifteen 
of these 17 patients with a cardiovascular event had been treated with combination-
chemotherapy. This low CVD incidence corresponds to the low (3%) 10-year FRS 
cardiovascular risk estimation in our cohort. However, the risk estimates should be 
considered cautiously as it is well-known that FRS calculations for persons under the 
age of forty are less specific.
In GCT patients, the 2.6 to 8.0% prevalence of cardiovascular disease in GCT 
patients does not correspond with the expected CVD risk based on MetS population 
measurements. A possible explanation could be that the definition of MetS does not 
take into account several important risk factors such as age, gender, a history of 
smoking, or serum total cholesterol concentrations.  Furthermore, the association 
between the severity of risk factors and CVD risk is not considered in the dichotomous 
nature of the MetS criteria, although other investigators found little or no increase 
in the predictive power for cardiovascular events by adding abdominal obesity, 
triglycerides or fasting blood glucose, which are factually more accurate predictors 
of type II diabetes.216 These additional factors may add to long-term CVD risk, but 
this requires validation in prospective studies.
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Metabolic changes during chemotherapy
We hypothesized that cisplatin-based chemotherapy would induce metabolic 
disturbances which may possibly be visualized over time. Our data showed (Chapter 
3) that in a cohort of metastasized, but otherwise healthy testicular cancer patients, 
significant increases of plasma insulin, total cholesterol and LDL-cholesterol, insulin 
resistance, body mass index (BMI), and a concomitant increase in the volume 
of the abdominal visceral and subcutaneous fat mass occurred. The changes in 
lipid and fat distribution in GCT patients occurred concomitantly with changes in 
serum gonadotrophin concentrations. These changes may be a result of a direct 
early effect of cytostatics or of the combined result of partial hypogonadism and 
other metabolic disturbances such as chemotherapy-induced insulin resistance. In 
vitro and in vivo animal studies show that chemotherapy agents such as cisplatin 
and bleomycin induce endothelial damage 62. Although we found no difference 
in aortic pulse wave velocity before and after chemotherapy there was a clear 
alteration in left ventricular (LV) end diastolic volume and LV stroke volume after 
treatment. These subclinical changes in cardiac diastolic function may precede the 
development of clinical dysfunction. Were these early changes to be predictive for 
later abnormalities in cardiac function, they could be used to monitor GCT patients 
treated with chemotherapy for cardiovascular risk more specifically, and possibly 
enable protection of GCT patients against the increased CVD risk of chemotherapy.
Iron parameters
In addition to the associated untoward metabolic effects, treatment of GCT patients 
with chemotherapy is also associated with acute vascular toxicity.21;153 We identified 
a striking increase of NPBI and of total serum iron which exceeded the capacity 
of iron binding proteins within 24 hours after a single administration of etoposide 
and cisplatin in 26 GCT patients, as reported in Chapter 5. Interestingly, these 
changes persisted several days after cytostatic infusions and iron parameters only 
slowly returned to baseline values.  Similar changes in iron parameters were also 
observed during the following chemotherapy course. There are several explanations 
for these changes in iron status. Chemotherapy-induced tumour-cell lysis, in 
particular in chemosensitive tumours, and cellular damage to other tissues, are 
possible sources of excess iron.  Another mechanism is the binding of cisplatin to 
haemoglobin, leading to dissociation of haem from the haemoglobin molecule.166 
Thirdly, preclinical studies and a few case reports suggest that lysis of iron-rich 
liver tissue or erythrocytes occur during chemotherapy. Regardless of its source, 
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the observed release of iron during chemotherapy could be a potential source for 
vascular cell wall damage. Chemotherapy-associated iron overload and release of 
potentially harmful catalytic non-protein bound iron in these otherwise healthy young 
men may thus hold significant clinical implications in cured long-term GCT survivors. 
Based on these findings we therefore recommend monitoring of the iron status in 
GCT patients undergoing curative chemotherapy with the perspective that iron-
chelating treatment might possibly prevent late unwanted side-effects observed in 
these otherwise healthy patients.
Vertebral fractures and bone mineral density
In GCT patients, chemotherapy-induced hypogonadism may potentially lead to 
altered bone metabolism and decreased bone mass density (BMD) in GCT survivors. 
Although mean BMD appeared to be largely unaffected in our cohort of GCT patients, 
we measured a high prevalence of osteopenia (41.7%) and osteoporosis (5.5%) in 
GCT survivors after unilateral orchidectomy with or without additional chemotherapy. 
These findings are in keeping with the high prevalence of osteopenia and osteoporosis 
in a large cohort of 823 GCT survivors reported by Ondrusova et al.53  We also 
reported an incidence of morphometric vertebral deformities in 32.6% of newly 
diagnosed patients with GCT, within three months of unilateral orchidectomy and in 
40.2% of long-term GCT survivors. The vertebral deformities appear to be sustained 
independently of BMD, age, tumour type or stage, prior chemotherapy, glucocorticoid 
use and presence of hypogonadism. The underlying mechanism by which these 
vertebral deformities develop in GCT patients remains unclear. Although we did not 
find a direct relationship between serum concentrations of gonadal hormones and 
the number or severity of vertebral fractures (VF), the increased serum FSH and LH 
concentrations reflect a decrease in germinative cell-function which may lead in the 
long-term to a disturbed bone metabolism.25;30;185 Another possible explanation is 
the still speculative existence of a testicular dysgenesis syndrome in GCT 7;191, which 
comprises abnormal fertility, androgen insensitivity and/or undescended testis. In 
GCT patients, this androgen insensitivity may be potentially responsible for altered 
bone quality leading to increased skeletal fragility.
Pfeilschifter and Diel hypothesized that GCT patients may experience accelerated 
bone loss through the effects of chemotherapy 200, but three cross-sectional studies 
addressing this issue have reported no increased incidence of osteoporosis in long-
term survivors.50-52 However, we prospectively measured BMD in a cohort of 63 
GCT survivors of whom 36 had received cisplatin-based combination chemotherapy 
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because of metastasized disease. In our cohort, the patients with metastatic disease 
who received combination chemotherapy had a significant 2% decrease in femoral 
and lumbar spine BMD within one year of treatment, which persisted up to five 
years of follow-up. Low BMD was independent of smoking, gonadal status, vitamin 
D deficiency or markers of bone turnover. Potential additional risk factors for the 
decline in BMD were the concomitant administration of corticosteroids and possible 
malnutrition due to chemotherapy-induced nausea. It is hoped that future long-term 
studies will be able to clarify the mechanism by which treatment results in deleterious 
effects on the skeleton in GCT patients. Based on our data demonstrating an increased 
incidence of silent morphometric vertebral deformities, we recommend that all GCT 
patients with metastasized disease treated with combination chemotherapy should 
be evaluated for the presence of osteoporosis and vertebral fractures.
ConSideraTionS
We have shown that GCT patients treated with cisplatin-based chemotherapy have a 
more than twofold increase in risk of acquiring the Metabolic Syndrome. We have also 
demonstrated a direct relationship between low serum testosterone levels and the 
development of Metabolic Syndrome in these patients. It has been clearly established 
that hypogonadism is associated with increased cardiovascular risk 217-219, and several 
studies have shown a protective effect of testosterone supplementation on CVD risk 
and risk factors for developing the metabolic Syndrome in hypogonadal men.220-
224 It remains unclear, however, whether in GTC patients chemotherapy- induced 
hypogonadism is associated with an increased incidence of cardiovascular events. 
This should be further explored using two possible study designs. A cross-sectional 
study design in which, all GCT patients who have been treated with cisplatin-based 
chemotherapy would be studied for incident cardiovascular events during long-term 
follow-up, relating these events to severity and duration of the post chemotherapy 
hypogonadism and using as controls GCT patients who did not incur cardiovascular 
events during follow-up. A second approach would be to prospectively follow all 
GCT patients treated in our hospital and to examine the incidence of cardiovascular 
events in patients with low serum testosterone values after chemotherapy compared 
to those with normal serum testosterone concentrations. Although this approach 
requires a long-term study, it would also provide the possibility of studying the effect 
of testosterone supplementation on CVD risk in the long-term by randomly allocating 
treatment to half of the population studied.
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A number of factors other than hypogonadism have been suggested to contribute to 
the increased cardiovascular risk in GCT patients including increased caloric intake 
and chemotherapy-induced endothelial damage. We have been able to measure 
the acute changes in lipid and fat distribution occurring in GCT patient treated with 
chemotherapy and it would be interesting to see whether these metabolic changes 
are associated with increased incidence of the MetS and CVD risk in the long term. 
To this effect it would be necessary to measure body composition and serum lipid 
spectra in all GCT patients before and immediately after anti-cancer treatment and 
to identify the patients who would go on to sustain a cardiovascular event. Since the 
increased cardiovascular risk becomes apparent only twenty to thirty years after 
initial cancer diagnosis and treatment in GCT patients, it will take decennia before 
a clear relationship between CVD and chemotherapy-induced metabolic changes 
could be established. We should also be able to find out which long-term GCT 
survivors acquired CVD and go on to perform a case-control study of GCT patients 
with compared to  those without CVD,  checking in the process the role of treatment 
related effects, predisposition to CVD and known CVD risk factors.
As suggested in this thesis, the increase in non-protein bound iron in GCT patients 
could be at the source of the chemotherapy-induced endothelial damage. We have 
shown that an increase in NPBI is directly related to the increase in serum iron 
and decrease in LIBC.  We were not able, however, to measure an acute effect 
of cisplatin-based chemotherapy on aortic pulse wave velocity, possibly because 
more time may be required to develop vascular changes. In GCT patients treated 
with chemotherapy a prospective analysis of serum iron and LIBC measurement in 
combination with ultrasound measurements of common carotid artery intima-media 
thickness might strengthen our hypothesis that free iron may play a major role in the 
pathogenesis of chemotherapy-induced cardiovascular risk.225 
We have shown that GCT patients have a high prevalence of osteopenia, osteoporosis 
and vertebral fractures. The fact that these vertebral fractures are present in the 
absence of significant decreases in BMD suggests that bone quality is decreased in 
GCT patients. To determine whether this is the case, we could study components of 
bone quality by performing thick needle biopsies of the iliac crest and use micro-CT 
or other newer modalities to study the bone microarchitecture.226






De onderzoeken die beschreven zijn in dit proefschrift werden opgezet om de korte en 
lange termijn effecten van chemotherapie te meten bij patiënten met (gemetastaseerde) 
teelbalkanker. In Hoofdstuk 2 beschrijven we dat patiënten die een behandeling 
met chemotherapie voor teelbalkanker hebben ondergaan vaker het zogenaamde 
metabool syndroom ontwikkelen dan een groep gezonde personen. Daarbij was 
het opvallend dat patiënten met lage concentraties testosteron in het bloed het 
hoogste risico hadden op ontwikkelen van het metabool syndroom. Daarnaast laten 
we zien dat het gebruik van twee veel gebruikte definities voor het bepalen van het 
metabool syndroom (IDF en NCEP-ATPIII)42;79 leidt tot sterk afwijkende prevalenties in 
zowel patiënten als gezonde personen.85 Desondanks blijkt dat, onafhankelijk van de 
gebruikte definitie voor het metabool syndroom, het relatief risico op het ontwikkelen 
van het metabool syndroom twee keer zo hoog is voor patiënten die behandeld 
zijn met een orchidectomie en chemotherapie ten opzichte van patiënten die alleen 
behandeld zijn met een orchidectomie en ook ten opzichte van gezonde vrijwilligers. 
Dit suggereert dat de chemotherapie zelf of een verder gevorderd stadium van 
de teelbaalkanker van invloed kunnen zijn op het ontwikkelen van het metabool 
syndroom. Van de vijf criteria die gebruikt worden om het metabool syndroom vast te 
stellen, komen voornamelijk overgewicht, hypertensie en hypertriglyceridemie vaker 
voor bij patiënten die behandeld werden met chemotherapie. Daarnaast hebben alle 
patiënten die behandeld zijn voor teelbalkanker een significant verhoogde nuchtere 
LDL-cholesterol concentratie in hun bloed ten opzichte van gezonde personen. 
Insuline resistentie werd echter even vaak gevonden bij patiënten als bij gezonde 
vrijwilligers.
Het door ons gevonden verhoogde risico op ontwikkelen van het metabool syndroom 
komt overeen met de door Nuver en collega’s gemeten prevalentie in een kleine 
groep patiënten uit Noord-Nederland.46 Deze bevindingen contrasteren echter met 
de bevindingen van twee Noorse onderzoeksgroepen waarbij prevalenties van bijna 
45% werden gerapporteerd.47;48 Een mogelijke verklaring voor dit grote verschil is dat 
deze Noorse onderzoekers niet één van de standaard definities van het metabool 
syndroom hebben gebruikt.42;79 De door hen gebruikte methodieken maakten de 
kans op een overschatting van de prevalentie van het metabool syndroom zeer 
waarschijnlijk. Mede daarom concluderen wij dat weliswaar het risico op ontwikkelen 
van het metabool syndroom verhoogd is bij patiënten met teelbalkanker maar niet zo 
hoog als eerder in de literatuur beschreven.
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Meerdere onderzoeksgroepen hebben het risico op de ontwikkeling van hart- en 
vaatziekten bij patiënten met teelbalkanker gemeten.28;29 Als de bestaande literatuur 
over dit onderwerp wordt samengevat dan is het relatief risico op de ontwikkeling 
van hart- en vaatziekten voor patiënten ten opzichte van gezonde leeftijdsgenoten 
ongeveer 2.5 keer groter. Bij de patiëntengroep die wij onderzocht hebben, 
stelden we vast dat na een gemiddelde follow-up van 22 jaar 2.6% procent van 
de patiënten een cardiovasculair incident heeft doorgemaakt. Dit risico komt goed 
overeen met de door ons berekende Framingham Risk Score in de groep van 199 
patiënten.82 Onze gegevens suggereren dat het risico op het krijgen van hart- en 
vaatziekten bij patiënten die behandeld werden voor teelbalkanker mogelijk lager is 
dan wordt aangenomen. De volgende beperkingen zijn echter verbonden aan onze 
waarnemingen: ten eerste zou het kunnen dat wij de patiënten niet lang genoeg 
hebben vervolgd. Daarnaast is de Framingham Risk Score bij mensen jonger dan 40 
jaar minder specifiek en onze patiëntengroep is relatief jong.227
Sommige patiënten met teelbalkanker hebben een verminderde vruchtbaarheid. 
Voorts leidt chemotherapie tot verminderde vruchtbaarheid.25;32;206 De patiënten met 
gemetastaseerde teelbalkanker die behandeld moeten worden met chemotherapie 
hebben daarom een grote kans op onvruchtbaarheid. Chemotherapie leidt tot 
hypogonadisme, maar het hypogonadisme kan in 2 tot 5 jaar weer herstellen.9;30 
Bij gezonde mannen zijn lage bloedconcentraties testosteron en sex-hormoon 
bindend globuline (SHBG) risicofactoren voor het ontwikkelen van het metabool 
syndroom.90;91;214 Wij bevestigden dat patiënten met testosteronwaarden in 
het laagste kwartiel (laagste 25%) een sterk verhoogd risico hebben op het 
ontwikkelen van het metabool syndroom. Daarom pleiten wij voor het controleren 
van de geslachtshormonen en het zo nodig suppleren hiervan in deze specifieke 
groep patiënten. Hoewel bekend is dat suppletie van testosteron de afzonderlijke 
risicofactoren op ontwikkelen van het metabool syndroom vermindert 220-222;228-231, 
weten wij niet of suppletie in hypogonadale patiënten met teelbalkanker ook op lange 
termijn het risico op het metabool syndroom en hart- en vaatziekten vermindert. 
De controle bij deze groep patiënten is nu voornamelijk gericht op het vinden 
van recidieven en metastasen van teelbalkanker. Wij pleiten daarom ook voor het 
opstellen van een internationale richtlijn voor patiënten met teelbalkanker waarin 
uitdrukkelijk aandacht is voor leefstijladviezen en controle op hypogonadisme om de 
kwaliteit van leven van deze (overwegend jonge) patiëntenpopulatie na succesvolle 
behandeling van teelbalkanker te optimaliseren.
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Naast een verhoogd risico op het krijgen van het metabool syndroom zijn er voor 
de patiënten met teelbalkanker nog andere risico’s verbonden aan de behandeling 
met chemotherapie. Al in 1992 is beschreven dat behandeling met chemotherapie 
vrijwel direct leidde tot een toename van de cholesterolconcentraties in bloed.60;232 
Het is mogelijk dat deze door chemotherapie geïnduceerde veranderingen in het 
vetmetabolisme ook een rol spelen bij het versneld krijgen van hart- en vaatziekten bij 
patiënten met teelbalkanker die met chemotherapie behandeld worden. Behandeling 
met chemotherapie leidt soms tot insuline resistentie 46;49 en kan daarom theoretisch 
via een ontregeld glucosemetabolisme zorgen voor een verhoogd risico op het 
metabool syndroom en indirect op een hoger risico op hart en vaatziekten.
In het derde en vierde hoofdstuk van het proefschrift beschrijven we de bevindingen 
van ons onderzoek waarbij met behulp van magnetische resonantie beeldvorming 
(MRI) en spectroscopie MRI (MRS) metingen werden verricht aan vetmassa in buik, hart 
en lever.104 Deze metingen werden in een kleine groep patiënten met gemetastaseerd 
teelbalkanker verricht voor en na de behandeling met 3 of 4 chemotherapie kuren. 
Bij deze chemotherapie werden de gebruikelijke doseringen bleomycine, etoposide 
en cisplatine toegediend. Met de MRI-metingen stelden we vast dat zowel de 
abdominale subcutane als de viscerale vetmassa significant toenam. Bij deze 
patiënten stegen ook de concentraties cholesterol, LDL-cholesterol en insuline in het 
bloed (Hoofdstuk 3). Opvallend was verder dat deze veranderingen gepaard gingen 
met gelijktijdige veranderingen in testosteron, LH en FSH. De concentratie van 
triglyceriden in de lever, die gemeten werd door middel van MRS, steeg slechts in de 
helft van de patiënten. Of de veranderingen in serum lipiden, insuline-gevoeligheid 
en abdominaal lichaamsvet een direct effect zijn van de chemotherapie of het gevolg 
zijn van een combinatie van factoren waarin ook hypogonadisme een rol speelt, 
kunnen we uit ons onderzoek niet opmaken.
Zowel in vitro als dierexperimenteel onderzoek toont aan dat chemotherapeutica 
zoals cisplatine en bleomycine endotheelschade veroorzaken.62 Eerder onderzoek 
door onze afdeling heeft laten zien dat behandeling van teelbalkanker met 
chemotherapie geassocieerd is met acute schade aan bloedvaten.21;153 Bij 
vaatschade vermindert de elasticiteit van de vaatwand en neemt de snelheid van de 
bloedstroom toe. Wij hoopten, met door MRI gemeten aortale bloedstroomsnelheid, 
indirect chemotherapie geïnduceerde vaatschade te kunnen waarnemen.66;67 We 
konden deze hypothese echter niet bevestigen en vonden geen verschil in de aortale 
bloedstroomsnelheid voor en na chemotherapie (Hoofdstuk 4). Onze bevindingen 
kunnen betekenen dat onze hypothese niet juist was, maar alternatieve verklaringen 
zijn dat de groep patiënten te klein was, het effect te klein was, of dat er meer 
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tijd verstrijkt voordat acute vaatwandschade leidt tot meetbare veranderingen in 
vaatwandelasticiteit. In dezelfde patiëntengroep zijn ook voor en na behandeling 
met chemotherapie een aantal (functionele) metingen aan het hart verricht. Hierbij 
stelden we vast dat het volume van het linker ventrikel, het diastolisch hartvolume 
en het linker ventrikel slagvolume van het hart significant daalden na de behandeling 
met chemotherapie (Hoofdstuk 4). De combinatie van deze veranderingen die min 
of meer acuut na de chemotherapie optrad (daling diastolisch hartvolume, negatieve 
veranderingen van het vetmetabolisme, insuline-resistentie, verandering in serum 
geslachtshormoon-spiegels) zou mogelijk een rol kunnen spelen in de pathogenese 
van het metabool syndroom en in de verhoogde lange termijn risico’s op hart- en 
vaatziekten in patiënten met teelbalkanker.
Eerder onderzoek heeft aangetoond dat behandeling met chemotherapie, en in het 
bijzonder als de chemotherapie bestaat uit bleomycine en/of cisplatine, aanleiding 
geeft tot het vrijkomen van ijzermoleculen.55 IJzermoleculen zijn normaliter ingebouwd 
in andere moleculen of ze circuleren in het bloed terwijl ze aan eiwitten gebonden 
zijn. Als echter een relatief grote hoeveelheid ijzermoleculen tegelijkertijd vrijkomt, 
kan de bindingscapaciteit van de eiwitten worden overschreden waardoor vrij ijzer 
in de circulatie terecht komt. Dat is een ongewenste situatie omdat ongebonden 
ijzer een toxische verbinding is, ook voor hart en bloedvaten. In Hoofdstuk 5 worden 
de resultaten beschreven van een onderzoek waarbij periodieke bepalingen van 
ijzer, ongebonden ijzer (NPBI) en de ijzerbindingscapaciteit (LIBC) werden verricht 
in het bloed van 26 patiënten met teelbalkanker die werden behandeld met 3 of 4 
combinatie kuren bleomycine, etoposide en cisplatine. Al 24 uur na het starten van 
chemotherapie verdubbelde de concentratie van NPBI in het bloed en gedurende de 
gehele eerste week van de chemotherapie bleven de NPBI concentraties verhoogd. 
Deze stijging ging gepaard met een daling van de LIBC. De daling in LIBC was 
omgekeerd evenredig aan de concentratie van totaal en vrij ijzer in het bloed. Een 
week na de chemotherapie normaliseerden de ijzerparameters maar bij de volgende 
kuur werden dezelfde veranderingen in totaal en vrij ijzer en de ijzerbindingscapaciteit 
waargenomen. Er zijn meerdere verklaringen voor de stijging van het serum ijzer 
en NPBI. Chemotherapie induceert celdood van (tumor)cellen en dit kan zorgen 
voor een grotere beschikbaarheid van ijzer. Een tweede verklaring is dat de binding 
die cisplatine met de rode bloedcellen aangaat, leidt tot het vrijkomen van de ijzer-
bevattende haem groep.166 Ten derde suggereren enkele preklinische studies dat 




Hoewel het niet precies duidelijk is hoe chemotherapeutica zorgen voor de grotere 
beschikbaarheid van (vrij) ijzer is het waarschijnlijk dat deze zeer toxische moleculen 
bijdragen aan de waargenomen morbiditeit en mogelijk mortaliteit bij patiënten 
met teelbalkanker. Wij pleiten voor het meten van de serum ijzer concentraties 
in teelbalkanker patiënten tijdens de behandeling met chemotherapie omdat 
behandeling met chelatoren bij hoge waarden van vrij ijzer mogelijk een positief 
effect heeft op de kwaliteit van leven van deze verder gezonde patiëntenpopulatie.
Patiënten met teelbalkanker, en in het bijzonder diegenen die chemotherapie 
hebben gekregen, zijn gemiddeld tot twee jaar na de behandeling hypogonadaal.30 
Hypogonadisme heeft een negatieve invloed op het botmetabolisme 190, wat resulteert 
in een verlaagde botdichtheid (BMD) en mogelijk een verhoogd risico op (wervel)
fracturen. In Hoofdstuk 6 beschrijven we ons onderzoek naar de aanwezigheid van 
fracturen in de lumbale wervelkolom bij 199 genezen patiënten die eerder werden 
behandeld voor teelbalkanker en bij 45 nieuw gediagnosticeerde patiënten. In 
80 van de genezen patiënten (40.2%) en in 14 nieuwe patiënten (31,3%) werden 
wervelfracturen gediagnosticeerd. Het risico voor patiënten op een wervelfractuur 
was niet gerelateerd aan botdichtheid, leeftijd, tumor stadium, het gebruik van 
corticosteroïden of de behandeling met chemotherapie. Omdat we geen relatie 
vonden tussen de concentraties van LH en FSH in het serum en het voorkomen van 
wervelfracturen en de wervelfracturen in min of meer gelijke mate voorkwamen bij met 
chemotherapie behandelde en onbehandelde patiënten, is een meer waarschijnlijke 
oorzaak voor de wervelfracturen het zogenaamde “testicular dysgenesis syndrome” 
waarbij een verminderde androgeen-sensitiviteit leidt tot een veranderde botkwaliteit. 
De aanwezigheid van, al dan niet door chemotherapie versterkt, hypogonadisme zou 
theoretisch kunnen bijdragen aan het verstoorde botmetabolisme.
In Hoofdstuk 7 beschrijven we de resultaten van een prospectieve cohort studie 
waarbij in 63 nieuw gediagnostiseerde patiënten met testiscarcinoom tot vijf jaar na 
orchidectomie de botdichtheid werd gemeten. Direct na de orchidectomie was de 
BMD van patiënten met gemetastaseerde ziekte niet significant afwijkend van de BMD 
bij patiënten zonder metastasen. Bij de laatste groep bleef de BMD gedurende de 
gehele observatieperiode onveranderd. De BMD van patiënten met gemetastaseerde 
teelbalkanker daalde met gemiddeld 2% binnen één jaar na behandeling met 
chemotherapie. De BMD van deze patiënten bleef gedurende de follow-up periode 
significant verlaagd. De veranderingen in BMD konden niet gerelateerd worden aan 
bloedconcentraties van geslachtshormonen, rookgewoonten, vitamine-D tekort 
of verandering in botmarkers. Hierdoor blijft het onduidelijk of het verschil in BMD 
tussen de twee patiëntengroepen gerelateerd is aan de tumor en zijn metastasen, de 
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behandeling met chemotherapie en/of het gelijktijdig gebruik van steroïden. Gezien 
het regelmatig voorkomen van wervelfracturen en de gemeten veranderingen in BMD 
adviseren we om bij patiënten die voor teelbalkanker met chemotherapie behandeld 
worden, regelmatig de BMD te controleren met behulp van een bot densitometrie 
meting. Hierdoor zouden deze patiënten bij een vermindering van de botdichtheid 
tijdig met medicijnen behandeld kunnen worden, waardoor ook een deel van de 
(wervel) fracturen mogelijk voorkomen kan worden bij patiënten die behandeld zijn 
voor teelbalkanker.
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ALAT  alanine aminotransferase
AP  alkaline phosphatase
ASAT  aspartate aminotransferase
AUC7 seven times the area under the curve (carboplatin dose)
β-CTX beta-carboxyl-terminal cross-linking telopeptide of type I collagen
β-HCG  beta unit of human chorionic gonadotrophin
BEP  bleomycin, etoposide and cisplatin combination chemotherapy
BMD  bone mineral density
BMI  body mass index
CIS  carcinoma in situ
CRP  C-reactive protein
CT  chemotherapy
CTGCT contralateral (metachronous) testicular germ cell tumour
CVA  cerebrovascular accident
CVD cardiovascular disease
DXA  dual-energy X-ray absorptiometry
E2 estradiol
EDV  end-diastolic volume
EF  ejection fraction
EP etoposide and cisplatin combination chemotherapy
E/A ratio  early and atrial filling velocities across the mitral valve
FRS  Framingham Risk Score
FSH  follicle-stimulating hormone
FT  free testosterone
GCT germ cell tumour
HDL  high-density lipoprotein
1H-MRS  proton magnetic resonance spectroscopy
HOMA  homeostatic model assessment
HTC  hepatic triglyceride content
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Abbreviations
IDF  International Diabetes Federation
IGCCCG  International Germ Cell Cancer Collaborative Group
IQR  interquartile range
LDH  lactate dehydrogenase
LDL  low-density lipoprotein
LH  luteinizing hormone
LIBC  latent iron-binding capacity
LSMs least square means
LUMC  Leiden University Medical Center
LV  left ventricular
LVED left ventricular end-diastolic mass
MetS  metabolic syndrome
MRI  magnetic resonance imaging
MR-PWV  magnetic resonance measured pulse wave velocity
NASH  non-alcoholic steatohepatitis
NCEP-ATPIII  Adult Treatment Panel of the National Cholesterol Education Program
NHANES National Health and Nutrition Examination Surveys
NPBI  non-protein bound iron
NSGCT  non-seminoma germ cell tumour 
NTA  nitrilotriacetate
NTBI  non-transferrin bound iron
PTH parathyroid hormone
PVB cisplatin, vinblastin and bleomycin combination chemotherapy
PWV  pulse wave velocity
P1NP procollagen type 1 N-terminal propeptide
RR  blood pressure
RT  radiotherapy
RV  right ventricular
SCORE  Systemic Coronary Risk Evaluation
SGCT  seminoma germ cell tumour
SHBG  sex hormone binding globulin
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TC  testicular cancer
TGC  triglyceride
TGCT testicular germ cell tumour
TT  total testosterone
VF  vertebral fracture
WBC white blood cell count
WHO  World Health Organization
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